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Abstract 
 
Cisplatin has been used to treat various types of cancers for over 30 years, 
however, a number of serious side-effects of cisplatin have stimulated the quest for 
other metal-based anticancer agents. Iridium complexes are generally thought to be 
too inert to possess high reactivity, and therefore, there are only a few previous 
reports of the antitumour activity of iridium complexes.  
In this thesis a wide range of organometallic Ir
III
 cyclopentadienyl complexes of 
the type [(η5-Cpx)Ir(XY)Cl]0/+ (where Cpx = pentamethylcyclopentadienyl (Cp*), 
tetramethyl(phenyl)cyclopentadienyl (Cp
xph
) or tetramethyl(biphenyl)cyclopenta-
dienyl (Cp
xbiph
), XY = N,N-, N,O- or C^N-chelating ligand) has been synthesised 
and characterised. All the complexes hydrolyse rapidly in aqueous solution. 
Complexes with N,N-chelating ligands readily form adducts with 9-ethylguanine 
but not 9-ethyladenine; C^N- or N,O-chelated complexes bind to both purines. 
Guanine residues are preferential binding sites for 1,10-phenanthroline complexes 
on plasmid DNA. Replacement of the neutral N,N-bound chelating ligand by the 
negatively-charged C,N-bound analogues can improve biological activity. In 
addition, cytotoxic potency towards A2780 human ovarian cancer cells increases 
with phenyl substitution on Cp*: Cp
xbiph
 > Cp
xph
 > Cp*. This can be rationalised by 
increased hydrophobicity with more extended phenyl ring, resulting in increased 
cellular uptake and increased intercalative ability. Notably, several complexes 
exhibited submicromolar anticancer activity. 
The interconversion of 1,4-NADH and NAD
+
 through hydride-transfer reactions 
in the presence of cyclopentadienyl Ir
III
 aqua complexes was studied. It is shown 
that the Ir
III
 aqua complexes not only converts NAD
+
 to 1,4-NADH using formate 
as the hydride source, but can also catalyse the reverse reaction with hydride 
donation from 1,4-NADH to a iridium centre, recovered by protonation of bound 
hydride with generation of H2. 
This work demonstrates how the aqueous chemistry, nucleobase binding and 
anticancer activity of the Ir
III
 cyclopentadienyl complexes can be controlled and 
fine-tuned by the modification of the chelating and cyclopentadienyl ligands. The 
results suggest that this new class of organometalic Ir(III) complexes is well suited 
for development as anticancer agents. 
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2 
This Chapter introduces metallodrugs as anticancer agents, especially focusing on 
the previous studies on ruthenium, osmium and iridium organometallic anticancer 
complexes. Finally, the involvement of Ir
III
 complexes in biologically relevant 
hydride-transfer reactions is described. 
 
1.1 Metal-Based Anticancer Agents 
Cancer is caused when genetic damage to cells prevents them from being 
responsive to normal tissue controls. Each year, approximately 12.7 million people 
worldwide are diagnosed with cancer. In 2008 it caused about 13% of all human 
deaths worldwide (7.6 million), and is becoming the leading cause of death.
1
 
Different therapies, such as chemotherapy, radiotherapy and surgery, can be used to 
treat cancer, depending on the type of cancer and the extent of the disease.
2,3
 Most 
commonly, chemotherapy is an effective way to kill cancer cells. 
Metal complexes have played key roles in the development of pharmacy and 
modern chemotherapy.
4,5
 Medicinal applications of metal complexes as therapeutic 
agents can be traced back almost 5000 years.
6
 In modern medicinal inorganic 
chemistry, the most successful metal-based anticancer drug is cisplatin, cis-
[PtCl2(NH3)2] (Figure 1.1), discovered about 40 years ago.
7,8
 Today, cisplatin is still 
one of the world’s best selling anticancer drugs. It is mainly used in the treatment of 
ovarian, head and neck, bladder, cervical and lymphomas cancers. Over the past 
decades, more than 3000 platinum complexes have been synthesised and tested for 
their biological activity and less than 30 compounds have entered clinical trials.
9,10
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At present, four platinum drugs have entered world-wide clinical use: cisplatin, 
carboplatin, oxaliplatin and nedaplatin (Figure 1.1). It is estimated that 50%–70% of 
cancer patients are treated with a platinum drug.
11
 
Nuclear DNA is now widely accepted to be the ultimate target of cisplatin and 
related platinum therapeutics. The main mechanism of action of cisplatin is that it 
becomes activated by aquation to form [Pt(NH3)2Cl(H2O)]
+
 and [Pt(NH3)2(H2O)2]
2+
 
once inside the cell, and subsequently coordinatively bind to DNA via N7 positions 
of purines bases to afford primarily 1,2- or 1,3-intrastrand crosslinks and a lower 
number of interstrand crossslinks, Figure 1.2.
12
 Although the activated (aquated) 
cisplatin can interact with other biomolecules, its antitumour activity derives from 
its capability to form bifunctional DNA cross-links.
13
 The coordination of platinum 
to two adjacent bases causes the DNA to bend (kink) by around 45°, Figure 1.3.
14
 
The cisplatin–DNA adducts cause various cellular responses, such as replication 
arrest, transcription inhibition, cell-cycle arrest, DNA repair and apoptosis.
12
 
Pt
Cl
Cl
H3N
H3N
Pt
NH3
NH3
O
O
O
O
Pt
N
H2
H2
N
O
O
O
O
Pt
NH3
NH3
O
O
O
Cisplatin Carboplatin
Oxaliplatin Nedaplatin  
Figure 1.1. The chemical structures of currently marketed platinum anticancer 
drugs.  
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Figure 1.2. Formation and effects of cisplatin adducts.
12
  
 
 
 
 
 
 
 
 
 
Figure 1.3. X-ray structure of cis-[Pt(NH3)2(d(pGpG))] showing the kinking of 
DNA by cisplatin.
14
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Regardless of the achievements of current platinum drugs, there are some major 
drawbacks which are restricting their clinical use: they are efficient only in a limited 
range of cancers, some tumours can have acquired or intrinsic resistance and they 
often cause severe side-effects like nausea, bone marrow suppression and kidney 
toxicity. The clinical success and drawbacks of platinum-based anticancer drugs, 
therefore, have stimulated the exploration for other metal-based anticancer 
complexes (circled metals in Figure 1.4),
15
 which may address the problems 
associated with platinum drugs, produce significantly different lesions on DNA, and 
exhibit more potent cytotoxicity towards tumours which are non-responsive to 
current chemotherapy. 
 
 
Figure 1.4. Metals (red circled) with known anticancer compounds. 
 
In this frame, ruthenium compounds are considered to be suitable candidates for 
anticancer drug design since they have a rich redox chemistry (Ru
II
 and Ru
III
), and 
exhibit a similar spectrum of kinetics to platinum(II).
16
 A number of ruthenium 
compounds have been shown to display promising anticancer activity and two 
Chapter 1: Introduction 
 
 
6 
ruthenium(III) complexes have entered clinical trials, [trans-RuCl4(Ind)2][IndH] 
(KP1019, Ind = indazole) and [trans-RuCl4(DMSO)(Im)][ImH] (NAMI-A, DMSO 
= dimethylsulfoxide, Im = imidazole), Figure 1.5. NAMI-A showed marked 
efficacy against metastases,
17,18
 whereas the structurally-similar KP1019 exhibited 
activity against colon carcinoma and some primary explanted human tumours.
19,20
 
Previous work has shown that Ru
III
 complexes are activated by reduction in vivo to 
more reactive Ru
II
 due to the reduced stability of Ru
II–Cl bonds.21,22 This has 
resulted in increased interest in the anticancer Ru
II
 complexes, especially 
organometallic Ru
II
 arene complexes. These complexes are discussed in section 
1.2.2. 
 
HN
N
Ru
NH
N
Cl
Cl
Cl
Cl
NH
H
N HN
N
Ir
NH
N
Cl
Cl
Cl
Cl
NH
H
N
                  
SOMe2
Ru
Cl
Cl
Cl
Cl
HN
NH
N
HN  
Figure 1.5. Chemical structures of KP1019 (left) and NAMI-A (right). 
 
An anticancer gold phosphine compound has been reported (Figure 1.6), which 
shows a different mechanism of action compared to cisplatin and targets 
mitochondria; it destroys membrane potentials.
23
 Gallium salts are also known to 
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exhibit anticancer activity, and Ga(III) maltolate (Figure 1.6) has recently entered 
clinical trials for the treatment of bone disease and related conditions.
24
 
 
 
 
 
 
Figure 1.6. Chemical structures of the gold(I) phosphine and gallium(III) maltolate 
anticancer compounds.  
 
1.2 Organometallic Anticancer Complexes 
Organometallic chemistry evolved rapidly during the second half of the 20
th
 
century.
25
 Organometallic complexes have at least one metal-carbon bond, 
according to most definitions. Organometallics have a wide choice of metals and 
ligands, varying oxidation states and coordination numbers, great structural variety 
(linear, octahedral, etc.), and kinetic stability. Therefore, organometallic complexes 
provide a platform for the development of anticancer agents.
26
 
 
Au
Ph2P
Ph2P PPh2
PPh2
Ga
O
O O
O
O
O
O
O
O
+
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1.2.1  Cyclopentadienyl Anticancer Complexes 
A range of organometallic complexes, containing one or more six-electron-donor 
η5-cyclopentadienyl ligand (C5H5
−
, abbreviated as Cp), exhibit promising anticancer 
activity. The Cp ligands are generally bound via all 5 carbon atoms to a metal centre 
(π-bonded, η5-coordination). 
Sandwich ferrocenium salts [(C5H5)2Fe
III
]
+
 were the first antineoplastic iron 
complexes,
27
 which sparked the development of organometallic anticancer 
complexes.
28,29
 Ferrocene [(C5H5)2Fe
II
] does not possess anticancer activity, 
however, large number of modified ferrocene complexes showed promising 
anticancer activity owing to their redox activity. A notable example is ferrocifen, 
Figure 1.7, which consists of ferrocene modified tamoxifen (an organic drug for 
breast cancer treatment). Ferrocifen has a very significant effect on breast cancers 
which are not treatable by tamoxifen. This appears benefit from oxidative damage 
to DNA after oxidation of the ferrocenyl group to ferrocenium in the cells.
30
  
 
O(CH2)2NMe2
O(CH2)4NMe2
Fe
Tamoxifen Ferrocifen  
Figure 1.7. Tamoxifen and ferrocifen: active against breast cancer cells. 
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Titanocene dichloride Cp2TiCl2, Figure 1.8 A, entered clinical trials as an 
anticancer agent in the 1990s. It was designed because of the possibility of forming 
bifunctional cross-links on DNA in a similar manner to cisplatin, which might 
induce apoptosis and cancer cell death. However, the complex binds more strongly 
to phosphate backbone than to DNA.
31
 Also it is difficult to identify the active 
species and formulate for administration due to complicated hydrolysis, loss of the 
Cp ligand and formation of hydroxo species. Clinical results for titanocene 
dichloride were not satisfactory and the trials have now been abandoned.
32,33
 
Nonetheless, there is continuing interest in substituted titanocenes which might 
offer greater aqueous stability or cytotoxicity (Figure 1.8 B and C).
34-36
 For example, 
titanocene Y (Figure 1.8C) containing methoxyphenyl substitutions on Cp rings 
showed more potent cytotoxicity.
35
 Some other metallocenes, like Cp2VCl2 and 
Cp2NbCl2, also possess anticancer activity.
37
 
 
Ti
Cl
Cl
Ti
Cl
Cl
N
Ti
Cl
Cl
MeO
MeO
(A) (B) (C)  
Figure 1.8. Examples of titanocene anticancer complexes. 
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The increasing use of pentamethylcyclopentadienyl (Cp*) compounds in recent 
years is a significant development of organometallic chemistry. Not only are such 
compounds usually more soluble and more readily crystallised than their 
unsubstituted cyclopentadienyl (Cp) analogs, but they are generally more stable as a 
result of the steric and electron-donation effects of the five methyl groups. This is 
particularly so for the Cp* iridium complexes, where the η5-C5Me5 acts as an 
excellent stabilising ligand toward Ir(III).
38
 The [Cp*Ir] fragment is often used to 
stabilise the elusive molecule 1,4-dithiobenzoquinone.
39,40
 In addition, the formed 
iridium complexes showed promising anticancer activity against A2780 human 
ovarian cancer cell line. The pentamethylcyclopentadienyl iridium anticancer 
complexes are discussed in section 1.3.2. 
 
1.2.2  Ruthenium and Osmium Arene Anticancer Complexes 
This section is focused on recent data concerned with the chemistry and 
anticancer activity of Ru
II
 and Os
II
 arene complexes. It is believed that the activity 
of the Ru
III
 compounds is dependent on in vivo reduction to the more reactive 
Ru
II
.
21,22 
Neutral η6-coordinated (π-bound) arenes can stabilise ruthenium and 
osmium in their +2 oxidation state. With these in mind, work in the Sadler 
laboratory has focused on the anticancer potential of half-sandwich Ru
II
 and Os
II
 
arene complexes of the type, [(η6-arene)(Ru/Os)(YZ)(X)], where YZ is a bidentate 
chelating ligand and X is a good leaving group (e. g. Cl), Figure 1.9. The structure 
of Ru
II
/Os
II
 half-sandwich complexes allows for variations of the three main 
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building blocks, the monodentate ligand X, the bidentate ligand YZ and the arene, 
to design and tune the kinetic parameters and pharmacological properties of these 
complexes. 
 
                                                
M
X
Y
Z
R
M = Ru/Os  
Figure 1.9. General structure of Ru
II
/Os
II
 arene compounds. 
 
Ru
R
H2N
NH2
Cl
+
tetrahydroanthracene (tha)dihydroanthracene (dha)
biphenyl (bip)p-cymene (p-cym)benzene (bz)
 
Figure 1.10. [(η6-arene)Ru(en)Cl]+ anticancer complexes (arene shown in right).  
 
Ruthenium arene complexes containing the chelating ligand ethylenediamine, 
(en), [(η6-arene)Ru(en)Cl]+, showed promising anticancer activity both in vitro and 
in vivo, Figure 1.10.
41,42
 The mechanism of action for this type of complexes first 
involves hydrolysis of the Ru–Cl bond (replacement of Cl− by a water molecule). 
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Importantly, this step is suppressed in the blood because of the high chloride 
concentration (ca. 100 mM). Once the complexes cross the cell and nuclear 
membranes, the complexes are largely hydrolysed to give the reactive species [(η6-
arene)Ru(en)(H2O)]
2+
 because of the much lower chloride concentration (4 mM).
43
 
The aqua species are then thought to bind to nuclear DNA with a high affinity to the 
N7 position of guanine bases.
44-46
 Despite these similarities with cisplatin, [(η6-
arene)Ru(en)Cl]
+
 complexes also showed some obviously different mechanism of 
action with cisplatin. For example, the Ru arene complexes only form 
monofunctional adducts while cisplatin form bifunctional adducts. In addition, the 
[(η6-arene)Ru(en)Cl]+ complexes is active against cisplatin-resistant cancer cell 
lines.
42
  
For this type of complex, it also has been found that the cytotoxicity against 
human ovarian A2780 cancer cell line increases with the size of the coordinated 
arene in the order benzene (IC50 = 17 µM, where IC50 is the concentration that 
inhibits cell growth by 50%) < p-cymene (IC50 = 10 µM) < biphenyl (IC50 = 5 µM) 
< dihydroanthracene (IC50 = 2 µM) < tetrahydroanthracene (IC50 = 0.5 µM).
42
 This 
might indicate that the hydrophobic arene can be involved in increased cellular 
uptake, and in addition might be involved in the increased ability of intercalation 
into the main target DNA. Indeed, the X-ray crystal structure of 9-ethylguanine (9-
EtG) adduct [(η6-dha)Ru(en)(9EtG-N7)]2+ has shown the base-stacks between the 
extended dha arene and the coordinated 9-EtG, Figure 1.11.
46
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Figure 1.11. (A) X-ray structure for [(η6-dha)Ru(en)(9EtG-N7)]2+; (B) A space-
filling model of the ruthenium complex bound to B-DNA, illustrating how the 
extended dha arene can intercalate between guanine base pairs.
46
 
 
Compared with the lighter congener ruthenium, osmium organometallics have 
been little explored as therapeutic agents, probably due to its reputation of being 
relatively substitution inert and highly toxic. However the Sadler group have 
recently explored a new class of potential osmium(II) arene anticancer agents. 
The osmium analogue of the active ethylenediamine (en) Ru
II
 complex, [(η6-
bip)Os(en)Cl]
+
, Figure 1.12A, also exhibited promising activity against the human 
ovarian cancer A2780 cell line (IC50 = 9 µM). However, the hydrolysis rate of the 
osmium en compound is ca. 40 times slower than that of the Ru
II
 analogue, 
highlighting the lower reactivity of Os
II
.
47
 In addition, aqua adducts of osmium 
complexes were significantly more acidic by 1-2 units than their ruthenium 
analogues.
47,48
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Os
H2N
NH2
Cl
+
Os
ClO
O
Os
Cl
N
O
O
(A) (B) (C)  
Figure 1.12. Osmium (II) arene complexes with N,N-, O,O- and N,O-chelating 
ligands. (A) [(η6-bip)Os(en)Cl]+; (B) [(η6-p-cym)Os(acac)Cl]; (C) [(η6-p-
cym)Os(pico)Cl]. 
 
Changing the chelating ligand from the neutral N,N-bound en to the anionic O,O-
chelator acetylacetonate (acac) (Figure 1.12B), significantly increases the extent 
and rate of hydrolysis (too fast to monitor by NMR at 298 K). Density functional 
theory (DFT) calculations have shown that the hydrolysis barrier of the Os
II
 acac 
complex is significantly lower than that of the en complex by nearly 30 kJ·mol–1.49 
However, hydrolysis of the acac compounds is complicated by the formation of the 
hydroxo-bridged dimer {[(η6-arene)Os]2(µ-OH)3}
+
, with loss of the acac ligand. 
This hydroxo-bridged dimer is the only observed species at micromolar 
concentrations in solutions similar to those used in biological cell culture tests,
47
 
which resulted in the inactivity toward the human ovarian (A2780) and human lung 
(A549) cancer cell lines.  
Intermediate behaviour to that of the N,N- and O,O-chelated osmium arene 
complexes is observed for complexes containing anionic N,O-chelators. The 
representative is the complex containing picolinate (pico) as the N,O-chelating 
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ligand (Figure 1.12C). This complex hydrolyses at an intermediate rate, is stable in 
aqueous solutions at micromolar concentrations, and is active towards both A549 
and A2780 cell lines.
50
 A series of osmium(II) arene anticancer complexes 
containing picolinate derivatives have also been studied.
51
  
The organometallic osmium arene azopyridine complex [(η6-p-cym)Os(4-(2-
pyridylazo)-N,N-dimethylaniline)I]PF6, shows nanomolar activity in vitro in a few 
of human cancer cell lines,
52
 and exhibits activity in vivo against HCT116 human 
colon cancer xenografts in mice.
53
 Its activity may involve redox mechanisms.  
 
1.3 Iridium Anticancer Agents 
Iridium is a transition metal of the platinum-group family, which is located in the 
middle of osmium and platinum in the periodic table. Like osmium, iridium 
complexes are also generally thought to be too inert to possess high reactivity. This 
tenet seems to be proved by the fact that [Ir(acac)(COD)] (COD = cis,cis-1,5-cyclo-
octadiene) showed much less antitumour activity than the rhodium analogue,
54,55
 
and that trans-[IrCl4(DMSO)(Im)][ImH]
56
 and trans-[IrCl4(Im)2][ImH] (ImH = 
imidazole),
57
 (analogues of NAMI-A and the imidazole analogue of indazole 
complex KP1019, respectively) have all been found to be biologically inactive. In 
comparison with ruthenium and platinum complexes, the group 9 iridium 
complexes have attracted only little interest as potential anticancer agents. 
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1.3.1  Iridium(I) Anticancer Complexes 
The majority of the complexes of iridium(I) are 4-coordinate and have square-
planar geometry.  
[Ir(acac)(COD)] (COD = cis,cis-1,5-cyclo-octadiene) is one of the earliest 
iridium anticancer complexes (Figure 1.13). It was found to give 100% cures in 
mice bearing Ehrlich ascites carcinoma without toxic deaths at dose levels of 50 and 
100 mg/kg/day in 1978.
55
 In contrast to [Rh(acac)(COD)], the iridium(I) analogue 
had no effect on lung metastases.
54
 
Interestingly, the dinuclear iridium(I) compound, [IrCl(COD)]2, Figure 1.13, was 
found to have antimetastatic activity in the Lewis lung model, although it did not 
inhibit primary tumours.
58
 
              
Ir
O
O
         
Figure 1.13. Early Ir
I
 anticancer complexes [Ir(acac)(COD)] and [IrCl(COD)]2. 
 
1.3.2  Iridium(III) Anticancer Complexes 
Iridium complexes with a d
6
 (Ir
III
) electron configuration are coordinatively-
saturated when the coordination number is 6. Iridium(III) complexes generally have 
an octahedral geometry. 
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In one of the earliest studies, no activity was found for several iridium(III) 
ammine complexes when tested against the solid Sarcoma 180 tumour.
59 
Compound 
mer-[Ir(NH3)3Cl3] also showed inactivity against the Sarcoma 180 and the 
ADJ/PC6A systems while its rhodium(III) analogue, mer-[Rh(NH3)3Cl3], inhibited 
both tumours. 
Although the anticancer properties of iridium compounds have been explored 
almost 40 years, Ir
III
 anticancer agents started to attract attentions just a few years 
ago. From 2007, Sheldrick and coworkers reported a series of cytotoxic 
pentamethylcyclopentadienyl and trichlorido Ir
III
 complexes containing N,N-
chelating polypyridyl ligands, Figure 1.14.
60-63
 
 
Ir
Cl
Cl
Cl
S
O
H3C
H3C
N
N
N
N
bpy
phen
dpq
dppz
dppn
Ir
L
N
N
N
N
dpq
dppz
dppn
n+
L = Cl
     (NH2)2CS
     (NMe2)2CS
 
Figure 1.14. Ir
III
 anticancer complexes containing N,N-chelating polypyridyl 
ligands.
60,61
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Table 1.1. IC50 (μM) of Ir
III
 Anticancer Complexes Containing N,N-chelating 
Polypyridyl Ligands.
60-62
 
Compound 
IC50 (μM) 
MCF-7              HT-29 
[(η5-C5Me5)Ir(phen)Cl]
+
 >100 >100 
[(η5-C5Me5)Ir(dppz)Cl]
+
 2.3(0.4) 7.4(0.9) 
[(η5-C5Me5)Ir(dppn)(NMe2)2CS)]
2+
 0.17(0.02) 0.41(0.16) 
fac-[IrCl3(DMSO)(bpy)] >100 >100 
fac-[IrCl3(DMSO)(phen)] 4.6(0.5) 4.6(0.2) 
fac-[IrCl3(DMSO)(dpq)] 5.5(0.9) 6.1(0.7) 
fac-[IrCl3(DMSO)(dppz)] 0.8(0.3) 1.5(0.2) 
fac-[IrCl3(DMSO)(dppn)] 0.21(0.11) 1.3(0.4) 
 
In general, the antiproliferative effects of this type of N,N-bound polypyridyl Ir
III
 
complexes are governed by the size of the polypyridyl ligands in the order of bpy < 
phen, dpq < dppz < dppn, Table 1.1. Increasing the surface area of the polypyridyl 
ligand generally results in a significant increase in the intercalative binding strength. 
A side-on intercalation mode was established by 2D NOESY for the interaction of 
[(η5-C5Me5)Ir(dppz)(H2metOMe)]
3+ 
(HmetOH = L-methionine) with the 
hexanucleotide d(GTCGAC)2.
64
 The polypyridyl Ir
III
 complexes interact with DNA 
via coordination, intercalation or a combination of both. For example, complexes 
[(η5-C5Me5)Ir(pp)Cl]
+
 (pp = dpq, dppz, dppn) interact with DNA initially through 
kinetically preferred intercalation, followed by thermodynamically preferred 
coordination to DNA after relatively slow substitution of labile chloride.
60
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Increasing the size of polypyridyl ligands also resulted in higher cellular uptake, 
correlated well with their cytotoxicity.
61
  
Lo and co-workers have reported a series of luminescent cyclometalated Ir(III) 
complexes containing polypyridine as biological labels and probes.
65,66
 Some of 
these complexes were also found to be highly cytotoxic toward HeLa cells.  
The Dyson group has explored a series of pentamethylcyclopentadienyl Ir
III
 
complexes containing monodentate ligands PTA (1,3,5-triaza-7-phosphatricyclo-
[3.3.1.1]decane) and mPTA (1-methyl-1,3,5-triaza-7-phosphaadamantane), Figure 
1.15. In contrast to Ru p-cymene analogue RAPTA-C, which showed effective 
inhibition against bovine cat B with IC50 value of 2.5 ± 0.5 μM,
67
 all these Ir
III
 
complexes were inactive in vitro against A2780 human ovarian cancer cell line and 
bovine cat B cells (IC50 > 300 μM).
68
 Complex [(Cp*)Ir(PTA)Cl2] is considered to 
undergo rapid hydrolysis in water to give mono hydroxo species, 
[(Cp*)Ir(PTA)(OH)Cl], similar to [(Cp*)Ir(PTA)2Cl]
+
, followed by further 
substitution by sulphur atom of the cysteine residue in the active site of cat B. 
However, Ir
III
 complex forms the weakest M-S bond compared to RuII and OsII 
analogues by DFT calculation, which may caused the inactivity against bovine cat 
B cells. 
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+
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N N+P
N
N
N
Ru
Cl
Cl P
N
N N
[(Cp*)Ir(mPTA)Cl2]
+
[(Cp*)Ir(PTA)(mPTA)Cl]2+ RAPTA-C  
Figure 1.15. Ir
III
 and Ru
II
 monodentate PTA and mPTA complexes.  
 
For [(η6-arene)Ru(Y)(Z)(X)]n+ complexes, replacing the monodentate Y and Z 
ligands by a bidentate chelating group YZ generally tends to improve anticancer 
activity and stability in aqueous solution.
42
 Several pentamethylcyclopentadienyl 
Ir
III
 anticancer complexes containing N,O- or N,N-chelating ligands have been 
studied. N,O-bound 1,2-naphthoquinone-1-oximate complex [(η5-C5Me5)Ir(η
2
-
C10H6N2O)Cl], Figure 1.16A, exerted a more potent cytotoxicity against HeLa 
(cervical carcinoma) and HL60 (leukemia) cancer cells than cisplatin.
69
 However, 
no interaction with double-stranded DNA was observed for the cytotoxic complex. 
Another N,O-bound quinolin-8-ol complex [(η5-C5Me5)Ir(qol)Cl], Figure 1.16B, 
showed reasonable effectiveness against C-32, SNB-19 and SK-Mel tumour cells.
70
 
Despite the anticancer activity, the mechanism of action of the complex is still 
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unknown. N,N-bound 2-(pyridine-2-yl)thiazole complex [(η5-C5Me5)Ir(pyTz)Cl], 
Figure 1.16C, is inactive toward A2780 human ovarian cancer cell line and 
cisplatin-resistant variant (A2780cisR) with IC50 value > 300 μM.
71
 The inactivity 
may be due to the absence of interaction with DNA since the complex lacks of 
either intercalating group or strong hydrogen bond donors on the N,N-chelating 
ligand. 
 
Ir
O
N
Cl
O
Ir
ClN
O
Ir
ClN
S
N
(A) (B) (C)
 
Figure 1.16. Iridium(III) anticancer complexes containing N,O- or N,N-chelating 
ligands.
69-71
 
 
1.4 Ir
III
 Pentamethylcyclopentadienyl Complexes as Catalytic 
Agents 
The global demand for iridium in 2007 was 3700 kg, out of which 750 kg was for 
catalysis.
72
 Recently, remarkable efforts have been devoted towards the 
development of aqueous-phase organometallic catalysis due to the relatively easy 
recycling of water-soluble catalysts in aqueous-organic biphasic reaction 
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mixtures.
73
 Iridium(III) pentamethylcyclopentadienyl (Cp*) complexes are 
extremely useful in synthesis due to their ability to catalyse an array of synthetic 
transformations, often with unique selectivity, such as in C=O hydrogenation, 
hydroamination, and asymmetric allylic substitutions.
74
 The iridium Cp* dimer 
[(Cp*)IrCl2]2 is an effective catalyst for conversion of alcohols into amides via 
oximes.
75
 Some iridium aqua complexes are reported to catalyse CO2 hydrogenation 
due to formation of active hydride complexes.
76
 Ir
III
 Cp* compounds are also used 
as catalysts in a range of other reactions. For example, a number of Ir
III
 Cp* 
complexes containing C^N, or N,N-chelating ligands are highly active for water-
oxidation when driven with a chemical oxidant.
77
  
Transfer hydrogenation reactions provide an alternative to direct hydrogenation 
for the reduction of a range of substrates. Catalytic iridium complexes are the most 
important catalyst for transfer hydrogenation reactions.
78
 In the reduction of ketones 
and aldehydes (one of the fundamental applications of transfer hydrogenation), 
iridium hydride species are often formed as actually effective agents in the reaction 
pathway. Typically, formic acid, formate, or alcohol can be used as the source of 
hydride. A water-soluble iridium hydride complex [(Cp*)Ir(bpy)H]
+
 (bpy = 2,2'-
bipyridine) has been reported as a robust catalyst for acid-catalysed transfer 
hydrogenation of carbonyl compounds, Eq. 1.1.
79
 HCOOH and HCOONa are used 
as hydrogen donors to form the hydride complex and the crystal structure is shown 
in Figure 1.17. 
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C
R2R1
O
+ [Ir-H]+
H+
H2O
CR1 R2
H
OH
+ [Ir-OH2]
2+
(Eq. 1.1)
 
 
 
Figure 1.17. Crystal structure of hydride complex [(Cp*)Ir(bpy)H]
+
.
79
 
 
For another example, a Cp* Ir
III
 catalyst containing a diamine ligand (HCOONa 
as hydrogen donor) showed a higher activity in transfer hydrogenation of aldehydes 
than its ruthenium and rhodium analogues.
80
 
In numerous biological hydrogen transfer reactions, an important example is the 
reduction of coenzyme NAD
+
 (β-nicotinamide adenine dinucleotide) to its reduced 
form 1,4-NADH (Figure 1.18), by accepting two electrons and a proton from a 
substrate in the presence of an enzyme. NAD
+
/NADH have been known as classic 
molecules involving in energy metabolism, reductive biosynthesis and 
antioxidation.
81-83
 Various transition metal hydrides have been studied as catalysts 
for the reduction of NAD
+
 and NAD
+
-models to the corresponding 1,4-NADH and 
its derivatives.
84-86
 Ir
III
 Cp* complex containing 1,10-phenanthroline derivative has 
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shown to catalyse the reduction of NAD
+
 in the presence of formate as the hydride 
source.
87 
This reduction is regioselective, giving the biologically relevant 1,4-
NADH isomer. 
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Figure 1.18. Coenzyme NAD
+
 (β-nicotinamide adenine dinucleotide) and the 
reduced form 1,4-NADH. 
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1.5 Aims  
The general aim of this thesis is to investigate the design and reactivity of 
organometallic anticancer iridium(III) complexes containing different substituted 
cyclopentadienyl and chelating ligands. The studies are focused on systematic 
variations in the design of the complexes and studying the relationships between 
their physical, chemical and biological properties. More specific aims are as follows. 
 
1. To synthesise and characterise organometallic iridium(III) complexes 
with variations to the cyclopentadienyl and chelating ligands with a view 
to tune their reactivity and improve their biological properties. 
2. To develop structure-activity relationships, investigate the influences of 
changing cyclopentadienyl ligands with different substitution and 
chelating ligands on their aqueous chemistry and biological activity, 
including rates and extent of hydrolysis, acidity of bound water, 
nucleobase binding, cytotoxicity, distribution in cellular fractions, 
cellular uptake and DNA binding. 
3. To investigate the conversion between NAD+ and NADH using 
organometallic iridium complexes as catalysts, explore the possibility of 
hydride-transfer reactions using 1,4-NADH as a hydride source.  
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This Chapter describes the main experimental techniques used in this work. More 
specific methods relating to individual experiments are described in the appropriate 
Chapters. The synthesis and characterisation of the cyclopentadienyl ligands and 
dimers used for the synthesis of the iridium complexes in subsequent Chapters is 
also covered here. 
 
2.1 Instrumentation and Methods 
2.1.1 Nuclear Magnetic Resonance Spectroscopy (NMR)
1-3
 
Nuclear magnetic resonance (NMR) spectroscopy is a powerful technique which 
exploits the magnetic properties of nuclei to determine physical and chemical 
properties of atoms or molecules. All chemical elements that possess a nuclear spin 
of ½ or greater are in principle observable by NMR. Most studied nuclei with NMR 
are 
1
H, 
13
C and 
15
N. When placed in a magnetic field (B0), nuclei with a spin ½ will 
distribute over two states with different energies (α and β), and process around B0 at 
a characteristic frequency (Larmor frequency). The slight population difference 
between the α and β states results in a bulk magnetization vector (M0) along the 
axes of B0. The application of a second magnetic field (B1) at the Larmor frequency 
of the nuclei will cause the nuclei to resonate. In most NMR experiments, the nuclei 
are irradiated with brief pulses of B1, allowing the spins to return to their 
equilibrium between the pulses referred to as relaxation. The relaxation of the spins 
causes the NMR signal to decay with time, producing the observed Free Induction 
Decay or FID. The FID can be Fourier transformed to produce a NMR spectrum 
Chapter 2: Experimental Methods and Materials 
 
36 
where signals are plotted as a function of frequency. Depending on the local 
chemical environment, different nuclides in a molecule resonate at slightly different 
frequencies and this gives rise to the different chemical shifts observed in the NMR 
spectra. The chemical shift can be used to obtain structural information about the 
molecule by understanding the different chemical environments of the atoms in the 
molecule.  
2D NMR spectra provide more information about a molecule than 1D NMR 
spectra and are especially useful in determining the structure of a molecule, 
particularly for molecules that are too complicated to work with using 1D NMR. In 
the COSY (correlation spectroscopy), TOCSY (total correlation spectroscopy) or 
NOESY (nuclear Overhauser effect spectroscopy) 2D NMR experiments, a second 
frequency domain is introduced to reveal structural connections through magnetic 
interactions between nuclei. In both the COSY and TOCSY experiments, two 
essentially identical chemical shift axes are plotted orthogonally to each other, with 
the 1D NMR spectra appearing on the diagonal of the plot. In a COSY experiment, 
all the spin-spin coupled protons are indicated by cross peaks which are 
symmetrically placed along the diagonal. COSY spectra typically can show two- 
and three-bond coupled protons, however long-range bonding can be emphasised 
through introducing extra delays in the pulse sequence. In TOCSY experiments, the 
connectivity of a whole spin system can be shown as cross peaks are found for all 
protons that are connected within it. 2D NOESY was used to establish structural 
information resulting from through-space interactions between protons that are 
close in spatial proximity. 
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2.1.1.1  Experimental 
1
H NMR spectra were acquired in 5 mm NMR tubes at 298K (unless stated 
otherwise) on either Bruker AV-400, Bruker DRX 500, AVA 600 or Bruker AV II 
700 NMR spectrometers. 
1
H NMR chemical shifts were internally referenced to 
(CHD2)(CD3)SO (2.50 ppm) for DMSO-d6, CHCl3 (7.26 ppm) for chloroform-d1, 
CHD2OD (3.33 ppm) for methanol-d4 and to 1,4-dioxane (3.75 ppm) for aqueous 
solutions. The data were processed using TOPSPIN (version 2.1 Bruker UK Ltd).  
 
2.1.1.2  Water Suppression 
Many experiments in this thesis were performed on samples in aqueous solutions 
(99.9% D2O, or 5% MeOD-d4/95% D2O, or 10% MeOD-d4/90% H2O,) so as to be 
of biological relevance. The use of such aqueous solutions results in a large HOD 
signal that can obscure the other signals in the 
1
H spectrum. To minimize this, the 
HOD signal was suppressed with either presaturation or Shaka techniques.
4
 
Presaturation involves the saturation of the HOD peak by irradiating the frequency 
of water in between pulse sequences. Shaka water suppression, or Double Pulse 
Field Gradient Spin Echo (DPFGSE), uses pulsed field gradient spin echoes in 
which the refocusing pulse is the sequence soft π(x)-hard π(-x). The disadvantage of 
this technique is that signals close to the water peak are also reduced in intensity. 
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2.1.2 pH Measurements 
pH values were measured at ambient temperature, using a Corning 240 pH meter 
equipped with a micro combination KNO3 (chloride free) electrode calibrated with 
Aldrich buffer solutions of pH 4, 7 and 10. pH* values (pH meter reading) of NMR 
samples in D2O were measured directly in the NMR tube, before and after recording 
NMR spectra using the same method. 
 
2.1.3 Determination of pKa Values 
To generate the aqua complexes, chlorido complexes were dissolved in D2O and 
0.98 mol equiv of AgNO3 were added. The solution was stirred for 24 h at 298 K, 
and AgCl was removed by filtration. For determinations of pKa* values (pKa values 
for solutions in D2O) the pH* values of solutions of the aqua complexes in D2O 
were varied from ca. pH* 2 to 11 by the addition of dilute NaOD and DClO4, and 
1
H NMR spectra were recorded. The chemical shifts of the chelating ligand protons 
and/or methyl protons of Cp
x
 were plotted against pH*. The pH* titration curves 
were fitted to the Henderson-Hasselbalch equation using ORIGIN version 8.0. 
These pKa* values can be converted to pKa values by use of the equation pKa = 
0.929pKa* + 0.42 as suggested by Krezel and Bal
5
 for comparison with related 
values in the literature. 
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2.1.4 X-ray Crystallography 
X-ray diffraction (XRD) is a widely used technique for the precise determination 
of the position of atoms in molecules in the crystalline solid state. XRD was used in 
this thesis to characterise the crystal structures of several synthesised compounds. 
All diffraction data were obtained on an Oxford Diffraction Gemini four-circle 
system with a Ruby CCD area detector using Mo Kα radiation. Absorption 
corrections were applied using ABSPACK.
6
 The crystals were mounted in oil and 
held at 100(2) K with the Oxford Cryosystem Cobra. The structures were solved by 
direct methods using SHELXS (TREF)
7
 with additional light atoms found by 
Fourier methods. Complexes were refined against F
2
 using SHELXL.
8
 Data 
collection and solution of the structures were carried out by Dr. Guy Clarkson 
(Department of Chemistry, University of Warwick). Details of the acquisition and 
solving of the individual crystal structures are explained in the corresponding 
Chapters. 
 
2.1.5 Elemental Analysis 
Elemental analysis determines the percentage of C, H and N composition in a 
sample. Comparing the obtained C, H, N values of a sample of the complex to 
theoretical values provides information about the purity of the compound and was 
used for this purpose in this thesis. CHN elemental analyses were carried out on a 
CE-440 elemental analyzer by Exeter Analytical (UK) Ltd. 
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2.1.6 Electrospray Ionisation Mass Spectrometry (ESI-MS)
9
 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-
charge ratios of charged particles. It is used for determining masses of particles, and 
for elucidating the chemical structures of molecules. The MS principle consists of 
ionizing chemical compounds to generate charged molecules or molecule fragments 
and measuring their mass-to-charge ratios. Electrospray ionization (ESI) is a 
technique used in mass spectrometry to produce ions. The sample must be present 
in the form of ions in solution and this is typically achieved by adding small 
amounts of acid or base to respectively protonate (ESI positive) or deprotonate (ESI 
negative) the solution. ESI-MS was used routinely in this work for the 
characterisation of the complexes. 
ESI-MS were obtained on a Bruker Esquire 2000 Ion Trap Spectrometer. Samples 
were prepared in 50% CH3CN and 50% H2O (v/v). The mass spectra were recorded 
with a scan range of m/z 50–1000 for positive ions. Data were processed using Data 
Analysis 3.3 (Bruker Daltonics). 
 
2.1.7 Inductively Coupled Plasma Mass Spectroscopy (ICP-MS)
9,10
 
ICP-MS is a very sensitive technique that can be used to determine the elemental 
concentrations of solutions. More than 75 elements can be determined; most of 
them at detection limits of less than 1 part per billion (100 ppt–2 ppb). It is based on 
coupling together inductively coupled plasma as a method of producing ions 
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(ionization) with mass spectrometry as a method of separating and detecting the 
ions.  
All ICP-MS analyses were carried out on an Agilent Technologies 7500 series 
ICP-MS instrument. The water used for ICP-MS analysis was doubly deionised 
(DDW) using a Millipore Milli-Q water purification system and a USF Elga UHQ 
water deionizer. The iridium Specpure plasma standard (Alfa Aesar, 1000 ppm in 
10% HCl) was diluted with 3% HNO3 DDW to freshly prepare calibrants at 
concentrations 1000, 800, 400, 200, 100, 50, 10, 1 and 0.1 ppb. The ICP-MS 
instrument was set to detect 
193
Ir with typical detection limits of ca. 2 ppt using no 
gas mode. 
 
2.1.8 UV-Vis Absorption Spectroscopy 
UV-Vis spectroscopy is routinely used in analytical chemistry for the quantitative 
determination of different analytes, such as transition metal ions, highly conjugated 
organic compounds, and biological macromolecules.
9
 
This method is used in this thesis to monitor hydrolysis of iridium chloride 
complexes and reactions with NADH or NAD
+
. A Cary 300 UV-Vis recording 
spectrophotometer was used with 1 cm path-length quartz cuvettes (0.5 mL) and a 
PTP1 Peltier temperature controller. Spectra were processed using UVWinlab 
software. Experiments were carried out at 298 K unless otherwise stated. 
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2.1.9 Computational Methods 
Calculations in Chapter 3 and 4 were performed by Dr. Luca Salassa 
(Department of Chemistry, University of Warwick). 
The Gaussian 03 package
11
 was employed for all calculations. Geometry 
optimization calculations for some iridium complexes were performed in the gas 
phase with the hybrid functional PBE1PBE.
12
 The LanL2DZ basis set and effective 
core potential
13
 were used for the Ir atom, and the 6-31G** basis set was used for 
all other atoms.
14
 The nature of all stationary points was confirmed by performing a 
normal-mode analysis. Electrostatic potential surfaces (EPSs) for some iridium 
complexes were calculated and mapped on electron density of the molecules. The 
electrostatic potential is represented with a colour scale ranging from red to blue.  
 
2.1.10 Determination of Partition Coefficient, Log P 
The Log P value, or partition coefficient, is the ratio of concentrations of a 
compound in a mixture of two immiscible solvents at equilibrium, typically water 
and a hydrophobic solvent such as octanol. The partition coefficient gives a 
measure of how hydrophilic or hydrophobic a compound is. This is useful in 
estimating the distribution of drugs within the body, e.g. hydrophobic compounds 
with high partition coefficients are preferentially distributed to hydrophobic 
compartments such as lipid bilayers of cells while hydrophilic compounds (low 
partition coefficients) preferentially are found in hydrophilic compartments. 
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In this thesis, octanol-saturated water (OSW) and water-saturated octanol (WSO) 
were prepared using analytical grade octanol and 0.2 M aqueous NaCl solution (to 
suppress hydrolysis of the chlorido complexes). Aliquots of stock solutions of 
iridium complexes in OSW were added to equal volumes of WSO and shaken in an 
IKA Vibrax VXC basic shaker for 4 h at 500 g/min to allow partition at ambient 
temperature. The aqueous layer was carefully separated from the octanol layer for 
iridium analysis. 
193
Ir was quantified from aliquots taken from the octanol-saturated 
aqueous samples before and after partition. Partition coefficients of Ir
III
 complexes 
were calculated using the equation log P = log ([Ir]WSO/[Ir]OSW), where [Ir]WSO was 
obtained by subtraction of the Ir content of the aqueous layer after partition from the 
Ir content of the aqueous layer before partition. 
 
2.1.11 Cancer Cell Growth Inhibition 
2.1.11.1  Cytotoxicity against A2780 Human Ovarian Cancer Cells 
The cytotoxicity of iridium complexes against A2780 human ovarian cancer cells 
was performed by Dr. Ana M. Pizarro (Department of Chemistry, University of 
Warwick). The following sections outline the general cell experiments used in this 
thesis.  
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2.1.11.1.1  Materials and Maintenance 
The A2780 human ovarian cancer cell line was obtained from the European 
Collection of Cell Cultures (ECACC, Salisbury, U.K.). The cells were maintained 
in RPMI 1640 medium, which was supplemented with 10% fetal calf serum, 1% 
glutamine and 1% penicillin/streptomycin. Experiments were performed with cells 
within 15 passages from each other. All cells were split two to three times a week 
when around 80–95% confluence was reached using 0.25% trypsin/EDTA. 
 
2.1.11.1.2  In Vitro Growth Inhibition Assay 
IC50 values (concentration at which 50% of the cell growth is inhibited) against 
A2780 human ovarian cancer cells were determined as part of this thesis. 
Plates containing 8 rows × 12 columns, in total 96 wells with 300 µL capacity 
were used. The A2780 cancer cells were plated at a density of 5000 cells/well. All 
cells were grown for 48 h at 310 K in 5% humidified atmosphere, before addition of 
Ir
III
 complexes. Cisplatin (CDDP) was bought from Sigma and was included in 
every assay as control. 
Stock solutions of the iridium complexes or CDDP were made up in 5% DMSO 
and saline, by initial dissolution in DMSO followed by dilution with saline. 
Sonication was sometimes used to facilitate complete dissolution. These stock 
solutions were diluted with medium to give final concentrations of 400 µM, 200 
µM and 20 µM (0.5% DMSO final concentration). Aliquots of 50 µL of these 
solutions were added to the wells in the 96-well plate (triplicate) already containing 
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150 µL of media, so that the final concentrations were 100 µM, 50 µM and 5 µM 
(0.125% DMSO final concentration), respectively. These three concentrations were 
used in an initial screen for activity, and candidates were classified as either: 
a) inactive <50% growth inhibition at 100 µM, 
b) modest 80% to 50% growth inhibition at 50 µM, 
c) potent >50% growth inhibition at 5 µM. 
 
IC50 values were obtained by testing at typically six different concentrations, 
ranging from 0.05 µM to 100 µM. Each assay includes cisplatin which acts as a 
positive and comparative control as well as 16 wells free of drug solution, which 
acts as the 100% cell survival control. Each concentration of cisplatin or complex 
was tested in triplicate so that three compounds plus cisplatin could be tested per 
plate. Each assay was done in duplicate, so that each concentration was tested a 
total of six times.  
After 24 h exposure (at 310 K in a 5% CO2 humidified atmosphere), the drug 
containing medium was removed, the cells washed with 50 µL phosphate buffered 
saline (PBS) and 200 µL of fresh medium was added. The cells were left to grow 
for three doubling times (72 h) at 310 K in a 5% humidified atmosphere. 
The remaining biomass after this time was determined using the sulforhodamine 
B (SRB) assay.
15
 Cells were fixed to the 96-well plate by adding 50 µL 50% 
trichloroacetic acid (TCA) to each well (final concentration 10%) and incubating at 
277 K for 1 h before washing five times with tap water. Plates were dried with the 
Chapter 2: Experimental Methods and Materials 
 
46 
assistance of a hairdryer until no standing moisture was visible. The TCA-fixed 
cells were stained by adding 50 µL of 0.4% (w/v) sulforhodamine B (SRB) 
dissolved in 1% acetic acid, and left to stand for 30 min at ambient temperature. 
The excess dye was removed with four quick rinses of 1% acetic acid and again 
dried with the assistance of a hairdryer until no standing moisture was visible. The 
cell-bound dye was solubilised by addition of 150 µL of 10 mM Tris base 
(tris(hydroxomethyl)aminoethane, pH 10.5) and plates were left standing at ambient 
temperature for 1 h to allow the solutions to become homogeneous. The optical 
density was then measured at 540 nm on a BioHit BP800 plate reader. IC50 values 
were obtained from plots of % cell survival against the Log of the drug 
concentration and fitted with a sigmoidal equation using ORIGIN 8.0. 
 
2.1.11.2  NCI/DTP Cytotoxicity 
Five iridium complexes studied in Chapters 3 and 4 were further evaluated by the 
National Cancer Institute Developmental Therapeutics Program (NCI/DTP, U.S.A.) 
for in vitro cytotoxic test against ca. 60 human cancer cell lines. The protocol for 
the determination of cytotoxicity on the 60 cell line panel can be found at 
http://dtp.nci.nih.gov/branches/btb/ivclsp.html. The DTP homepage can be accessed 
at http://dtp.cancer.gov/.  
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2.2 Synthesis and Characterisation of Starting Materials 
The ligands tetramethyl(phenyl)cyclopentadiene (Cp
xph
H) and 
tetramethyl(biphenyl)cyclopentadiene (Cp
xbiph
H), and iridium dimers of the type 
[(η5-Cpx)IrCl2]2 (Cp
x
 = pentamethylcyclopentadienyl, Cp*; tetramethyl(phenyl)- 
cyclopentadienyl, Cp
xph
; tetramethyl(biphenyl)cyclopentadienyl, Cp
xbiph
), Figure 2.1, 
were synthesised and characterised, in which the ligand Cp
xph
H
16
 and the dimer 
[(η5-C5Me5)IrCl2]2 (1),
17
 were prepared according to literature methods.  
 
CpxH
Cp*H CpxphH CpxbiphH
Ir Cl
Cl Ir
Cl
Cl
Cpx
Cpx
dimerCpx
Cpxph
Cpxbiph
2
3
Cp* 1
 
Figure 2.1. Cyclopentadiene ligands and iridium dimers studied in this work. 
 
The derivative Cp
xbiph
H, in which one of the methyls of Cp* is replaced by a 
biphenyl group, has not been previously reported. All the synthesised ligands and 
dimers were fully characterized by 
1
H NMR spectroscopy and CHN elemental 
analysis. 
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2.2.1 Materials 
IrCl3·nH2O, 1,2,3,4,5-pentamethylcyclopentadiene (95%), butyllithium solution 
(1.6 M in hexane), 2,3,4,5-tetramethyl-2-cyclopentenone (95%), and lithium wire 
(99.9%), were purchased from Sigma-Aldrich. 
 
2.2.2 Syntheses 
Cp
xbiph
H. A solution of 4-bromo-biphenyl (5.7 g, 24.5 mmol) in dry THF (100 
mL) was treated with 1.6 M n-BuLi/hexane solution (15.3 mL, 24.5 mmol) at 195 K. 
After stirring at this temperature for 3 h, 2,3,4,5-tetramethyl-2-cyclopentenone (4.1 
g, 29.4 mmol) was added. The reaction mixture was allowed to warm slowly to 
ambient temperature with stirring overnight. The resulting yellow solution was 
acidified with HCl (36%). The organic layer was separated and the aqueous layer 
was further extracted with diethyl ether (20 × 2 mL). The combined organic 
portions were dried over with anhydrous MgSO4, filtered, and the solvents 
evaporated to dryness on a rotary evaporator to afford a light yellow powder. The 
product was recrystallised from chloroform and hexane (3:1). Yield: 2.7 g (40%). 
1
H NMR (CDCl3): δ = 7.64 (m, 4H), 7.44 (m, 2H), 7.33 (m, 3H), 3.25 (m, 1H), 2.08 
(s, 3H), 1.95 (s, 3H), 1.88 (s, 3H), 1.00 (d, 3H, J = 7.5 Hz). Anal. Calcd for C21H22 
(274.40): C, 91.92; H, 8.08. Found: C, 92.56; H, 7.93. 
 
[(η5-C5Me4C6H5)IrCl2]2 (2). A solution of Cp
xph
H (1.7 g, 8.5 mmol) and 
IrCl3·nH2O (1.7 g, 5.7 mmol) in MeOH (60 mL) was heated under reflux in an N2 
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atmosphere for 48 h. The reaction mixture was allowed to cool to ambient 
temperature and the dark green precipitate was filtered off. The volume of the dark 
red filtrate was reduced to ca. 15 mL on a rotary evaporator. Upon cooling to 
ambient temperature, an orange precipitate appeared which was collected by 
filtration. The product was washed with methanol and diethyl ether and dried in air. 
Yield: 1.0 g (39%). 
1
H NMR (CDCl3): δ = 7.58 (m, 2H), 7.35 (m, 3H), 1.72 (s, 6H), 
1.63 (s, 6H). Anal. Calcd for C30H34Ir2N (920.84): C, 39.13; H, 3.72. Found: C, 
39.21; H, 3.66. Crystals suitable for X-ray diffraction were obtained by evaporation 
of a chloroform/hexane solution at ambient temperature.  
 
[(η5-C5Me4C6H4C6H5)IrCl2]2 (3). The synthesis was performed as for 2 using 
Cp
xbiph
H (2.7 g, 9.9 mmol) and IrCl3·nH2O (2.9 g, 9.9 mmol). Yield: 1.7 g (22%). 
1
H NMR (DMSO-d6): δ = 7.70 (m, 4H), 7.46 (m, 2H), 7.35 (m, 3H), 2.02 (s, 3H), 
1.91 (s, 3H), 1.84 (s, 3H), 0.90 (s, 3H). Anal. Calcd for C42H42Cl4Ir2 (1073.03): C, 
47.01; H, 3.95. Found: C, 47.34; H, 4.16. 
 
2.2.3 X-ray Crystal Structure 
The X-ray crystal structure of dimer [(η5-C5Me4C6H5)IrCl2]2 (2) was determined. 
The atom numbering scheme is shown in Figure 2.2. Crystallographic data are 
shown in Table 2.1, and selected bond lengths and angles are listed in Table 2.2. X-
ray crystallographic data for 2 have been deposited in the Cambridge 
Crystallographic Data Centre under the accession number CCDC 802289. 
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In the structure of the Cp
xph
 dimer 2, the chlorides acts as a bridging ligand to a 
symmetry-related molecule across an inversion centre. The Ir−Ir bond distance is 
3.7157(4) Å and the angle between mean planes through the phenyl and the 
cyclopentadienyl groups is 68.21°. The phenyl group is involved in a weak π-π 
interaction with a symmetry-related phenyl group of a neighbouring ligand in the 
unit cell (Figure 2.3). The two interacting π systems are parallel, with a 
centroid−centroid distance of 3.956 Å. The bond distances and angles in [(η5-
C5Me4C6H5)IrCl2]2 (2) compare well to those found for the corresponding Cp* 
analogue [(η5-C5Me5)IrCl2]2 (1).
18
 The Ir–Cl(bridging)–Ir and Cl(bridging)–Ir–
Cl(bridging) angles in 2 are 1.2° more acute and obtuse, respectively, than those of 
the Cp* analogue. 
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Figure 2.2. X-ray crystal structure with atom numbering scheme for [(η5-
C5Me4C6H5)IrCl2]2 (2), with thermal ellipsoids drawn at 50% probability. The 
hydrogen atoms have been omitted for clarity. 
 
3.956
 
Figure 2.3. Diagram showing π-stacking between the phenyl rings of neighbouring 
molecules in the X-ray crystal structure of [(η5-C5Me4C6H5)IrCl2]2 (2). The 
centroid–centroid distance between the phenyl rings of independent molecules is 
3.956 Å. 50% ellipsoids. H atoms have been omitted for clarity. 
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Table 2.1. Crystallographic Data for the Dimer [(η5-C5Me4C6H5)IrCl2]2 (2) 
          2 
formula C30H34Cl14Ir2 
MW 920.77 
cryst colour orange block 
cryst size (mm) 0.20× 0.20 × 0.06 
λ (Å) 0.71073 
temp(K) 100 
cryst syst monoclinic 
space group P2(1)/c 
a (Å) 11.5964(5) 
b (Å) 11.5025(3) 
c (Å) 11.9780(5) 
α (°) 90 
β (°) 115.150(5) 
γ (°) 90 
vol(Å
3
) 1446.24(9) 
Z 2 
R(Fo
2
) 0.0202 
Rw(Fo
2
) 0.0402 
GOF 0.940 
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Table 2.2. Selected Bond Lengths (Å) and Angles (deg) for the Dimer [(η5-
C5Me4C6H5)IrCl2]2 (2) 
     2 
Ir−C(Cp ring)  2.119(3) 
 2.127(3) 
 2.137(3) 
 2.148(3) 
 2.162(3) 
Ir−C(centroid) 1.749 
Ir−Cl(2) 2.4378(8) 
Ir−Cl(2) 2.4411(8) 
Ir−Cl(1) 
Ir−Ir 
 
2.3899(7) 
3.7157(4) Cl(2)−Ir− Cl(2) 80. 79(3) 
Cl(1)−Ir−Cl(2) 86.79(3) 
Cl(1)−Ir−Cl(2) 88.52(3) 
Ir−Cl(2)−Ir 99.21(3) 
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3.1 Introduction 
The clinical success of cisplatin, carboplatin and oxaliplatin
1,2
 has stimulated the 
search for other transition metal complexes which possess anticancer activity. New 
metal-based anticancer drugs may be able to widen the spectrum of treatable 
cancers, reduce toxic side-effects, and overcome platinum resistance. Interest in 
bio-organometallic chemistry and the design of organometallic complexes as 
anticancer agents is currently increasing.
3-8
 Carbon-bound arenes and 
cyclopentadienyl ligands can provide control of the hydrophilicity and 
hydrophobicity of the faces of the coordination complex (which influences cell 
uptake and targeting).
9-11
 Most metallodrugs are prodrugs and control over ligand 
substitution is vital if the complex is to reach and react with its target site. In this 
respect octahedral low-spin d
6
 complexes are attractive for drug design since they 
are often kinetically inert. Inertness increases from 1
st
 to 2
nd
 to 3
rd
 row of transition 
metals.
12,13
 The lifetime for exchange of an aqua ligand on [Ir(H2O)6]
3+
, for example, 
is about 300 years!
14,15
 There are only a limited number of reported studies on the 
biological activity of iridium complexes. Early studies were concerned with non-
organometallic Ir
I
 and Ir
III
 complexes,
16-20
 and more recently a few studies of 
organometallic Ir
III
 complexes have been reported.
21-31
 Iridium(III) complexes are 
generally thought to be too inert to possess high reactivity. Indeed, the inertness of 
Ir
III 
has allowed the design of complexes which function as rigid scaffolds and 
inhibit kinase enzymes, for example.
32
 The biological inactivity of trans-
[IrCl4(DMSO)(Im)][ImH]
33
 and trans-[IrCl4(Im)2][ImH] (ImH = imidazole),
34
 Ir
III
 
analogs of the Ru
III
 anticancer drugs NAMI-A and the imidazole analogue of the 
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indazole complex KP1019, respectively, has been attributed to the kinetic inertness 
of Ir
III
.  
Organometallic Ru
II
 and Os
II
 arene anticancer complexes of the type [(η6-
arene)(Ru/Os)(NN)Cl]
+
, where NN is a chelating diamine ligand, can be activated 
by hydrolysis of the Ru/Os–Cl bond, followed by binding to DNA.35,36 The arene is 
important in determining the anticancer activity and nature of the DNA distortions. 
In particular when the arene has an extended ring system (e.g. biphenyl or 
tetrahydroanthracene) direct binding to DNA bases (largely guanine) can be 
accompanied by arene intercalation between the bases.
37,38
  
Neutral arene ligands do not stabilise Ir
III
. In contrast, negatively-charged 
pentamethylcyclopentadienyl (Cp*) is an excellent stabilising ligand for Ir
III
. In this 
Chapter the design concepts discovered for Ru
II
 and Os
II
 arene complexes was 
applied to Ir
III
 Cp* and functionalized Cp* complexes [(η5-Cpx)Ir(XY)Cl]0/+ 
containing N,N- or N,O-bound chelating ligands. Iridium(III) Cp* complexes have 
attracted recent attention as catalysts, for example in hydrogen transfer reactions.
39
 
Only a few iridium complexes containing functionalized Cp* ligands have been 
reported previously.
40-43
 The effect of Cp* functionalization on the rate of 
hydrolysis, acidity of the aqua adducts, interactions with nucleobases, 
hydrophobicity (octanol/water partition), cell accumulation (the net effect of uptake 
and efflux) and distribution, interaction with DNA, and cytotoxicity to cancer cells 
have been studied in this Chapter. It is found that such complexes can be 
thermodynamically stable and yet kinetically labile towards substitution reactions 
and that substituents on the cyclopentadienyl ring and chelating ligand can have a 
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dramatic effect on chemical and biological activity. This appears to be the first time 
that tetramethyl(phenyl)cyclopentadienyl (Cp
xph
) and tetramethyl(biphenyl)cyclo- 
pentadienyl (Cp
xbiph
) have been used as ligands in iridium complexes. 
 
3.2 Experimental Section 
3.2.1 Materials  
9-Ethylguanine (9-EtG), 9-ethyladenine (9-EtA), 1,10-phenanthroline 
monohydrate (phen), 2,2′-bipyridine (bpy), ethylenediamine (en), 2-picolinic acid 
(pico), octan-1-ol (≥99%), 1,10-phenanthroline-5-amine (phen-5-amine), 2,2′-
bipyridine-3,3′-diol (bpy(OH)2), 4,4′-dimethyl-2,2′-bipyridine (bpy-Me2), 4-(2-
pyridylazo)-N,N-dimethylaniline (azpy-NMe2), ammonium hexafluorophosphate 
and NaCl (>99.999%, used in the log P experiment) were purchased from Sigma-
Aldrich. Cisplatin and transplatin were obtained from Sigma (Prague, Czech 
Republic). Ligand p-dimethylaminophenyliminopyridine (impy-NMe2) was kindly 
provided by Ying Fu in our group. [Pt(dien)Cl]Cl (dien = diethylenetriamine) was a 
kind gift of Prof. Giovanni Natile (University of Bari, Italy). Ethylenediamine was 
distilled over sodium prior to use. Methanol was distilled over magnesium/iodine 
prior to use. The syntheses of dimer [(η5-C5Me4C6H5)IrCl2]2 (2) and [(η
5
-
C5Me4C6H4C6H5)IrCl2]2 (3) is described in Chapter 2. Dimer [(η
5
-C5Me5)IrCl2]2 
(1),
44
 ligands dipyrido[3,2-f:2′,3′-h]quinoxaline (dpq) and dipyrido[3,2-a:2′,3′-
c]phenazine (dppz),
45,46
 and complexes [(η5-C5Me5)Ir(phen)Cl]Cl (4·Cl),
47
 [(η5-
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C5Me5)Ir(bpy)Cl]Cl (7·Cl),
47
 and [(η5-C5Me5)Ir(pico)Cl] (12),
48
 were prepared 
according to literature methods. 
 
3.2.2 Syntheses 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6 (5·PF6). A solution of [(η
5
-C5Me4C6H5)IrCl2]2 
(45 mg, 0.05 mmol), 1,10-phenanthroline monohydrate (24.3 mg, 0.12 mmol) in 
MeOH (40 mL) was heated under reflux in an N2 atmosphere for 10 h and filtered. 
The volume was slowly reduced to half on a rotary evaporator and NH4PF6 (45 mg, 
0.28 mmol) was added. After standing at 277 K, a microcrystalline product formed. 
This was collected by filtration, washed with diethyl ether, and recrystallised from 
methanol/diethyl ether. Yield: 27 mg (37%). 
1
H NMR (DMSO-d6): δ = 9.08 (d, 2H, 
J = 5.3 Hz), 8.99 (d, 2H, J = 8.5 Hz), 8.39 (s, 2H), 8.19 (dd, 2H, J = 5.3, 5.5 Hz), 
7.56 (m, 5H), 1.84 (s, 6H), 1.73 (s, 6H). Anal. Calcd for C27H25ClF6IrN2P (750.16): 
C, 43.23; H, 3.36; N, 3.73. Found: C, 43.01; H, 3.31; N, 3.86. Crystals suitable for 
X-ray diffraction were obtained by slow evaporation of a methanol/diethyl ether 
solution at ambient temperature. 
 
[(η5-C5Me4C6H4C6H5)Ir(phen)Cl]PF6 (6·PF6). The synthesis was performed as 
for 5·PF6 using [(η
5
-C5Me4C6H4C6H5)IrCl2]2 (50 mg, 0.05 mmol) and 1,10-
phenanthroline monohydrate (24.3 mg, 0.12 mmol). Yield: 15 mg (23%). 
1
H NMR 
(CDCl3): δ = 9.16 (d, 2H, J = 5.5 Hz), 8.78 (d, 2H, J = 8.3 Hz), 8.22 (s, 2H), 8.17 
(dd, 2H, J = 5.3, 5.5 Hz), 7.76 (d, 2H, J = 8.3 Hz), 7.60 (d, 2H, J = 7.5 Hz), 7.45 (d, 
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2H, J = 8.3 Hz), 7.52 (t, 2H, J = 7.3 Hz), 7.44 (t, 1H, J = 7.3 Hz), 2.05 (s, 6H), 1.85 
(s, 6H). Anal. Calcd for C33H29Cl2F6IrN2P (826.23): C, 47.97; H, 3.54; N, 3.39. 
Found: C, 47.61; H, 3.63; N, 3.52. 
 
[(η5-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6). A solution of [(η
5
-C5Me4C6H5)IrCl2]2 
(2) (45 mg, 0.05 mmol), 2,2′-bipyridine (18.7 mg, 0.12 mmol) in MeOH (40 mL) 
was heated under reflux in an N2 atmosphere for 16 h and filtered. The volume was 
slowly reduced to half on a rotary evaporator and NH4PF6 (45 mg, 0.28 mmol) was 
added. After standing at 277 K, the mixture formed a microcrystalline product. This 
was collected by filtration, washed with diethyl ether, and recrystallised from 
methanol/diethyl ether. Yield: 57 mg (73%). 
1
H NMR (DMSO-d6): δ = 8.84 (d, 2H, 
J = 8.2 Hz), 8.71 (d, 2H, J = 5.4 Hz), 8.35 (t, 2H, J = 7.5 Hz), 7.81 (t, 2H, J = 7.5 
Hz), 7.50 (m, 5H), 1.77 (s, 6H), 1.67 (s, 6H). Anal. Calcd for C25H25ClN2IrPF6 
(726.10): C, 41.35; H, 3.47; N, 3.86. Found: C, 40.85; H, 3.35; N, 3.83. Crystals 
suitable for X-ray diffraction were obtained by slow evaporation of a 
methanol/diethyl ether solution at ambient temperature. 
 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6). The synthesis was performed as 
for 8·PF6 using [(η
5
-C5Me4C6H4C6H5)IrCl2]2 (3) (50 mg, 0.05 mmol) and 2,2′-
bipyridine (18.7 mg, 0.12 mmol). Yield: 43 mg (58%). 
1
H NMR (DMSO-d6): δ = 
8.81 (d, 2H, J = 8.0 Hz), 8.74 (d, 2H, J = 6.0 Hz), 8.35 (t, 2H, J = 7.8 Hz), 7.82 
(overlapped m, 4H), 7.75 (d, 2H, J = 8.0 Hz), 7.60 (d, 2H, J = 8.0 Hz), 7.50 (t, 2H, J 
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= 7.8 Hz), 7.42 (t, 1H, J = 7.3 Hz), 1.78 (s, 6H), 1.72 (s, 6H). Anal. Calcd for 
C31H29ClF6IrN2P (802.21): C, 46.41; H, 3.64; N, 3.49. Found: C, 45.85; H, 3.55; N, 
3.63. Crystals suitable for X-ray diffraction were obtained by slow evaporation of a 
methanol/diethyl ether solution at ambient temperature. 
 
[(η5-C5Me5)Ir(en)Cl]PF6 (10·PF6). [(η
5
-C5Me5)IrCl2]2 (50 mg, 0.06 mmol) was 
suspended in dry methanol (15 mL), and ethylenediamine (9.0 mg, 0.15 mmol) was 
added in one portion. The mixture was stirred for 1 h at ambient temperature and 
filtered. The volume of solvent was slowly reduced to half on a rotary evaporator 
and NH4PF6 (102.2 mg, 0.63 mmol) was added. After standing at 277 K, a 
microcrystalline product was formed. This was collected by filtration, washed with 
diethyl ether, and recrystallised from methanol/diethyl ether. Yield: 39.9 mg (56%). 
1
H NMR (DMSO-d6): δ = 5.70 (b, 2H), 4.86 (b, 2H), 2.54 (b, 2H), 2.28 (b, 2H), 
1.68 (s, 15H). Anal. Calcd for C12H23ClF6IrN2P (568.08): C, 25.38; H, 4.08; N, 4.93. 
Found: C, 25.07; H, 3.89; N, 4.99.  
 
[(η5-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4). The synthesis was performed as for 
10·PF6, using [(η
5
-C5Me4C6H5)IrCl2]2 (45 mg, 0.05 mmol), ethylenediamine (9.0 
mg, 0.15 mmol), and NH4BPh4 (102.3 mg, 0.30 mmol). Yield: 19.9 mg (23%). 
1
H 
NMR (DMSO-d6): δ = 7.38 (m, 2H), 7.33 (m, 3H), 7.24 (b, 8H), 6.89 (t, 8H, J = 7.3 
Hz), 6.75 (t, 4H, J = 7.3 Hz ), 5.75 (b, 2H), 4.64 (b, 2H), 2.64 (b, 2H), 2.35 (b, 2H), 
1.77 (s, 6H), 1.65 (s, 6H). Anal. Calcd for C41H45BClIrN2 (804.29): C, 61.65; H, 
Chapter 3: Cyclopentadienyl Iridium Complexes Containing N,N- or N,O-Chelating Ligands  
 
 
63 
5.74; N, 3.44. Found: C, 61.76; H, 5.89; N, 3.39. Crystals suitable for X-ray 
diffraction were obtained by slow evaporation of a methanol/diethyl ether solution 
at ambient temperature. 
 
[(η5-C5Me4C6H5)Ir(pico)Cl] (13). A solution of [(η
5
-C5Me4C6H5)IrCl2]2 (45 mg, 
0.05 mmol), 2-picolinic acid (16.7 mg, 0.13 mmol) and sodium methoxide (7.3 mg, 
0.13 mmol) in MeOH (50 mL) was refluxed under N2 atmosphere for 3 h and 
filtered. The solvent was removed in vacuo, the product extracted with CH2Cl2 (10 
mL), and the volume was reduced to ca. 0.5 mL on a rotary evaporator. A yellow 
precipitate formed at 253 K on addition of diethyl ether and was collected by 
filtration, washed with diethyl ether, and dried in air. Yield: 25.4 mg (43%). 
1
H 
NMR (DMSO-d6): δ = 8.65 (d, 1H, J = 4.5 Hz), 8.15 (t, 1H, J = 8.3 Hz), 7.93 (d, 1H, 
J = 7.8 Hz), 7.81 (t, 1H, J = 7.0 Hz), 7.52 (m, 5H), 1.74 (s, 6H), 1.64 (s, 6H). Anal. 
Calcd for C21H21ClIrNO2 (547.09): C, 46.10; H, 3.87; N, 2.56. Found: C, 45.89; H, 
3.65; N, 2.73. Crystals suitable for X-ray diffraction were obtained by slow 
evaporation of a methanol/diethyl ether solution at ambient temperature. 
 
[(η5-C5Me4C6H4C6H5)Ir(pico)Cl] (14). The synthesis was performed as for 13 
using [(η5-C5Me4C6H4C6H5)IrCl2]2 (50 mg, 0.05 mmol), picolinic acid (12.3 mg, 
0.10 mmol) and sodium methoxide (5.4 mg, 0.10 mmol). Yield: 22 mg (37%). 
1
H 
NMR (DMSO-d6): δ = 8.70 (d, 1H, J = 5.7 Hz), 8.16 (t, 1H, J = 7.8 Hz), 7.97 (d, 1H, 
J = 8.0 Hz), 7.77 (t, 1H, J = 6.5 Hz), 7.72 (m, 4H), 7.64 (d, 2H, J = 8.3 Hz), 7.48 (t, 
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2H, J = 7.3 Hz), 7.39 (t, 1H, J = 7.3 Hz), 1.74 (d, 6H, J = 7.3 Hz), 1.69 (s, 3H), 1.65 
(s, 3H). Anal. Calcd for C27H25ClIrNO2 (623.16): C, 52.04; H, 4.04; N, 2.25. Found: 
C, 52.09; H, 4.15; N, 2.33. 
 
[(η5-C5Me5)Ir(phen-5-amine)Cl]PF6 (15·PF6). To a suspension of [(η
5
-
C5Me5)IrCl2]2 (50 mg, 0.06 mmol) in dry, freshly distilled methanol (25 ml), 1,10-
phenanthroline-5-amine, (25.4 mg, 0.13 mmol) was added. The reaction mixture 
was stirred at ambient temperature overnight. The volume was slowly reduced to 
half on a rotary evaporator and NH4PF6 (45 mg, 0.28 mmol) was added. After 
standing at 277 K, the mixture formed a microcrystalline product. This was 
collected by filtration, washed with diethyl ether, and recrystallised from 
acetone/pertroleum ether. Yield: 55.9 mg (71.0%). 
1
H NMR (DMSO-d6): δ = 9.33 
(d, 1H, J = 5.0 Hz), 8.96 (d, 1H, J = 8.5 Hz), 8.92 (d, 1H, J = 7.5 Hz), 8.33 (d, 1H, J 
= 8.5 Hz), 8.06 (dd, 1H, J = 5.3 Hz), 7.82 (dd, 1H, J = 5.0 Hz), 7.12 (s, 1H), 1.68 (s, 
15H). Anal. Calcd for C22H24ClF6IrN3P (703.09): C, 37.58; H, 3.44; N, 5.98. Found: 
C, 37.23; H, 3.50; N, 5.73. 
 
[(η5-C5Me5)Ir(bpy(Me)2)Cl]PF6 (16·PF6). The synthesis was performed as for 
5·PF6 using [(η
5
-C5Me5)IrCl2]2 (50 mg, 0.06 mmol), 4,4′-dimethyl-2,2′-bipyridine 
(24.0 mg, 0.13 mmol). Yield: 58 mg (67%). 
1
H NMR (DMSO-d6): δ = 8. 82 (d, 2H, 
J = 5.7 Hz), 8.68 (s, 2H), 7.68 (d, 2H, J = 5.7 Hz), 2.62 (s, 6H), 1.64 (s, 15H). Anal. 
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Calcd for C22H27ClN2IrPF6 (688.20): C, 38.18; H, 3.93; N, 4.05. Found: C, 38.24; H, 
3.95; N, 3.98. 
 
[(η5-C5Me4C6H5)Ir(bpy(Me)2)Cl]PF6 (17·PF6). The synthesis was performed as 
for 5·PF6 using [(η
5
-C5Me4C6H5)IrCl2]2 (45 mg, 0.05 mmol), 4,4′-dimethyl-2,2′- 
bipyridine (20.2 mg, 0.11 mmol). Yield: 45.2 mg (60%). 
1
H NMR (DMSO-d6): δ = 
8.66 (s, 2H), 8.51 (d, 2H, J = 5.7 Hz), 7.62 (d, 2H, J = 5.7 Hz), 7.46 (m, 5H), 2.60 
(s, 6H), 1.76 (s, 6H), 1.66 (s, 6H). Anal. Calcd for C27H29ClN2IrPF6 (754.17): C, 
43.00; H, 3.88; N, 3.71. Found: C, 43.21; H, 3.95; N, 3.68. Crystals suitable for X-
ray diffraction were obtained by slow evaporation of a methanol/diethyl ether 
solution at ambient temperature. 
 
[(η5-C5Me4C6H4C6H5)Ir(bpy(Me)2)Cl]PF6 (18·PF6). The synthesis was 
performed as for 5·PF6 using [(η
5
-C5Me4C6H4C6H5)IrCl2]2 (50 mg, 0.05 mmol), 
4,4′-dimethyl-2,2′-bipyridine (18.4 mg, 0.10 mmol). Yield: 39 mg (51%). 1H NMR 
(DMSO-d6): δ = 8.67 (s, 2H), 8.31 (d, 2H, J = 6.0 Hz), 7.79 (d, 2H, J = 8.5 Hz), 
7.75 (d, 2H, J = 6.5 Hz), 7.65 (d, 2H, J = 5.7 Hz), 7.57 (d, 2H, J = 8.3 Hz), 7.50 (t, 
2H, J = 7.8 Hz), 7.42 (t, 1H, J = 7.6 Hz), 2.60 (s, 6H), 1.77 (s, 6H), 1.71 (s, 6H). 
Anal. Calcd for C33H33ClN2IrPF6 (830.26): C, 47.74; H, 4.01; N, 3.37. Found: C, 
47.26; H, 4.03; N, 3.43. 
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[(η5-C5Me5)Ir(bpy(OH)O)Cl] (19). To a suspension of [(η
5
-C5Me5)IrCl2]2 (50 
mg, 0.06 mmol) in dry, freshly distilled methanol (25 ml), 2,2′-bipyridine-3,3′-diol 
(24.5 mg, 0.13 mmol) was added. The reaction mixture was stirred at ambient 
temperature overnight, filtered and the volume was reduced until the onset of 
precipitation. It was kept at 277 K for 24 h to allow further precipitation to occur. 
The fine yellow solid was collected by filtration, washed with methanol followed by 
ether, and dried in vacuum. It was recrystallised from methanol/ether. Yield: 33.6 
mg (51.0%). 
1
H NMR (DMSO-d6): δ = 8.06 (d, 2H, J = 5.3 Hz), 7.28 (dd, 2H, J = 
8.3 Hz), 7.06 (d, 2H, J = 8.3 Hz), 1.54 (s, 15H). Anal. Calcd for C20H22ClN2O2Ir 
(550.07): C, 43.67; H, 4.03; N, 5.09. Found: C, 42.99; H, 4.15; N, 5.33. Crystals 
suitable for X-ray diffraction were obtained by slow evaporation of a 
methanol/diethyl ether solution at ambient temperature. 
 
[(η5-C5Me4C6H5)Ir(bpy(OH)O)Cl] (20). The synthesis was performed as for 19 
using [(η5-C5Me4C6H5)IrCl2]2 (45 mg, 0.05 mmol), 2,2′-bipyridine-3,3′-diol (18.8 
mg, 0.10 mmol). Yield: 34 mg (55%). 
1
H NMR (CDCl3): δ = 7.81 (d, 2H, J = 5.5 
Hz), 7.46 (m, 5H), 7.15 (d, 2H, J = 8.5 Hz), 6.99 (dd, 2H, J = 8.5 Hz), 1.64 (s, 12H). 
Anal. Calcd for C25H24ClN2O2Ir (612.12): C, 49.05; H, 3.95; N, 4.58. Found: C, 
48.77; H, 4.03; N, 4.43. 
 
[(η5-C5Me4C6H4C6H5)Ir(bpy(OH)O)Cl] (21). The synthesis was performed as 
for 19 using [(η5-C5Me4C6H4C6H5)IrCl2]2 (50 mg, 0.05 mmol), 2,2′-bipyridine- 3,3′- 
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diol (18.8 mg, 0.10 mmol). Yield: 30.7 mg (47%). 
1
H NMR (MeOD-d4): δ = 8.08 
(d, 2H, J = 7.3 Hz), 7.73 (d, 2H, J = 7.3 Hz), 7.68 (d, 2H, J = 7.9 Hz), 7.59 (d, 2H, J 
= 7.9 Hz), 7.47 (t, 2H, J = 7.3 Hz), 7.41 (t, 1H, J = 7.9 Hz), 7.20 (m, 4H), 1.73 (s, 
6H), 1.69 (s, 6H). Anal. Calcd for C31H29ClN2O2Ir (688.20): C, 54.1; H, 4.1; N, 
4.07. Found: C, 53.99; H, 4.25; N, 3.98. Crystals suitable for X-ray diffraction were 
obtained by slow evaporation of a methanol/diethyl ether solution at ambient 
temperature. 
 
[(η5-C5Me4C6H5)Ir(dpq)Cl]PF6 (22·PF6). A solution of [(η
5
-C5Me4C6H5)IrCl2]2 
(45 mg, 0.05 mmol) and ligand dipyrido[3,2-f:2′,3′-h]quinoxaline (dpq, 23 mg, 0.10 
mmol) in MeOH (40 mL) was refluxed under N2 atmosphere for 2 h and filtered. 
The volume was slowly reduced to half on a rotary evaporator and NH4PF6 (45 mg, 
0.28 mmol) was added. After standing at 277 K, a microcrystalline product formed. 
This was collected by filtration, washed with diethyl ether, and recrystallised from 
methanol/diethyl ether. Yield: 44 mg (55%). 
1
H NMR(CDCl3): δ = 9.68 (d, 2H, J = 
8.5 Hz), 9.13 (s, 2H), 8.96 (d, 2H, J = 6.0 Hz), 8.06 (dd, 2H, J = 8.0 Hz), 7.72 (m, 
2H), 7.59 (m, 3H), 1.91 (s, 6H), 1.83 (s, 6H). Anal. Calcd for C29H25ClF6IrN4P 
(802.10): C, 43.42; H, 3.14; N, 6.98. Found: C, 43.21; H, 3.21; N, 6.86. 
 
[(η5-C5Me4C6H5)Ir(dppz)Cl]Cl (23·Cl). A solution of [(η
5
-C5Me4C6H5)IrCl2]2 
(45 mg, 0.05 mmol) and ligand dipyrido[3,2-a:2′,3′-c]phenazine (dppz, 28 mg, 0.10 
mmol) in MeOH (40 mL) was refluxed under N2 atmosphere for 2 h and filtered. 
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The volume was slowly reduced to 2 mL on a rotary evaporator. After standing at 
277 K, a microcrystalline product formed. This was collected by filtration, washed 
with diethyl ether, and recrystallised from methanol/diethyl ether. Yield: 45 mg 
(60%). 
1
H NMR(DMSO-d6): δ = 9.79 (d, 2H, J = 8.3 Hz), 9.15 (d, 2H, J = 6.0 Hz), 
8.52 (dd, 2H, J = 6.3 Hz), 8.31 (dd, 2H, J = 7.8 Hz), 8.21 (dd, 2H, J = 6.5 Hz), 7.54 
(m, 2H), 7.51 (m, 3H), 1.87 (s, 6H), 1.76 (s, 6H). Anal. Calcd for C33H27Cl2IrN4 
(742.12): C, 53.37; H, 3.66; N, 7.54. Found: C, 53.14; H, 3.61; N, 7.60. 
 
[(η5-C5Me4C6H4C6H5)Ir(dpq)Cl]Cl (24·Cl). The synthesis was performed as for 
23 using [(η5-C5Me4C6H4C6H5)IrCl2]2 (50 mg, 0.05 mmol) and ligand dipyrido[3,2-
f:2′,3′-h]quinoxaline (dpq, 23 mg, 0.10 mmol). Yield: 33 mg (43%). 1H 
NMR(MeOD-d4): δ = 9.82 (d, 2H, J = 8.3 Hz), 9.30 (s, 2H), 9.24 (d, 2H, J = 6.0 
Hz), 8.28 (dd, 2H, J = 8.0 Hz), 7.83 (m, 2H), 7.76 (m, 4H), 7.52 (t, 2H, J = 7.3 Hz), 
7.44 (t, 1H, J = 7.3 Hz), 1.97 (s, 6H), 1.90 (s, 6H). Anal. Calcd for C35H29Cl2IrN4 
(768.14): C, 54.68; H, 3.80; N, 7.29. Found: C, 54.29; H, 3.71; N, 7.34. 
 
[(η5-C5Me4C6H4C6H5)Ir(dppz)Cl]Cl (25·Cl). The synthesis was performed as 
for 23 using [(η5-C5Me4C6H4C6H5)IrCl2]2 (50 mg, 0.05 mmol) and ligand 
dipyrido[3,2-a:2′,3′-c]phenazine (dppz, 28 mg, 0.10 mmol). Yield: 37 mg (45%). 
1
H 
NMR(MeOD-d4): δ = 9. 90 (d, 2H, J = 8.3 Hz), 9.19 (d, 2H, J = 6.0 Hz), 8.50 (dd, 
2H, J = 6.3 Hz), 8.26 (dd, 2H, J = 7.6 Hz), 8.15 (dd, 2H, J = 6.7 Hz), 7.81 (m, 2H), 
7.77 (m, 4H), 7.50 (t, 2H, J = 7.6 Hz), 7.41 (t, 1H, J = 7.6 Hz), 1.95 (s, 6H), 1.89 (s, 
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6H). Anal. Calcd for C39H21Cl2IrN4 (818.16): C, 57.21; H, 3.82; N, 6.84. Found: C, 
56.86; H, 3.69; N, 6.76. 
 
[(η5-C5Me5)Ir(azpy-NMe2)Cl]PF6 (26·PF6). A solution of [(η
5
-C5Me5)IrCl2]2 (50 
mg, 0.06 mmol), and ligand 4-(2-pyridylazo)-N,N-dimethylaniline (azpy-NMe2, 27 
mg, 0.12 mmol) in MeOH (20 mL) was stirred for 12 h at ambient temperature. The 
volume was slowly reduced to half on a rotary evaporator and NH4PF6 (45 mg, 0.28 
mmol) was added. After standing at 277 K, a microcrystalline product formed. This 
was collected by filtration, washed with diethyl ether, and recrystallised from 
methanol/diethyl ether. Yield: 68 mg (77%). 
1
H NMR (DMSO-d6): δ = 8.82 (d, 1H, 
J = 6.0 Hz), 8.51 (d, 1H, J = 8.5 Hz), 8.28 (t, 1H, J = 7.0 Hz), 8.02 (m, 2H), 7.76 (t, 
1H, J = 6.7 Hz), 7.02 (m, 2H), 3.31 (s, 6H), 1.55 (s, 15H). Anal. Calcd for 
C23H29ClF6IrN4P (734.14): C, 37.63; H, 3.98; N, 7.63. Found: C, 37.41; H, 4.01; N, 
7.76. 
 
[(η5-C5Me4C6H5)Ir(azpy-NMe2)Cl]PF6 (27·PF6). The synthesis was performed 
as for 26·PF6 using [(η
5
-C5Me4C6H5)IrCl2]2 (45 mg, 0.05 mmol), azpy-NMe2 (23 
mg, 0.10 mmol). Yield: 56 mg (70%). 
1
H NMR (CDCl3): δ = 8.34 (d, 1H, J = 8.0 
Hz), 8.25 (d, 1H, J = 5.5 Hz), 8.11 (m, 2H), 8.03 (t, 1H, J = 8.0 Hz), 7.47 (m, 5H), 
7.13 (t, 1H, J = 7.0 Hz), 6.65 (m, 2H), 3.31 (s, 6H), 1.75 (s, 3H), 1.69 (s, 3H), 1.65 
(s, 3H), 1.49 (s, 3H). Anal. Calcd for C28H31ClF6IrN4P (796.15): C, 42.24; H, 3.92; 
N, 7.04. Found: C, 42.32; H, 3.91; N, 7.16. 
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[(η5-C5Me4C6H5)Ir(impy-NMe2)Cl]PF6 (28·PF6). The synthesis was performed 
as for 26·PF6 using [(η
5
-C5Me4C6H5)IrCl2]2 (45 mg, 0.05 mmol), p-
dimethylaminophenyliminopyridine (impy-NMe2, 23 mg, 0.10 mmol). Yield: 60 mg 
(75%). 
1
H NMR (CDCl3): δ = 8.77 (s, 1H), δ = 8.21 (dd, 2H, J = 10.0 Hz), 7.98 (t, 
1H, J = 8.2 Hz), 7.68 (d, 2H, 8.5 Hz), 7.52 (m, 5H), 7.38 (t, 1H, J = 7.0 Hz), 6.71 (d, 
2H, 8.7 Hz), 3.36 (s, 6H), 1.80 (s, 3H), 1.55 (s, 3H), 1.46 (s, 3H), 1.39 (s, 3H). Anal. 
Calcd for C29H32ClF6IrN3P (795.22): C, 43.83; H, 4.06; N, 5.28. Found: C, 43.75; H, 
3.97; N, 5.26. 
 
3.2.3 Methods  
3.2.3.1   X-ray Crystallography 
The details of the diffraction instrumentation are described in Chapter 2. The 
structures of complexes 2, 5·PF6, 8·PF6, 9·PF6, 11·BPh4, 13, 17·PF6, 19 and 21 were 
solved by Dr. Guy Clarkson (Department of Chemistry, University of Warwick) 
using SHELXS (TREF)
49
 with additional light atoms found by Fourier methods. 
Complexes were refined against F
2
 using SHELXL,
50
 and hydrogen atoms were 
added at calculated positions and refined riding on their parent atoms. X-ray 
crystallographic data for complexes 5·PF6, 8·PF6, 9·PF6, 11·BPh4 and 13 have been 
deposited in the Cambridge Crystallographic Data Centre under the accession 
numbers CCDC 802288, 802287, 802291, 802290, and 802286, respectively. 
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3.2.3.2   Kinetics of Hydrolysis  
Solutions of complexes 4–10 and 12–14 with final concentrations of 0.2–0.7 mM 
in 5% MeOD-d4/95% D2O (v/v) were prepared by dissolution of the complexes in 
MeOD-d4 followed by rapid dilution with D2O. 
1
H NMR spectra were recorded 
after various time intervals. The rates of hydrolysis were determined by fitting plots 
of concentrations (determined from 
1
H NMR peak integrals) versus time to a first-
order rate equation using ORIGIN version 8.0. The hydrolysis of complexes 4, 7, 10, 
12, 13 and 14 was monitored by 
1
H NMR at 278 K (to slow down the rate and avoid 
freezing the samples), and for complexes 5, 6, 8 and 9 at 278, 283, 288 and 293 K. 
The Arrhenius equation ln(k) = ln(A) – Ea/RT was used to calculate the hydrolysis 
rate constants and half-lives of 5, 6, 8 and 9 at 310 K.  
 
3.2.3.3   Determination of pKa Values 
The pKa* and pKa values of complexes 4A−10A, and 12A−14A were determined 
from the pH* titration curves as described in Chapter 2. 
 
3.2.3.4   Computation 
Details of computational methods are described in Chapter 2. Geometry 
optimization calculations for complexes 4–14 were performed in the gas phase with 
the gradient-corrected correlation functional PBE0.
51
 Electrostatic potential surfaces 
(EPS) for chlorido complexes 4–6, 12–14, and aqua complexes 6A, 14A were 
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calculated and mapped on electron density (isovalue 0.004) of the molecules. The 
electrostatic potential is represented with a colour scale ranging from red (–0.100 au) 
to blue (0.150 au). This work was carried out by Dr. Luca Salassa (Department of 
Chemistry, University of Warwick). 
 
3.2.3.5   Interactions with Nucleobases 
The reaction of chloride complexes 4–14 and aqua complex 5A (ca. 1 mM) with 
nucleobases typically involved addition of a solution containing one mol equiv of 
nucleobase in D2O to an equilibrium solution of complexes 4–14 in 5% MeOD-
d4/95% D2O (v/v), or to a solution of the aqua complex 5A (prepared by the 
addition of 1 mol equiv of AgNO3 to a solution of 5 and removal of AgCl by 
filtration). 
1
H NMR spectra of these solutions were recorded at 310 K after various 
time intervals. 
 
3.2.3.6   Cytotoxicity 
Cytotoxicity assays on A2780 human ovarian cancer cell line were performed by 
Dr. Ana M. Pizarro (Department of Chemistry, University of Warwick) as described 
in Chapter 2 for complexes 4–14, 16–24, 26 and 27. Complexes 5·PF6, 6·PF6 and 
9·PF6 were further evaluated by the NCI/DTP as described in Chapter 2 for in vitro 
cytotoxic test against ca. 60 human cancer cell lines.  
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3.2.3.7   log P Determination 
The partition coefficients (log P) were determined for complexes 4–6 by Dr. Ana 
M. Pizarro and Sally A. Fletcher (Department of Chemistry, University of Warwick) 
as described in Chapter 2. 
 
3.2.3.8   Cell Accumulation, Cellular Distribution, and DNA Binding in A2780 
Human Ovarian Cancer Cells 
Work in this section was performed by Dr. Ana M. Pizarro and Sally A. Fletcher 
(Department of Chemistry, University of Warwick). A2780 cells were plated at a 
density of 5×10
6
 cells/100 mm Petri dish in 9 mL of culture medium on day 1 (three 
dishes were prepared per compound tested, and three untreated control dishes, in 
two independent experiments). On day 2 cells were exposed to the Ir
III
 complexes 
46. Stock solutions of the iridium compounds were prepared fresh in DMSO and 
diluted in 0.9% saline and medium (1:1; 0.5% v/v DMSO final concentration) to a 
final concentration of Ir on the plates of 5 μM. After 24 h of drug exposure at 310 K 
on a 5% CO2 incubator, the drug-containing medium was removed and the cells 
were washed, trypsinized, and counted using a haemocytometer. One-third of the 
cells was centrifuged, quickly washed with PBS, and stored at 253 K for 
determination of total cell accumulation (the net effect of uptake and efflux) of 
iridium. Another third of the samples was used for cytosol, nucleus, 
membrane/particulate and cytoskeleton fractionation, using a FractionPREP™ cell 
fractionation kit from BioVision (Mountain View, CA). The last third of the 
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samples was used for quantification of Ir bound to DNA using the Nucleon genomic 
DNA extraction kit (GE healthcare, Amersham, UK; BACC-1 protocol). All the cell 
pellets and solid cell fractions were digested in freshly distilled 72% HNO3 in 
Wheaton V-Vials with a PTFE-faced rubber lined cap (Sigma-Aldrich) for 16 h at 
373 K. After cooling, the samples were diluted with DDW to a maximum final 
concentration of 7.2% HNO3 (suitable for ICP-MS analysis) prior quantification of 
iridium. 
 
3.2.3.9   Sequence Preference of DNA Adducts 
Works in this section was performed by Prof. Viktor Brabec and colleagues 
(Institute of Biophysics, Academy of Sciences of the Czech Republic). The primer 
extension footprinting assay was used to evaluate the sequence selectivity of DNA 
modification by complexes 4–6. A fragment of pSP73KB DNA linearised by HpaI 
(2464 bp) was incubated with Ir
III
 complexes in 10 mM NaClO4 for 24 h at 310 K to 
obtain rb = 0.01 (bound Ir/base). The excess of drug was removed by ethanol 
precipitation. Circum VentTM Thermal Cycle Sequencing Kit with Vent(exo
-
) 
DNA polymerase was used along with the protocol for thermal cycle DNA 
sequencing with 5′ end-labeled 20-mer SP6 primer recommended by the 
manufacturer with small modifications.
52
 The synthesis products were separated by 
electrophoresis on a denaturing polyacrylamide (PAA) gel [6% polyacrylamide 
(PAA)/8M urea]; sequence ladders were obtained in parallel using untreated control 
DNA fragment. 
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3.2.3.10   Fluorescence Measurements 
This work was performed by Prof. Viktor Brabec and colleagues (Institute of 
Biophysics, Academy of Sciences of the Czech Republic), using a Shimadzu RF 40 
spectrofluorophotometer using a 1 cm quartz cell. Fluorescence measurements of 
CT DNA modified by Ir
III
 complexes, cisplatin or [Pt(dien)Cl]Cl (dien = 
diethylenetriamine), in the presence of EtBr, were performed at an excitation 
wavelength of 546 nm, and the emitted fluorescence was analyzed at 590 nm. The 
fluorescence intensity was measured at 298 K in 0.4 M NaCl to avoid secondary 
binding of EtBr to DNA.
53,54
 The concentrations were 0.01 mg/mL for DNA and 
0.04 mg/mL for EtBr, which corresponded to the saturation of all intercalation sites 
for EtBr in DNA.
53
 
 
3.2.3.11   Viscometry 
These studies were performed by Prof. Viktor Brabec and colleagues (Institute of 
Biophysics, Academy of Sciences of the Czech Republic). The relative viscosity of 
the solutions of CT DNA nonmodified or modified by complexes 4–6 at the 
concentration of 150 µg/mL was measured by microviscometry (AMVn Automated 
Micro Viscometer, Anton Paar GmbH, Austria) using a 1.6-mm capillary tube at 
310 K. The densities of the solutions were measured using a Density Meter DMA 
4500 instrument (Anton Paar GmbH, Austria). 
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3.2.3.12   ICP-MS Analysis 
ICP analysis of all cell samples was carried out as described in Chapter 2. 
 
3.3   Results 
3.3.1   Synthesis and Characterisation 
25 Ir
III
 half-sandwich complexes of the type [(η5-Cpx)Ir(XY)Cl]0/+, where Cpx is 
pentamethylcyclopentadienyl, Cp*, or its phenyl Cp
xph
 or biphenyl Cp
xbiph 
derivatives, and XY is the N,N-chelating ligand 1,10-phenanthroline (phen, 4, 5 and 
6), 2,2'-bipyridine (bpy, 7, 8 and 9), ethylenediamine (en, 10 and 11), 1,10-
phenanthroline-5-amine (phen-5-amine, 15), 4,4′-dimethyl-2,2′-bipyridine 
(bpy(Me2), 16, 17 and 18), 2,2′-bipyridine-3,3′-diol (bpy(OH)O, 19, 20 and 21), 
dipyrido[3,2-f:2′,3′-h]quinoxaline (dpq, 22 and 24), dipyrido[3,2-a:2′,3′-c]phenazine 
(dppz, 23 and 25), 4-(2-pyridylazo)-N,N-dimethylaniline (azpy-NMe2, 26 and 27), 
p-dimethylaminophenyliminopyridine (impy-NMe2, 28) or N,O-chelating picolinate 
(pico, 12, 13 and 14), were synthesised in moderate yields by reaction of different 
chelating ligands with the appropriate dimer [(η5-Cpx)IrCl2]2  in methanol. 
Introduction of phenyl substituents on the Cp* ring decreased the reaction yields 
and increased difficulty to synthesise. Synthesis of the Ir
III
 complex containing 
Cp
xbiph
 and ethylenediamine proved to be difficult and it was not possible to study 
on this complex. Complexes 4, 7, 23–25 were isolated as Cl− salts, complex 11 as a 
BPh4
−
 salt, and complexes 5, 6, 8–10, 15–18, 22 and 26–28 as PF6
−
 salts. All the 
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synthesised complexes were fully characterised by 
1
H NMR spectroscopy and CHN 
elemental analysis. The cyclopentadienyl iridium(III) complexes studied in this 
Chapter are shown in Figure 3.1. Complexes 4–14 as typical complexes containing 
N,N- or N,O-chelating ligands are studied in more detail.  
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Figure 3.1. Iridium cyclopentadienyl complexes studied in this Chapter. 
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Z=Cl Z=D2O/H2O Z=9-EtG Z=9-EtA Cp
X
 XY 
4 4A 4G  Cp* phen 
5 5A 5G  Cp
xph
 phen 
6 6A 6G  Cp
xbiph
 phen 
7 7A 7G  Cp* bpy 
8 8A 8G  Cp
xph
 bpy 
9 9A 9G  Cp
xbiph
 bpy 
10 10A 10G  Cp* en 
11  11G  Cp
xph
 en 
12 12A 12G 12Ad Cp* pico 
13 13A 13G 13Ad Cp
xph
 pico 
14 14A 14G 14Ad Cp
xbiph
 pico 
15    Cp* phen-5-amine 
16    Cp* bpy(Me)2 
17    Cp
xph
 bpy(Me)2 
18    Cp
xbiph
 bpy(Me)2 
19    Cp* bpy(OH)O 
20    Cp
xph
 bpy(OH)O 
21    Cp
xbiph
 bpy(OH)O 
22    Cp
xph
 dpq 
23    Cp
xph
 dppz 
24    Cp
xbiph
 dpq 
25    Cp
xbiph
 dppz 
26    Cp* azpy-NMe2 
27    Cp
xph
 azpy-NMe2 
28    Cp
xph
 impy-NMe2 
 
Figure 3.1. Iridium cyclopentadienyl complexes studied in this Chapter. 
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The X-ray crystal structures of complexes [(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) 
[(η5-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6), [(η
5
-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6), 
[(η5-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4), [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13), [(η
5
-
C5Me4C6H5)Ir(bpy(Me)2)Cl]PF6·(C2H5)2O (17·PF6·(C2H5)2O), [(η
5
-C5Me5)Ir- 
(bpy(OH)O)Cl] (19), and [(η5-C5Me4C6H4C6H5)Ir(bpy(OH)O)Cl] (21) were 
determined. The complexes adopt the expected half-sandwich pseudo-octahedral 
“three-legged piano-stool” geometry with the iridium bound to a η5-
cyclopentadienyl ligand (Ir to ring centroid 1.760−1.793 Å), a chloride 
(2.384−2.415 Å) and a chelating ligand. Their structures and atom numbering 
schemes are shown in Figure 3.2. Crystallographic data are shown in Table 3.1, and 
selected bond lengths and angles are listed in Table 3.2. 
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Figure 3.2. X-ray crystal structures with atom numbering schemes for (A) [(η5-
C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6), (B) [(η
5
-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6), (C) 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6), (D) [(η
5
-C5Me4C6H5)Ir(en)Cl]BPh4 
(11·BPh4), (E) [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13), (F) [(η
5
-C5Me4C6H5)Ir- 
(bpy(Me)2)Cl]PF6·(C2H5)2O (17·PF6·(C2H5)2O), (G) [(η
5
-C5Me5)Ir(bpy(OH)O)Cl] 
(19), and (H) [(η5-C5Me4C6H4C6H5)Ir(bpy(OH)O)Cl] (21) with thermal ellipsoids 
drawn at 50% probability. The hydrogen atoms, solvent and counterions have been 
omitted for clarity. 
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Table 3.1. Crystallographic Data for Complexes [(η5-C5Me4C6H5)Ir(phen)Cl]PF6 
(5·PF6), [(η
5
-C5Me4C6H5)Ir(bpy)Cl]PF6 (8·PF6), [(η
5
-C5Me4C6H4C6H5)Ir- 
(bpy)Cl]PF6
 
(9·PF6), and [(η
5
-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4) 
      5·PF6      8·PF6      9·PF6   11·BPh4 
formula C27H25ClF6IrN2P C25H25ClF6IrN2P C31H29ClF6IrN2P C41H45BClIrN2 
MW 750.11 726.09 802.18 804.25 
cryst colour green block yellow block yellow block yellow block 
cryst size (mm) 0.10× 0.10 × 0.05 0.40 × 0.40 × 0.04  0.18× 0.16 × 0.12 0.32 × 0.22 × 0.20  
λ (Å) 0.71073 0.71073 0.71073 0.71073 
temp(K) 100 100 100 100 
cryst syst triclinic orthorhombic triclinic monoclinic 
space group P-1 Pna2(1) P-1 P2(1)/n 
a (Å) 8.3225(3) 15.0979(16) 8.3909(4) 11.93341(15) 
b (Å) 12.8863(4) 38.609(3) 12.2966(5) 18.9766(3) 
c (Å) 12.9181(4) 8.6693(3) 15.4848(6) 15.71286(17) 
α (°) 80.375(3) 90 68.541(4) 90 
β (°) 81.595(3) 90 75.835(4) 99.0672(12) 
γ (°) 71.565(3) 90 81.128(4) 90 
vol(Å3) 1289.37(7) 5053.5(7) 1438.04(10) 3513.80(8) 
Z 2 8 2 4 
R(Fo2) 0.0218 0.0445 0.0309 0.0430 
Rw(Fo2) 0.0555 0.0878 0.0640 0.1106 
GOF 1.026 0.930 1.094 1.049 
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Table 3.1. Crystallographic Data for Complexes [(η5-C5Me4C6H5)Ir(pico)Cl] (13), 
[(η5-C5Me4C6H5)Ir(bpy(Me)2)Cl]PF6·(C2H5)2O (17·PF6·(C2H5)2O), [(η
5
-C5Me5)Ir- 
(bpy(OH)O)Cl] (19), and [(η5-C5Me4C6H4C6H5)Ir(bpy(OH)O)Cl] (21) 
     13 17·PF6·(C2H5)2O 19 21 
formula C21H21ClIrNO2 C31H39ClF6IrN2OP C20H22ClIrN2O2 C31H28ClIrN2O2 
MW 547.04 828.26 550.05 688.20 
cryst colour yellow block yellow block yellow block yellow block 
cryst size (mm) 0.50× 0.10 × 0.05 0.18× 0.18 × 0.17 0.40 × 0.20 × 0.10  0.08× 0.08 × 0.06 
λ (Å) 0.71073 0.71073 0.71073 0.71073 
temp(K) 100 100 100 100 
cryst syst orthorhombic orthorhombic orthorhombic monoclinic 
space group Pna2(1) P2(1)2(1)2(1) P2(1)2(1)2(1) P2(1)/c 
a (Å) 17.6483(5) 13.7553(5) 8.4903(2) 13.4966(4) 
b (Å) 9.5691(3) 15.0335(6) 13..6369(4) 11.8473(3) 
c (Å) 11.0826(3) 15.2373(5) 15.7753(6) 17.1180(5) 
α (°) 90 90 90 90 
β (°) 90 90 90 111.367(3) 
γ (°) 90 90 90 90 
vol(Å3) 1871.60(9) 3150.9(2) 1826.48(10) 2549.00(12) 
Z 4 4 4 4 
R(Fo2) 0.0265 0.0237 0.0242 0.0201 
Rw(Fo2) 0.0465 0.0496 0.0541 0.0398 
GOF 0.905 0.976 1.017 0.954 
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Table 3.2. Selected Bond Lengths (Å) and Angles (deg) for Complexes [(η5-
C5Me4C6H5)Ir(phen)Cl]PF6 (5·PF6), [(η
5
-C5Me4C6H5)Ir(bpy)Cl]PF6 (8·PF6), [(η
5
-
C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6), [(η
5
-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4), 
and [(η5-C5Me4C6H5)Ir(bpy(Me)2)Cl]PF6·(C2H5)2O (17·PF6·(C2H5)2O) 
 
5·PF6 8·PF6 9·PF6 11·BPh4 17·PF6·(C2H5)2O 
Ir−C(Cp ring)  2.148(2) 2.148(7) 2.151(5) 2.158(4) 2.163(4) 
 2.157(2) 2.156(6)  2.155(5) 2.162(4) 2.166(4) 
 2.157(2) 2.181(7) 2.161(5) 2.165(4) 2.173(3) 
 2.167(2) 2.184(7) 2.172(5) 2.166(4) 2.174(4) 
 2.197(2) 2.201(8) 2.184(5) 2.169(4)  2.180(3) 
Ir−C(centroid) 1.783 1.789 1.787 1.789 1.790 
Ir−N1 2.0916(19) 2.083(6) 2.086(4) 2.134(3) 2.079(3) 
Ir−N2 2.1001(17) 2.096(6) 2.091(5) 2.136(4) 2.101(3) 
Ir−Cl 
 
2.3891(5) 2.3859(19) 2.3840(14) 2.4152(12) 2.4003(9) 
      
N1−Ir−N2 77.58(7) 76.4(3) 76.76(16) 79.83(14) 76.82(12) 
N1−Ir−Cl 84.23(5) 85.47(16) 84.84(11) 84.27(10) 84.66(8) 
N2−Ir−Cl 85.05(5) 87.4(2) 86.20(14) 82.70(13) 84.61(8) 
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Table 3.2. Selected Bond Lengths (Å) and Angles (deg) for Complexes [(η5-
C5Me4C6H5)Ir(pico)Cl] (13), [(η
5
-C5Me5)Ir(bpy(OH)O)Cl] (19), and [(η
5
-
C5Me4C6H4C6H5)Ir(bpy(OH)O)Cl] (21) 
 19 21  13 
Ir−C(Cp ring)  2.146(4) 2.145(2) Ir−C(Cp ring)  2.129(4) 
 2.155(4) 2.152(2)   2.135(4) 
 2.166(4) 2.171(2)  2.138(4) 
 2.183(4) 2.184(2)  2.154(4) 
 2.184(4) 2.203(2)  2.173(4) 
Ir−C(centroid) 1.791 1.793 Ir−C(centroid) 1.760 
Ir−N1 2.066(3) 2.0721(19) Ir−N 2.096(3) 
Ir−N2 2.066(3) 2.0772(19) Ir−O 2.113(3) 
Ir−Cl 
 
2.3957(11) 2.3836(6) Ir−Cl 
 
2.3860(10) 
     
N1−Ir−N2 76.26(14) 76.38(7) N−Ir−O 77.80(15) 
N1−Ir−Cl 85.65(10) 87.32(5) N−Ir−Cl 88.50(14) 
N2−Ir−Cl 84.97(10) 87.4(2) O−Ir−Cl 84.48(8) 
 
A weak intermolecular ring stacking is observed in the crystal structures of 
complex 5·PF6, between phen ligands in neighbouring molecules. The two 
interacting π systems are parallel, with a centroid−centroid distance of 3.518 Å, 
Figure 3.3.  
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3.518
 
Figure 3.3. Diagram showing π-stacking between the phen ligands of neighbouring 
molecules in the X-ray crystal structure of [(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6). 
The centroid–centroid distance between the phenyl rings of independent molecules 
is 3.518 Å. 50% ellipsoids. H atoms and PF6
− 
counter ions have been omitted for 
clarity. 
 
Stacking between the Cp
xbiph
 of neighbouring molecules is present in crystals of 
complex 9·PF6. The centroids of the three rings on independent molecules are 
separated by 4.447, 4.607 and 4.447 Å, at dihedral angles of 8.47, 0 and 8.47°, 
respectively, Figure 3.4. The twist angle between the cyclopentadienyl and the 
central ring is 45.23°, and between the central and the terminal phenyl ring is 46.34°. 
In contrast, the planes of the terminal and bound rings are only twisted by 8.47°. 
The propeller twist of the phenyl-tetramethylcyclopentadienyl ligand in complex 
11·BPh4 is 63.7°. The Ir−Cl bond length (2.4152(12) Å) is the longest of these X-
ray structures. 
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4.447 4.607 4.447.447 ..607
 
Figure 3.4. Diagram showing stacking between the planar Cp
xbiph
 of neighbouring 
molecules in the X-ray crystal structure of [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6). The centroids of three rings of independent molecules are separated by 
4.447, 4.607 and 4.447 Å, with dihedral angles of 8.47, 0 and 8.47°, respectively. 
50% ellipsoids. H atoms and the PF6
−
 counterion have been omitted for clarity. 
 
In the crystal structures of 19 and 21, (Figure 3.2), one of the bipyridinediol 
oxygens is deprotonated, an intramolecular hydrogen bond forms (O8∙∙∙H8∙∙∙O5, O-
O distance 2.387(5) Å and 2.396(2) Å, respectively), and the complexes are neutral. 
The bond lengths of complexes 4–14 were also calculated by using the functional 
PBE1PBE. Selected calculated bond lengths are listed in Table 3.3 and are in good 
agreement with the experimental X-ray structures. DFT calculations show that Ir–Cl 
and Ir–cyclopentadienyl ring bond distances remain similar on changing Cp* to 
substituted Cp* groups.  
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Table 3.3. Selected Calculated Bond Lengths (Å) for Complexes 4–14 
Complex Ir–Cl Ir–N1 Ir–N2 Ir–Centroid 
4 2.398 2.095 2.095 1.812 
5 2.400 2.095 2.095 1.810 
6 2.400 2.094 2.095 1.810 
7 2.398 2.083 2.083 1.816 
8 2.400 2.082 2.082 1.816 
9 2.400 2.082 2.084 1.815 
10 2.408 2.160 2.156 1.795 
11 2.409 2.159 2.153 1.791 
Complex Ir–Cl Ir–N1 Ir–O2 Ir–Centroid 
12 2.468 2.078 2.071 1.783 
13 2.458 2.091 2.071 1.783 
14 2.458 2.089 2.070 1.783 
 
Electrostatic potential surfaces (EPS) for phen chlorido complexes 4−6 and aqua 
adduct 6A, and the pico chlorido complexes 12−14 and aqua adduct 14A were 
calculated. N,N-chelating phen complexes 4−6 show more positive electrostatic 
potentials than the N,O-chelating pico complexes 12−14 (Figure 3.5). Moreover, 
higher electron density is present on the second phenyl ring of the Cp
xbiph
 ligand in 
complexes 6 and 14. The same trend is observed in the electrostatic potential 
surfaces of the aqua derivatives [(η5-C5Me4C6H4C6H5)Ir(phen)(H2O)]
2+
 (6A) and 
[(η5-C5Me4C6H4C6H5)Ir(pico)(H2O)]
+
 (14A), which as expected show more positive 
surfaces compared to their chlorido analogues, 6 and 14. 
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Figure 3.5. Electrostatic potential surfaces of the phen chlorido complexes 4–6 and 
aqua adduct 6A, and the pico chlorido complexes 12–14 and aqua adduct 14A. EPS 
surfaces are shown both in space (with positive and negative regions in blue and red, 
respectively) and mapped on electron density (isovalue 0.004) of the molecules. 
The electrostatic potential is represented with a colour scale going from red (–0.100 
au) to blue (0.150 au).  
 
3.3.2 Hydrolysis Studies 
Hydrolysis of M–Cl bonds can represent an activation step for transition metal 
anticancer complexes.
55
 M–OH2 aqua complexes are often more reactive than the 
relevant chlorido complexes.
56,57
 The hydrolysis of compounds 4–10 and 12–14 in 
5% MeOD-d4/95% D2O (v/v) was monitored by 
1
H NMR at different temperatures 
from 278 to 293 K. The presence of methanol ensured the solubility of the 
complexes.  
All these Ir
III
 complexes undergo relatively rapid hydrolysis. Complexes [(η5-
C5Me5)Ir(phen)Cl]
+
 (4), [(η5-C5Me5)Ir(bpy)Cl]
+
 (7), [(η5-C5Me5)Ir(en)Cl]
+
 (10) 
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containing Cp*, and [(η5-C5Me5)Ir(pico)Cl] (12), [(η
5
-C5Me4C6H5)Ir(pico)Cl] (13) 
and [(η5-C5Me4C6H4C6H5)Ir(pico)Cl] (14) containing picolinate hydrolysed too 
rapidly for the rates to be determined by 
1
H NMR spectroscopy even at 278 K: there 
was little change in the spectra between 5 min and 24 h, Figure 3.6. Attempts to 
observe hydrolysis of these complexes by UV-Vis at 288 K were also unsuccessful: 
equilibrium was reached before the first UV-Vis spectrum was acquired (< 1 min).  
 
8.008.509.00
(A) 5 min
(B) 24 h
8.008.509.00
ppm (t1)
8.008.509.00
ppm
12 12
12A+12
12A 12A12A
12
 
Figure 3.6. 
1
H NMR spectra showing the hydrolysis of complex [(η5-
C5Me5)Ir(pico)Cl] (12) (1 mM) in 5% MeOD-d4/95% D2O at 278 K. (A) after 5 min; 
(B) after 24 h. Almost no difference is observed between these two spectra. Peaks 
labeled 12A correspond to aqua complex [(η5-C5Me5)Ir(pico)(D2O)]
+
 (12A). 
 
To confirm the hydrolysis of these complexes, NaCl (1–4 mol equiv) was added 
to equilibrium solutions. With increase in NaCl concentration, 
1
H NMR peaks for 
the chlorido adducts increased whilst peaks for the aqua form decreased in intensity, 
Figure 3.7 and Figure 3.8. Similarly, addition of NaCl to an aqueous solution of the 
aqua complex 4A gave rise to peaks for the chlorido complex 4. 
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8.008.509.009.50
Chemist Zhe Liu
zl07hy after 24h
PROTONwet.w D2O /opt/topspin ZL 19
8.008.509.009.50
Chemist Zhe Liu
zl07hy + 30ul 7mM NaClmore (total 50uL)
PROTONwet.w D2O /opt/topspin ZL 2
8.008.509.009.50
Chemist Zhe Liu
zl07hy+ 50ul 7mM NaCl more(total 100uL)
PROTONwet.w D2O /opt/topspin ZL 2
8.008.509.009.50
Chemist Zhe Liu
zl07hy last one add 7.7ul 700mM NaCl
PROTONwet.w D2O /opt/topspin ZL 2
(A) Hydrolysis equilibrium, no NaCl
(B) 1 mol equiv NaCl
(C) 2 mol equiv NaCl
(D) 2.5 mol equiv NaCl
44A 4A+4 4A+4
4A
4
ppm
 
 
Figure 3.7. Confirmation of hydrolysis of Ir
III
 complex [(η5-C5Me5)Ir(phen)Cl]
+
 (4) 
by addition of various amounts of NaCl to an equilibrium solution of 4 (1 mM) in 
5% MeOD-d4/95% D2O (v/v) at 298 K. 
1
H NMR spectra recorded 10 min after 
addition of NaCl. The mol equiv NaCl is the total amount added. Complex 4A 
corresponds to the aqua complex [(η5-C5Me5)Ir(phen)(D2O)]
2+
. The peaks for the 
chlorido complex 4 increased in intensity while peaks for the aqua complex 4A 
decreased on addition of NaCl. 
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(A) Hydrolysis equilibrium
(B) 1 mol equiv NaCl
(C) 2 mol equiv NaCl
12 12 12+12A12A 12A12A
12
8.008.509.00
ppm (t1)
8.008.509.00
8.008.509.00
ppm (t1)
8.008.509.00
ppm
 
Figure 3.8. The picolinate CH region of the 
1
H NMR spectra of [(η5-
C5Me5)Ir(pico)Cl] (12, 1 mM) in 5% MeOD-d4/95% D2O (v/v). (A) at equilibrium, 
(B) after the addition of 1 mol equiv NaCl and (C) 2 mol equiv NaCl. 
1
H NMR 
spectra recorded 10 min after addition of NaCl at 298 K. The mol equiv NaCl is the 
total amount added. The anation reaction is evident from the decrease in intensity of 
the peaks for the chlorido complex 12 and increase in intensity of peaks for the aqua 
complex 12A [(η5-C5Me5)Ir(pico)(D2O)]
+
 on addition of NaCl. 
 
However the hydrolysis of complexes [(η5-C5Me4C6H5)Ir(phen)Cl]
+ 
(5), [(η5-
C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6), [(η5-C5Me4C6H5)Ir(bpy)Cl]
+ 
(8), and [(η5-
C5Me4C6H4C6H5)Ir(bpy)Cl]
+ 
(9), was slow enough to be studied by 
1
H NMR at low 
temperature. Hydrolysis was monitored at temperatures ranging from 278 K to 293 
K by observing the appearance of new 
1
H NMR peaks over time. The time 
dependence for formation of the aqua adducts of 5, 6, 8 and 9 was fitted to pseudo 
first-order kinetics (Figure 3.9), and their hydrolysis rate constants, half-lives and 
equilibrium constants (Kaq) for hydrolysis were determined (Table 3.4). At 278 K, 
the half-life for hydrolysis of the biphenyl substituted Cp
xbiph
 complex 6 was 32 min, 
about 1.3 times slower than that of the phenyl-Cp* complex 5 (25 min; Table 3.4). 
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The half-lives and extent of hydrolysis of complexes 4−6 at 278 K increase with the 
size of the ring system in the order Cp
xbiph
 > Cp
xph
 > Cp*. This trend is also 
observed for complexes 7−9. The hydrolysis rate constants and half-lives of 5, 6, 8 
and 9 at 310 K (body temperature) were calculated using the Arrhenius equation 
and are listed in Table 3.4. These range from 1 min for complexes 5 and 8 to 4 min 
for complex 6.  
 
    
 
Figure 3.9. Time dependence for formation of aqua complexes (A) 5A, (B) 6A, (C) 
8A and (D) 9A (based on 
1
H NMR peak integrals) during hydrolysis of [(η5-
C5Me4C6H5)Ir(phen)Cl]
+ 
(5), [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6), [(η5-
C5Me4C6H5)Ir(bpy)Cl]
+ 
(8), and [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]
+ 
(9) in 5% 
MeOD-d4/95% D2O (v/v) at 278 K ■; 283 K ▲; 288 K ●; and 293 K ★.  
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Table 3.4. Hydrolysis Data for Complexes 4−10 and 12−14 at Various 
Temperatures  
 
Complex
a
 
k (min
−1
) 
t1/2 (min) 
Kaq (mM)
b
 278 K 283 K 288 K 293 K 310 K
e
 
4 −
c
     0.04 
5 0.027 
25.4 
0.047 
14.6 
0.083 
8.3 
−
d 
0.65 
1.1 
0.06 
6 0.022 
31.8 
−
d 
0.044 
15.9 
0.065 
10.7 
0.18 
3.8 
0.29 
7 −
c
     0.05 
8 0.031 
22.1 
0.062 
11.1 
0.099 
7.0 
−
d
 
0.89 
0.8 
0.08 
9 0.026 
26.7 
0.041 
16.9 
−
d
 
0.078 
8.8 
0.23 
3.0 
1.45 
10 −
c
     0.44 
12 −
c
     0.78 
13 −
c
     1.11 
14 −
c
     2.33 
a
 The course of the hydrolysis of complex 11 was difficult to interpret from NMR 
spectra. 
b
 278 K. 
c
 too fast to be measured. 
d
 not determined. 
e 
obtained from 
Arrhenius equation.  
 
In each series of complexes containing different N,N- or N,O-chelating ligands, 
the equilibrium constants (Kaq) for hydrolysis at 278 K increased with increasing 
phenyl substitution on the Cp
x
 ligand, Table 3.4. 
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3.3.3 pKa Determination 
The pKa of coordinated water can have a significant influence on its reactivity 
since M−OH bonds are often much less labile than M−OH2 bonds;
36
 moreover 
hydroxide is a good bridging ligand and can give rise to oligomeric species.  
Changes in the 
1
H NMR chemical shifts for coordinated chelating ligands in aqua 
complexes 4A−9A, 12A−14A, and methyl groups of Cp* in aqua complex 10A, 
were followed with change in pH* over a range of 2−11 (Figure 3.10). 1H NMR 
peaks assigned to aqua complexes gradually shifted to high field with increase in 
pH*. The resulting pH titration curves were fitted to the Henderson-Hasselbalch 
equation, from which the pKa* values of the coordinated water were determined. 
This gave rise to pKa values between 6.28 and 7.99 (Table 3.5), with the bpy 
complexes being the most acidic (pKa values 6.28−6.86) and the pico complexes the 
least acidic (pKa values 7.52−7.99).  
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Figure 3.10. Dependence of the 
1
H NMR chemical shifts for coordinated chelating 
ligands in aqua complexes 4A−9A, 12A−14A, and methyl group in Cp* in aqua 
complex 10A on pH*. The curves are computer fits giving the pKa* values shown in 
Table 3.5. 
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Table 3.5. pKa* and pKa Values
a
 for the Deprotonation of the Coordinated D2O in 
Complexes 4A−10A, and 12A−14A 
Aqua Complex pKa* pKa 
[(η5-C5Me5)Ir(phen)(D2O)]
2+
 (4A) 7.88 7.74 
[(η5-C5Me4C6H5)Ir(phen)(D2O)]
2+
 (5A) 7.68 7.55 
[(η5-C5Me4C6H4C6H5)Ir(phen)(D2O)]
2+
 (6A) 7.50 7.38 
[(η5-C5Me5)Ir(bpy)(D2O)]
2+
 (7A) 6.94 6.86 
[(η5-C5Me4C6H5)Ir(bpy)(D2O)]
2+
 (8A) 6.31 6.28 
[(η5-C5Me4C6H4C6H5)Ir(bpy)(D2O)]
2+
 (9A) 6.68 6.63 
[(η5-C5Me5)Ir(en)(D2O)]
2+
 (10A) 7.66 7.54 
[(η5-C5Me5)Ir(pico)(D2O)]
+
 (12A) 8.15 7.99 
[(η5-C5Me4C6H5)Ir(pico)(D2O)]
+
 (13A) 7.75 7.62 
[(η5-C5Me4C6H4C6H5)Ir(pico)(D2O)]
+
 (14A) 7.65 7.52 
a
 pKa values calculated from pKa* according to Krezel and Bal.
58
 
 
3.3.4 Interactions with Nucleobases 
Since DNA is a potential target site for transition metal anticancer complexes,
59,60
 
the binding of 9-ethylguanine (9-EtG) and 9-ethyladenine (9-EtA) to complexes 
4−14, and aqua complex 5A were studied. The extent of nucleobase adducts 
formation by these complexes based on 
1
H NMR peak integrals is shown in Table 
3.6.  
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Table 3.6. Extent of 9-EtG and 9-EtA Adducts Formation for Complexes 4−14, and 
5A (ca. 1 mM) at 310 K after 24 h 
 Cp
x
 XY 
G adduct  
(%) 
A adduct 
(%) 
4 Cp* phen(N,N-) 83  0 
5 Cp
xph
 phen(N,N-) 42  0 
5A Cp
xph
 phen(N,N-) 74  0 
6 Cp
xbiph
 phen(N,N-) 90  0 
7 Cp* bpy(N,N-) 61  0 
8 Cp
xph
 bpy(N,N-) 47  0 
9 Cp
xbiph
 bpy(N,N-) 65  0 
10 Cp* en(N,N-) 100  0 
11 Cp
xph
 en(N,N-) 100  0 
12 Cp* pico(N,O-) 100  81 
13 Cp
xph
 pico(N,O-) 100  76 
14 Cp
xbiph
 pico(N,O-) 100  71 
 
Addition of 1 mol equiv of 9-EtG to an equilibrium solution of complex 5, [(η5-
C5Me4C6H5)Ir(phen)Cl]
+
 (1.0 mM), in 5% MeOD-d4/95% D2O (v/v, pH* 7.2) at 
310 K resulted in 15% of 5 reacting after 10 min, and a new 9-EtG H8 peak 
appearing at 7.68 ppm (species 5G, Figure 3.11), shifted by 0.15 ppm to high field 
relative to that of free 9-EtG. After 24 h, 42% of 5 had reacted. The ESI-MS of an 
equilibrium solution (Figure 3.12) contained a major peak at m/z 374.6, confirming 
the formation of the 9-EtG adduct 5G, [(η5-C5Me4C6H5)Ir(phen)(9-EtG)]
2+
 (calcd 
m/z 374.5). However, 65% of aqua complex 5A (prepared by treating a solution of 5 
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with 1 mol equiv of AgNO3) reacted with 9-EtG to form 5G after 10 min and 73% 
after 24 h. More than 80% of complexes 4 and 6 reacted with 9-EtG under the same 
conditions. 
 
8.008.509.009.50
Chemist Zhe Liu
zl33+9-EtG new 2
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8.008.509.009.50
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b
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d
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d
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bb' mc'
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Figure 3.11. Low field region of the 
1
H NMR spectra showing reaction of [(η5-
C5Me4C6H5)Ir(phen)Cl]
+
 (5) with 9-ethylguanine.
 
(A) 10 min after addition of 1 
mol equiv 9-ethylguanine to an equilibrium solution of complex 5 (1.0 mM) in 5% 
MeOD-d4/95% D2O (v/v) at 310 K, pH* 7.2; and (B) after 24 h reaction. Peak 
assignments are indicated on the structures. After 24 h, 42% of 5 had reacted.  
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Figure 3.12. ESI-MS of an equilibrium solution (0.2 mM) of 9-EtG and complex 
[(η5-C5Me4C6H5)Ir(phen)Cl]
+
 (5) in 50% CH3CN/50% H2O (v/v), 298 K. The major 
peak at m/z 374.6 is assignable to the G adduct 5G, [(η5-C5Me4C6H5)Ir(phen)(9-
EtG)]
2+
 (calcd m/z 374.5); The peak at m/z 285.1 is assignable to the fragment [(η5-
C5Me4C6H5)Ir(phen)]
2+
 (calcd m/z 284.9). The peak at m/z 180.2 is assignable to 9-
EtG (calcd m/z 179.2). 
 
Complexes [(η5-C5Me5)Ir(en)Cl]
+
 (10) and [(η
5
-C5Me4C6H5)Ir(en)Cl]
+
 (11) 
interestingly, showed an exceptionally high affinity for 9-EtG with 100% 
nucleobase adduct formation within 10 min. On addition of a solution of 1 mol 
equiv of 9-EtG gradually to an equilibrium solution of 10 (0.9 mM) in 5% MeOD-
d4/95% D2O (v/v) at 310 K, Figure 3.13, the methyl peak for 10 and 10A decreased 
in intensity and eventually disappeared. A new Cp* methyl peak (for 10G) 
appeared at 1.65 ppm. When 9-EtG was in excess, a set of new peaks assignable to 
free 9-EtG was clearly visible (Figure 3.13). 
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Figure 3.13. High-field region of the
 1
H NMR spectrum of [(η5-C5Me5)Ir(en)Cl]
+
 
(10, 0.9 mM) with increasing amounts of added 9-ethylguanine in 5% MeOD-
d4/95% D2O (v/v) at 310 K. (A) 10 min after addition of 0.5 mol equiv 9-EtG; (B) 
10 min after a further addition of 0.2 mol equiv 9-EtG; (C) 10 min after a further 
addition of 0.2 mol equiv 9-EtG; (D) 10 min after a further addition of 0.4 mol 
equiv 9-EtG (a total of 1.3 mol equiv of 9-EtG was added). Assignments: Peak 
labeled ★  represents methyl group of Cp* ring in [(η5-C5Me5)Ir(en)(9-EtG)]
2+
 
(10G); peak labeled ● represents methyl group of 10 + 10A; peak labeled ▲ 
corresponds to methyl group of bound 9-EtG in [(η5-C5Me5)Ir(en)(9-EtG)]
2+
 (10G). 
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Addition of 1 mol equiv of 9-EtA to an equilibrium solution of 5 (1.0 mM) in 5% 
MeOD-d4/95% D2O (v/v) at 310 K resulted in no additional 
1
H NMR peaks over a 
period of 24 h. Similarly, no reaction with 9-EtA was observed for other complexes 
containing N,N- chelating ligands (Table 3.6).  
In contrast, compounds 12−14 containing pico as chelating ligand formed both 9-
EtG and 9-EtA adducts to the extent of 100% and more than 70% completion, 
respectively, after 24 h, Table 3.6. Two adenine nucleobase adducts are formed in 
the reaction of complexes 12, 13 and 14 with 9-EtA, most likely through iridium 
binding to N1 or N7 of adenine forming 9-EtA adducts in ca. 1:3 ratio, Figure 3.14. 
 
free 9-EtA
unreacted
complex 12
methyl group 
of  9-EtA 
methyl group   
of  Cp* 
ppm1.301.401.501.601.701.801.90  
Figure 3.14. High-field region (methyl group of Cp* and 9-EtA) of the 
1
H NMR 
spectrum showing the formation of two adenine adducts of [(η5-C5Me5)Ir(pico)Cl] 
(12). Peaks labeled ▲ and ★ represent different adenine adducts, probably [(η5-
C5Me5)Ir(pico)(9-EtA-N7)]
+
 and [(η5-C5Me5)Ir(pico)(9-EtA-N1)]
+
. 
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3.3.5 Cytotoxicity 
The cytotoxicity of complexes 4−14 (studied in more details) towards A2780 
human ovarian cancer cells was investigated, see Table 3.7. The IC50 values 
(concentration at which 50% of the cell growth is inhibited) for Cp* complexes 4, 7, 
10, 12 and the Cp
xph
 pico complex 13 were all > 100 μM and are thus deemed as 
inactive. However, compounds 5, 6, 8, 9, 11 and 14, were all active. Complexes 5, 8 
and 11 containing Cp
xph
, and 14 containing Cp
xbiph
 showed good activity, displaying 
IC50 values of 6−17 μM. Complexes 6 and 9 containing Cp
xbiph 
exhibited potent 
cytotoxicity with IC50 values of 0.7 and 0.6 µM, respectively, ca. twice as active as 
cisplatin in the A2780 cell line (IC50 1.2 µM).  
The cytotoxicity of complexes 16−24, 26, and 27 towards A2780 human ovarian 
cancer cells was also investigated and listed in Table 3.7. 
For all series of complexes containing different chelating N,N- or N,O-chelating 
ligands, the trend of increasing of activity with increasing phenyl substitution was 
the same: Cp
xbiph
 > Cp
xph
 > Cp*. 
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Table 3.7. Inhibition of Growth of A2780 Human Ovarian Cancer Cells by 
Complexes 4−14, 16−24, 26, 27 and Comparison with Cisplatin 
Complex IC50
 a
 (μM) 
[(η5-C5Me5)Ir(phen)Cl]Cl (4·Cl) >100 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) 6.70 ± 0.62  
[(η5-C5Me4C6H4C6H5)Ir(phen)Cl]PF6
 
(6·PF6) 0.72 ± 0.01 
[(η5-C5Me5)Ir(bpy)Cl]Cl (7·Cl) >100 
[(η5-C5Me4C6H5)Ir(bpy)Cl]PF6
 
(8·PF6) 15.86 ± 1.49 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) 0.57 ± 0.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[(η5-C5Me5)Ir(en)Cl]PF6 (10·PF6) >100 
[(η5-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4) 16.97 ± 0.05 
[(η5- C5Me5)Ir(pico)Cl] (12) >100 
[(η5-C5Me4C6H5)Ir(pico)Cl] (13) >100 
[(η5-C5Me4C6H4C6H5)Ir(pico)Cl] (14) 16.30 ± 0.32 
[(η5-C5Me5)Ir(bpy(Me)2)Cl]PF6 (16·PF6) 
 
>100 
[(η5-C5Me4C6H5)Ir(bpy(Me)2)Cl]PF6 (17·PF6) 
 
9.22 ± 0.16 
[(η5-C5Me4C6H4C6H5)Ir(bpy(Me)2)Cl]PF6 (18·PF6) 0.51 ± 0.04 
[(η5-C5Me5)Ir(bpy(OH)O)Cl] (19) 17.2 ± 2.7 
[(η5-C5Me4C6H5)Ir(bpy(OH)O)Cl] (20) 
 
7.18 ± 0.73 
[(η5-C5Me4C6H4C6H5)Ir(bpy(OH)O)Cl] (21) 2.79 ± 0.08 
[(η5-C5Me4C6H5)Ir(dpq)Cl]PF6 (22·PF6) 0.87 ± 0.12 
[(η5-C5Me4C6H5)Ir(dppz)Cl]Cl (23·Cl) 0.26 ± 0.12 
[(η5-C5Me4C6H4C6H5)Ir(dpq)Cl]Cl (24·Cl) 0.88 ± 0.09 
[(η5-C5Me5)Ir(azpy-NMe2)Cl]PF6 (26·PF6) 1.38 ± 0.06 
[(η5-C5Me4C6H5)Ir(azpy-NMe2)Cl]PF6 (27·PF6) 0.40 ± 0.00 
cisplatin 1.22 ± 0.12 
a
 Drug-treatment period was 24 h. 
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Complexes [(η5-C5Me4C6H5)Ir(phen)Cl]PF6 (5·PF6), [(η
5
-C5Me4C6H4C6H5)Ir- 
(phen)Cl]PF6
 
(6·PF6) and [(η
5
-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) were further 
evaluated by the National Cancer Institute Developmental Therapeutics Program 
(NCI/DTP, U.S.A.) in vitro cytotoxic tests against ca. 60 human cancer cell lines 
within nine tumour type subpanels.
61
 The cells were treated by iridium complexes 
for 48 h at five concentrations ranging from 0.01 to 100 μM. Three endpoints are 
calculated: GI50 (the concentration that causes 50% cell growth inhibition), TGI (the 
concentration where causes 100% cell growth inhibition), and LC50 (the 
concentration that the drug decreases the original cell number by 50%).  
The mean graphs for complexes 5·PF6, 6·PF6 and 9·PF6 are listed in Figure 3.15. 
Bars in the mean graphs extending to the right represent sensitivity of cell line to 
the test agent in excess of the average sensitivity of all tested cell lines. Bars 
extending to the left correspondingly imply sensitivity less than the mean. Complex 
5·PF6, containing Cp
xph
 and 1,10-phenanthroline N,N-chelating ligand, shows high 
potency in wide range of cancer cell lines, selectively for leukemia, CNS cancer, 
melanoma, and prostate cancer (highlighted by red squares in Figure 3.15A). 
Complexes 6·PF6 and 9·PF6 containing Cp
xbiph
 show even higher potency with 
lowest GI50 value of 282 nM and 407 nM, respectively, and show selectivity not 
only towards leukemia, CNS cancer, melanoma, and prostate cancer, but also 
against colon cancer and breast cancer, Figures 3.15B and C.  
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Figure 3.15. (A) Mean graph for [(η5-C5Me4C6H5)Ir(phen)Cl]PF6 (5·PF6) from the 
National Cancer Institute Developmental Therapeutic Program. The complex is 
particularly active towards cell lines highlighted by red squares. 
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Figure 3.15. (B) Mean graph for [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]PF6
 
(6·PF6) from 
the National Cancer Institute Developmental Therapeutic Program. The complex is 
particularly active towards cell lines highlighted by red squares. 
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Figure 3.15. (C) Mean graph for [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) from 
the National Cancer Institute Developmental Therapeutic Program. The complex is 
particularly active towards cell lines highlighted by red squares. 
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The mean GI50, TGI and LC50 of complexes 5·PF6, 6·PF6, 9·PF6 and cisplatin 
against NCI cell lines are shown in Figure 3.16. Complex 5·PF6 possesses similar 
cytotoxic activity to that of cisplatin, whilst complex 9·PF6 is ca. 2.5× as potent as 
cisplatin toward NCI cancer cell lines. Interestingly, N,N-bound phen complex 
6·PF6 is ca. 2 times as potent as its bpy analogue, complex 9·PF6. All the three 
iridium complexes exhibit promising cytotoxicity toward cancer cell lines. 
 
 
Figure 3.16. Mean graph midpoint (MG-MID) GI50, TGI and LC50 values of 
complexes
 
[(η5-C5Me4C6H5)Ir(phen)Cl]PF6 (5·PF6), [(η
5
-C5Me4C6H4C6H5)Ir- 
(phen)Cl]PF6
 
(6·PF6), [(η
5
-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6), and comparison 
with cisplatin. Data for cisplatin are from NCI/DTP screening: October 2009, after 
48 h treatment of the cells.
62
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3.3.6 Hydrophobicity (log P) 
The octanol/water partition coefficients (log P) for the phen complexes [(η5-
C5Me5)Ir(phen)Cl]
+
 (4), [(η5-C5Me4C6H5)Ir(phen)Cl]
+
 (5), and [(η5-
C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6) were determined since lipophilicity correlates 
with cytotoxic potency for some reported series of metallodrugs.
63,64
 The 
determined values are listed in Table 3.8. Addition of NaCl (200 mM) was used in 
order to suppress hydrolysis of the compounds, ensuring that log P values for the 
chlorido and not aqua complexes were determined. The log P values increase in the 
order 4 < 5 < 6. Only complex 4, containing the unsubstituted Cp* ligand, has a 
negative log P value (partitions preferentially into water, Table 3.8). 
 
Table 3.8. log P Values for Complexes 4−6a  
 log P 
Complex mean SD 
4 –0.82 0.01 
5 0.48 0.03 
6 1.11 0.17 
a
Results are the mean of three independent experiments and are expressed as mean 
± SD. 
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3.3.7 Cell Accumulation and DNA Binding 
Since increased lipophilicity has often been linked to increased cell uptake and 
cytotoxicity,
65,66
 the accumulation and DNA binding of complexes [(η5-
C5Me5)Ir(phen)Cl]
+
 (4), [(η5-C5Me4C6H5)Ir(phen)Cl]
+
 (5), and [(η5-C5Me4C6H4- 
C6H5)Ir(phen)Cl]
+ 
(6) by A2780 ovarian cancer cells was determined after 24 h of 
exposure to 5 μM concentrations of the complexes. DNA from A2780 cells was 
isolated and the Ir content was determined. The Cp
xbiph
 complex 6 gave rise to the 
highest level of iridium on DNA, ca. 4× that of complex 5, and 20× that of complex 
4 (Table 3.9). Of the total Ir taken up by the cells, 7.7% for 4, 5.5% for 5, and 6.0% 
for 6 was bound to DNA.  
 
Table 3.9. Iridium Accumulation and Binding to DNA in A2780 Human Ovarian 
Cancer Cells
a
  
 
Complex 
cell accumulation 
 
 
(ng Ir/10
6
 cells) 
DNA binding 
(ng Ir/10
6
 cells) (ng Ir/10
6
 cells) (ng Ir/10
6
 cells) 
mean SD mean SD 
4 3.9 0.2 0.3 0.04 
5 23.5 3.7 1.3 0.3 
6 88.8 20.0 5.3 1.6 
a
 Drug-treatment period was 24 h with 5 μM IrIII complexes. Each value represents 
the mean ± SD for two independent experiments done in triplicate. 
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3.3.8 Distribution of Iridium in Cell Fractions 
The iridium content of the nucleus, cytosol, membrane and cytoskeleton fractions 
isolated from A2780 cells after 24 h of exposure to the phen complexes 4−6 was 
determined, and the results are shown in Table 3.10 and Figure 3.17. The extent of 
accumulation of the three complexes into the different cell fractions was similar to 
that observed for whole cell accumulation: 6 > 5 > 4.  
 
Table 3.10. Accumulation of Ir Complexes 4–6 into the Nucleus, Cytosol, 
Membrane and Cytoskeleton of A2780 Human Ovarian Cancer Cells 
 
 
 
Complex 
 
Accumulation (ng Ir/10
6
 cells)
a 
nucleus cytoskeleton cytosol membrane 
mean SD mean SD mean SD mean SD 
4 0.4 0.04 1.1 0.3 1.1 0.2 3.8 0.4 
5 1.3 0.3 1.3 0.4 3.3 0.6 16.4 3.3 
6 4.8 1.6 9.9 2.7 15.7 4.3 36.4 5.0 
  a
 Drug-treatment period was 24 h with 5 μM IrIII complexes. Each value represents 
the mean ± SD for six independent experiments. 
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Nucleus
Cytoskeleton
Cytosol
Membrane
Complex
 
Figure 3.17. Iridium content of the nucleus, cytosol, membrane and cytoskeleton 
fractions (ng Ir/10
6
 cells) of A2780 cells after 24 h of exposure to 5 μM 4−6. 
Results are the mean of two independent experiments in triplicate and are expressed 
as mean ± SD. 
 
The highest concentration of iridium was in the cell membrane/particulate 
fraction, accounting for 54% (6), 74% (5) and 59% (4) of the total Ir in the cell. For 
all complexes, the next highest concentration of Ir was in the cytosol, accounting 
for 24% (6), 15% (5) and 17% (4). For the two remaining fractions, the Ir 
concentration dropped significantly. For complexes 4 and 6, the cytoskeleton was 
the next major compartment for Ir accumulation. The amount of Ir in the nucleus 
was significant and similar for all three Ir
III
 complexes: 7.2% of the total Ir for 6, 
5.8% for 5, and 6.4% for 4, and similar in proportion to that bound to DNA. 
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3.3.9 Replication Mapping of Ir−DNA Adducts 
This procedure involved the extension by VentR(exo-) DNA polymerase of the 
3'-end of the primer up to the metal adduct on the template strand of pSP73KB 
DNA linearized by HpaI restriction endonuclease. The products of the synthesis 
were then examined on DNA sequencing gels, and the sequence specificity of 
iridium adduct formation was determined to the exact base pair. In vitro DNA 
synthesis on DNA templates containing the adducts of the phen complexes 4−6 
generated a population of DNA fragments, indicating that the adducts of these 
complexes effectively terminated DNA synthesis (Figure 3.18A, lanes 4−6). 
Complexes 4–6 exhibit a sequence dependence of the inhibition clearly different 
from that of cisplatin. The Ir compounds form more blocks on DNA for DNA 
polymerase than cisplatin and some of them occur at different sequences. These 
results are consistent with a less regular sequence specificity of complexes 4–6 in 
comparison with cisplatin. Identical patterns of blocks on DNA were observed if the 
template DNA was incubated with the metal complex for 8, 24 or 72 h.  
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Figure 3.18. Replication mapping of Ir–DNA adducts. (A) Autoradiogram of 6% 
polyacrylamide/8 M urea sequencing gel showing inhibition of DNA synthesis by 
VentR DNA polymerase on the pSP73KB plasmid DNA linearized by HpaI 
restriction enzyme and subsequently modified by Ir
III
 complexes, cisplatin or 
transplatin. (B) Schematic diagram showing a portion of the sequence used to 
monitor inhibition of DNA synthesis on the template containing adducts of Ir
III
 
complexes. The arrow indicates the direction of the synthesis. ○, major stop signals 
from panel A, lanes 4−6. The numbering of the nucleotides in this scheme 
corresponds to the numbering of the nucleotides in the pSP73KB nucleotide 
sequence map.  
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3.3.10 Ethidium Bromide (EtBr) Displacement 
The ability of the complexes to displace the DNA intercalator EtBr from CT 
DNA was probed by monitoring the relative fluorescence of EtBr bound to DNA 
after treating the DNA with varying concentrations of 4−6. Figure 3.19 shows a plot 
of relative fluorescence vs rb for complexes 4−6, cisplatin and monofunctional 
chloridobis(2-aminoethyl)amineplatinum(II) chloride ([Pt(dien)Cl]Cl).  
 
 
Figure 3.19. Plots showing the dependence of EtBr fluorescence on rb for calf 
thymus DNA modified by Ir
III
 complexes 4−6, cisplatin, and [Pt(dien)Cl]Cl in 10 
mM NaClO4 at 310 K for 24 h: (), complex 4; (), complex 5; (○), complex 6; 
(▲), cisplatin; (■), [Pt(dien)Cl]Cl. Data points measured in triplicate varied on 
average ±3% from their mean. 
 
The adducts of monofunctional Ir
III
 complexes competitively replaced 
intercalated EtBr more effectively than the adducts of monofunctional 
[Pt(dien)Cl]Cl, but slightly less than the adducts of bifunctional cisplatin. Notably, 
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the trend in ability to displace DNA intercalator EtBr from CT DNA was 6 > 5 > 4, 
which correlates with their cytotoxicity (Table 3.7). 
 
3.3.11 Viscometry 
The effects of complexes 4−6 on the viscosity of rod-like CT DNA (0.15 mg/mL 
or 0.47 mM in phosphorus content) are shown in Figure 3.20. On increasing the 
amounts of 4−6 bound to DNA (in the range of rb values of 0.005−0.04), the 
relative viscosity of CT DNA increased steadily; the effect follows the order 6 > 5 > 
4, which correlates with their cytotoxicity (Table 3.7) as well as with their ability to 
displace DNA intercalator EtBr from DNA (Figure 3.20). 
 
 
Figure 3.20. Plots showing the dependence of relative viscosity on rb for calf 
thymus DNA modified by Ir
III
 complexes [(η5-C5Me5)Ir(phen)Cl]
+
 (4), [(η5-
C5Me4C6H5)Ir(phen)Cl]
+
 (5), and [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6). The 
viscosity was measured in 10 mM NaClO4, pH 6 at 310 K. (), complex 4; (), 
complex 5; (○), complex 6. 
Chapter 3: Cyclopentadienyl Iridium Complexes Containing N,N- or N,O-Chelating Ligands  
 
 
117 
3.4 Discussion 
3.4.1 X-ray Crystal Structures 
A search of the Cambridge Crystallographic Database revealed that no structure 
of metal complexes containing the ligand Cp
xbiph
 has been reported. Complexes 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) and [(η
5
-C5Me4C6H4C6H5)Ir- 
(bpy(OH)O)Cl] (21) therefore appears to be the first such structures. The crystal 
structures of [(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6), [(η
5
-C5Me4C6H5)Ir(bpy)Cl]- 
PF6
 
(8·PF6), [(η
5
-C5Me4C6H5)Ir(en)Cl]BPh4 (11·BPh4), [(η
5
-C5Me4C6H5)Ir(pico)Cl] 
(13) and [(η5-C5Me4C6H5)Ir(bpy(Me)2)Cl]PF6·(C2H5)2O (17·PF6·(C2H5)2O) are the 
first examples with (η5-C5Me4C6H5) (Cp
xph
 ) coordinated to iridium.  
The Ir–Cl bond lengths in complexes 8·PF6 and 9·PF6 (2.3859(19) and 2.3840(14) 
Å, respectively, Table 3.2) are almost the same, however, the Ir–Cl bond length in 
complex 7 is slightly longer (2.404(2) Å).
47
 The twist angles in complex 9·PF6 are 
similar to those angles in Ru
II
 terphenyl arene complexes.
67
 The Ir–Cl bond length 
in complex 13 (2.3860(10) Å) is slightly shorter than that in complex 12 [(η5-
C5Me5)Ir(pico)Cl] (2.3997(15) Å).
48
 
The distance between Ir
III
 and the centroid of Cp ring in [(η5-
C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) (1.783 Å) is similar to that in [(η
5
-
C5Me5)Ir(phen)Cl]CF3SO3 (1.780 Å),
68
 and the Ir−Cl bond length in 5·PF6 
(2.3891(5) Å) is similar to that in [(η5-C5Me5)Ir(phen)Cl]CF3SO3 (2.395 Å).
68
 
Complexes [(η5-C5Me5)Ir(bpy(OH)O)Cl] (19) and [(η
5
-C5Me4C6H4C6H5)Ir- 
(bpy(OH)O)Cl] (21) also have similar Ir−Cl bond lengths (2.3957(11) and 2.3836(6) 
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Å, respectively) and similar distances from Ir
III
 to the centroid of Cp ring (1.791 and 
1.793 Å, respectively). On changing Cp* to substituted Cp* ligands, no significant 
change is observed by DFT calculations for Ir–Cl and Ir–cyclopentadienyl ring 
bond distances. These results suggest that the introduction of phenyl substituent on 
the Cp* ring does not give rise to significant change in structure.  
 
3.4.2 Hydrolysis and pKa of Aqua Adducts 
There are only a few previous studies of the aquation of organometallic Ir
III
 
complexes.
14,69
 In general, all the complexes studied in this Chapter hydrolyse 
rapidly. Complexes 4, 7 and 10 containing Cp*, and 12–14 containing picolinate 
hydrolysed too rapidly to be observed by conventional UV-Vis at 288 K (t1/2 < 1 
min). Even complex [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6), which hydrolysed the 
slowest of these complexes, had a calculated half life at 310 K of < 4 min (Table 
3.4). These results illustrate that Ir
III
 complexes are not always inert and can be 
quite labile. The hydrolysis of Ir–Cl bonds in iridium complexes is strongly 
dependent on the coordinated ligands. These Cp
x
 Ir
III
 complexes undergo even 
faster hydrolysis than low-spin d
6
 arene Ru
II
 and Os
II
 phen complexes,
35,70 
more 
than 2 orders of magnitude faster than Os
II
 for example. The electron-donor methyl 
groups on the Cp ring may contribute to the fast hydrolysis. These increase the 
effective charge on Ir and facilitate chloride loss. This behavior is consistent with 
that of hexamethylbenzene Ru
II
 complexes.
71
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Previous studies on the hydrolysis rates of Os
II
 arene compounds of the type [(η6-
arene)Os(XY)Cl]
n+
 have shown that the aqueous reactivity of these complexes is 
highly dependent on the nature of the chelating ligand.
72,73
 In particular the 
negatively-charged electron-donating picolinate ligand increases the rate of 
hydrolysis compared to complexes with diamine ligands, as seen here for 
complexes 12–14.  
The presence of bpy as a π-acceptor in complex [(η6-bip)Ru(bpy)Cl]PF6, where 
bip = biphenyl, decreases the rate of hydrolysis by a factor of two compared to the 
en analogue.
70,74
 The π-acceptor ligands bpy and phen can withdraw electron 
density from a metal centre, increasing the positive charge on the metal, making it 
less favorable for Cl
−
 to leave, slowing down the hydrolysis. As a result, complexes 
[(η5-C5Me4C6H5)Ir(phen)Cl]
+ 
(5), [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6), [(η5-
C5Me4C6H5)Ir(bpy)Cl]
+ 
(8), and [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]
+ 
(9) containing 
bpy or phen as the chelating ligand hydrolysed much more slowly than the en 
complex 10 and pico analogues, complexes 13 and 14. However, despite the 
electron withdrawing ability of bpy and phen, the hydrolysis rates of complexes 
[(η5-C5Me5)Ir(phen)Cl]
+
 (4) and [(η5-C5Me5)Ir(bpy)Cl]
+
 (7) are still relatively fast 
and appear to be controlled by the powerful electron donor Cp*. 
 
Previous work has shown that the interaction of [(η6-bip)Ru(en)Cl]+ with amino 
acids,
75
 proteins,
75
 peptides,
76
 and DNA bases
36
 involves aquation (substitution of 
Cl by H2O) as the first step. The anticancer drug cisplatin also undergoes aquation 
prior to platination of the target site, DNA.
57,77
 The equilibrium constants at 278 K 
for hydrolysis of complexes 4−6, 7−9, and 12−14, decrease in the order 6 > 5 > 4, 
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9 > 8 > 7, and 14 > 12, 13 (Table 3.4), which parallels their cytotoxicity (Table 3.7), 
perhaps indicating that activation by aquation is important for the mechanism of 
their cytotoxic action. 
When the pKa values of the aqua complexes (Table 3.5) are compared, it is 
evident that the presence of phenyl or biphenyl substitutent lowers the pKa value by 
ca. 0.4 units consistent with withdrawal of electron density from the Ir centre. 
Replacement of the π-acceptor ligand bpy in aqua complex [(η5-
C5Me5)Ir(bpy)(D2O)]
2+
 (7A) by the chelating diamine donor en in [(η5-
C5Me5)Ir(en)(D2O)]
2+
 (10A), leads to a significant increase in pKa by ca. 0.7 units, 
consistent with an increased electron density on the metal centre. Similarly, the 
replacement of the neutral chelated bpy ligand by the anionic pico ligand raises the 
pKa by 1.1 units. There appears to be no correlation between the pKa values of the 
aqua adducts and the cytotoxicity of these complexes. The pKa values of the pico, 
en and phen aqua complexes 4A, 6A, 10A, 12A−14A suggest that they will be 
present largely as the reactive aqua adducts as opposed to the less reactive 
hydroxido adducts at physiological pH (7.4), whereas the pKa values of the bpy 
complexes 7A−9A are significantly lower, especially 8A, and therefore most of the 
hydrolysed bpy complexes would be present as the hydroxo form (at pH 7.4). 
Despite this, complexes [(η5-C5Me4C6H5)Ir(bpy)Cl]
+ 
(8), and [(η5-
C5Me4C6H4C6H5)Ir(bpy)Cl]
+ 
(9) exhibit good activity. Their reactivity would be 
aided by the small lowering of pH which is thought to occur in tumours.
78
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For Ru
II
 complexes which contain biphenyl as the arene and bpy as chelating 
ligand, loss of the arene is observed in aqueous solution.
70
 In contrast, no loss of 
any Cp
x
 ligands was observed for any of the Ir
III
 complexes studied in this work. 
 
3.4.3 Interactions with Nucleobases 
DNA is often a target for cytotoxic transition metal anticancer complexes.
59,60
 
There is little reported work on interactions of iridium complexes with 
nucleobases.
79-82
 In the present study, the reactions of complexes 4−14, and aqua 
complex [(η5-C5Me4C6H5)Ir(phen)(D2O)]
2+
 (5A) with 9-ethylguanine (9-EtG) and 
9-ethyladenine (9-EtA) were investigated, Table 3.6. Complexes 4−11 and 5A 
containing a neutral N,N- chelating ligand all bind selectively to 9-EtG compared to 
9-EtA, with which no reaction was observed after 24 h. This result is consistent 
with the replication mapping experiments (Figure 3.18) which show that G residues 
are the preferential binding sites on polymeric DNA modified with complexes 4−6. 
The selectivity in nucleobase binding can be rationalised in terms of H-bonding, 
non-bonding repulsive interactions between the chelating ligand and nucleobase 
substituents, and the electronic properties of the various nucleobase coordination 
sites.
72
 Previous studies of Ru−N7 guanine adducts have revealed a strong H-
bonding interaction between one en NH and G C6O.
36
 This may explain the strong 
affinity of 9-EtG for the Ir
III
 en complexes 10 and 11. A phenanthroline ligand 
cannot provide a donor NH group, but instead the interaction with G C6O may be 
stabilised by a C−H H-bond similar to that observed in a bipyridine complex of 
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Ru
II
.
70
 This possibility was indicated by the DFT optimized structure of the 9-EtG 
adduct of 6 (Figure 3.21).  
 
 
 
Figure 3.21. Optimized geometry of complex [(η5-C5Me4C6H4C6H5)Ir(phen)(9-
EtG)]
2+ 
(6G), where phen appears to interact with 9-EtG through a C6O∙∙∙H−C H-
bond (2.169 Å). 
 
Complexes 4−11 containing an N,N-chelating ligand did not react with 9-EtA, 
most likely due to the steric hindrance of the NH2 group on the 6-position of the 
adenine ring. Compared to complexes containing an N,N-chelating ligand, 
compounds 12−14 which contain the N,O-chelating ligand pico, bind significantly 
(70−100%) to both nucleobases, see Table 3.6. These picolinate IrIII adducts of 
complexes 12, 13 and 14 with 9-EtA (12Ad, 13Ad, and 14Ad, respectively) can be 
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stabilised by hydrogen bonding between the NH2 group of adenine and a 
carboxylate oxygen of the picolinate ligand.
83
 
As expected, the aqua complex [(η5-C5Me4C6H5)Ir(phen)(D2O)]
2+
 (5A) reacted to 
a greater extent with 9-EtG compared to the chlorido complex 5, see Table 3.6, 
consistent with the increased reactivity of aqua adducts compared to their chlorido 
forms,
56
 but the selectivity for G versus A was the same.  
 
3.4.4 Hydrophobicity (log P) and Cell Accumulation 
log P values for octanol/water partition provide a measure of hydrophobicity 
which is often a factor relevant for cell uptake and anticancer activity. For several 
classes of metallo-anticancer complexes, a correlation between increased 
hydrophobicity and increased cytotoxic activity has been reported.
63-66
   
In this study, as expected, the log P values (Table 3.8) and hydrophobicity 
increase with increasing size of the substituted Cp* ligand. Additionally, the 
hydrophobicity, cancer cell activity, and cell accumulation correlate significantly, 
following the order 6 > 5 > 4. Complex [(η5-C5Me5)Ir(phen)Cl]
+ 
(4) is the least 
hydrophobic, the least cytotoxic, and the least taken up by the cells, whereas 
complex [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6) displays the highest hydrophobicity, 
is the most cytotoxic, and the most taken up by the cells. These data suggest that in 
the ovarian A2780 cancer cell line, the log P value is a useful parameter for 
predicting the cytotoxicity of this class of iridium complexes. These data also show 
that using more extended coordinated Cp
x
 ligands such as tetramethyl(biphenyl)-
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cyclopentadienyl (Cp
xbiph
) gives rise to an increased hydrophobicity leading to 
higher cellular uptake and higher cytotoxicity. 
 
3.4.5 Distribution of Iridium in Cells 
The accumulation of the three phen complexes [(η5-C5Me5)Ir(phen)Cl]
+
 (4), [(η5-
C5Me4C6H5)Ir(phen)Cl]
+
 (5), and [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6) into the 
different cell fractions was studied. A significant proportion of the total iridium 
(54−74%) was in the cell membrane fraction, see Figure 3.17. This may be related 
not only to Ir being transported into the cytoplasm but also to Ir being exported by 
cells. For all complexes, the next highest concentration of iridium was found in the 
cytosol showing that passage through the outer membrane readily occurs.  
Although the lowest proportion of iridium was found in the nucleus, especially 
for complexes 4 and 6, it is notable that there is a correlation between nucleus 
accumulation and cytotoxicity of the complexes, both of which follow the order 6 > 
5 > 4, suggesting that penetrating the nucleus and binding to nuclear DNA may 
provide an important contribution to the mechanism of cytotoxicity. A similar 
relationship between nucleus accumulation and cytotoxicity was observed for Os
II
 
arene complexes.
84
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3.4.6 DNA Binding in A2780 Human Ovarian Cancer Cells 
The amount of iridium found on the DNA of A2780 cells (Table 3.9) incubated 
with the complexes for 24 h follows the order 6 > 5 > 4, which correlates with their 
cytotoxicity, hydrophobicity (log P), and cellular accumulation (Table 3.9), and is 
similar to the total accumulation by cell nuclei. The extent of iridium binding of 
4−6 to DNA, 5.5−7.7% of the total iridium taken up by the cells, is higher than that 
reported for cisplatin (~1%)
85
 and Os
II
 arene complexes.
84
 DNA may therefore be a 
potential target for these cytotoxic iridium complexes, although the possibility that 
nuclear DNA may not be the only target cannot be ruled out.  
 
3.4.7 EtBr Displacement and Viscometry 
The fluorescent probe EtBr can be used to distinguish between intercalating and 
nonintercalating ligands.
86-88
 Viscosity measurements are also useful for probing the 
nature of DNA interactions since viscosity is sensitive to alterations in DNA length. 
For instance, complexes or ligands that intercalate cause an increase in overall DNA 
contour length due to the increase in separation of base pairs at the intercalation 
sites, which leads to an increase in viscosity of DNA solutions. On the other hand, 
drug molecules which bind in DNA grooves cause less pronounced changes in the 
viscosity of DNA solutions.
89
 
Modification of CT DNA by complexes [(η5-C5Me5)Ir(phen)Cl]
+
 (4), [(η5-
C5Me4C6H5)Ir(phen)Cl]
+
 (5), and [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6) resulted in 
a decrease of EtBr fluorescence intensity (Figure 3.19) and an increase in the 
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relative viscosity of CT DNA (Figure 3.20) in the same order 6 > 5 > 4, which 
correlates with their cytotoxicity. These results indicate that addition of phenyl 
substituents to the Cp* ring in these iridium complexes enhances the intercalative 
ability into DNA. Dual-mode intercalation/G N7 coordination DNA binding may 
therefore play an important role in the cytotoxicity of these Ir
III
 complexes. This 
observation parallels that of Ru
II
 and Os
II
 arene complexes for which extended 
arenes can also intercalate and increase the potency of the complexes.
37,90
 For 
example, the Ru
II
 anticancer complex [(η6-p-terp)Ru(en)Cl]+ (where p-terp = para-
terphenyl, a similar arene ligand to Cp
xbiph
) also exhibits combined intercalative and 
monofunctional (coordination) binding to DNA.
67
  
 
3.4.8 Cytotoxicity 
Complexes [(η5-C5Me5)Ir(phen)Cl]Cl (4·Cl), [(η
5
-C5Me5)Ir(bpy)Cl]Cl (7·Cl), 
[(η5-C5Me5)Ir(en)Cl]PF6 (10·PF6), [(η
5
-C5Me5)Ir(pico)] (12) and [(η
5
-C5Me5)Ir- 
(bpy(Me)2)Cl]PF6 (16·PF6) containing Cp* were non-toxic (IC50 > 100 μM) toward 
the human ovarian A2780 cancer cell line (Table 3.7). The cytotoxicity of 
complexes [(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6) and [(η
5
-C5Me4C6H4C6H5)Ir- 
(phen)Cl]PF6
 
(6·PF6) containing phenyl and biphenyl substituents, respectively, on 
the tetramethylcyclopentadienyl ring increases dramatically compared to the parent 
Cp* complex 4. Complex 6 containing Cp
xbiph 
is ca. twice as potent towards A2780 
human ovarian cancer cells as the anticancer drug cisplatin (Table 3.7). In addition, 
complexes [(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6), [(η
5
-C5Me4C6H4C6H5)Ir- 
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(phen)Cl]PF6
 
(6·PF6) and [(η
5
-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) show potent 
cytotoxicity toward NCI 60 cancer cell lines and have a broad spectrum of activity 
(Figures 3.15 and 3.16). The introduction of phenyl and biphenyl substituents also 
resulted in significant increases in activity for all other complexes studied in this 
Chapter, suggesting that the phenyl groups play a crucial role in the mechanism of 
action. This is consistent with our previous observations that the cytotoxicity of η6-
arene Ru
II
 compounds increases with the size of the arene ring system in the order 
benzene < p-cymene < biphenyl < dihydroanthracene < tetrahydroanthracene.
11
 The 
increase in potency on addition of phenyl substituents to the Cp ring, by about an 
order of magnitude for each of the additions (from 4 to 5 to 6) is more dramatic than 
in the case of ruthenium arene ethylenediamine complexes.
67,91
 For these iridium 
complexes, the phenyl substitutents not only enhance lipophilicity and cell 
accumulation, but also introduce an additional mode of DNA interaction 
(intercalation). 
Both complexes [(η5-C5Me4C6H5)Ir(bpy)Cl]
+ 
(8) and [(η5-C5Me4C6H5)Ir(pico)Cl] 
(13) contain Cp
xph
, however, 8 exhibits activity towards A2780 cancer cells whereas 
13 is inactive, which suggests that the chelating ligand also plays a role. 
Replacement of neutral bpy by anionic pico as the chelating ligand increases the 
rate and extent of hydrolysis, the pKa of the aqua complex (from 6.31 to 7.75 for 
ring = Cp
xph
, Table 3.5), and changes the nucleobase specificity. For complexes 7−9 
containing neutral bpy, there is exclusive binding to 9-EtG. In contrast, complexes 
12−14 containing anionic pico bind strongly to both 9-EtG and 9-EtA. However the 
picolinate complexes have lower cytotoxicity than the N,N-bound phen or bpy 
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complexes. The reasons for the low cytotoxicity are not clear. These complexes 
may be too reactive with components of the cell culture medium and/or the cells 
before they reach target sites, thus effectively being deactivated. For example, the 
amino acids (methionine or cysteine) or tripeptides can form S-bound adducts with 
Ir
III 
Cp* complexes.
79
 
The inactivity of Cp* complexes [(η5-C5Me5)Ir(phen)Cl]Cl (4·Cl) and [(η
5
-
C5Me5)Ir(bpy)Cl]Cl (7·Cl), may be correlated with poor cellular accumulation and 
lack of intercalation into DNA. These factors may also explain the inactivity of [(η5-
C5Me5)Ir(en)Cl]PF6 (10·PF6). Interestingly some ruthenium
92
 and osmium
35
 arene 
complexes containing phen or bpy derivatives also show poor or no activity against 
A2780 cells.  
Unlike [(η5-C5Me5)Ir(bpy)Cl]Cl (7·Cl), which is inactive toward the human 
ovarian A2780 cancer cell line, Cp* complex [(η5-C5Me5)Ir(bpy(OH)O)Cl] (19) 
showed moderate activity toward A2780 cell line (Table 3.7). This result is 
consistent with previous reports on bipyridine and bipyridinediol Ru
II
 arene 
complexes.
70
 Complexes 22−24 containing dpq or dppz chelating ligand showed 
potent cytotoxicity toward A2780 cancer cell line, which may benefit from the 
strong intercalation of the chelating ligands.
26
 The potent cytotoxicity of complexes 
[(η5-C5Me5)Ir(azpy-NMe2)Cl]PF6 (26·PF6) and [(η
5
-C5Me4C6H5)Ir(azpy-NMe2)Cl]- 
PF6 (27·PF6) containing azpy-NMe2 chelating ligand may be related to redox 
mechanisms.
93
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3.5 Conclusions 
The goal of the present study was to explore the rational design of organometallic 
half-sandwich Ir
III
 anticancer complexes based on knowledge of the features which 
contribute to the activity of half-sandwich Ru
II
 and Os
II
 arene complexes.
3-8,94-96
 The 
biological and medicinal chemistry of iridium complexes has been little explored 
previously,
16-28
 perhaps because it is often assumed that low-spin 5d
6
 Ir
III
 complexes 
are highly kinetically inert.
14,15,33,34
 The study in this Chapter shows that this is not 
always the case. Cyclopentadienyl ligands, whilst stabilising Ir
III
, can confer kinetic 
lability on trans monodentate ligands such as chloride. Moreover phenyl 
substituents on the Cp* ring as in Cp
xph
 and Cp
xbiph
 can have a major effect on the 
chemical and biological behaviour of [(η5-Cpx)Ir(XY)Cl]0/+ complexes. This 
appears to be the first time that Cp
xph
 and Cp
xbiph
 ligands have been used in iridium 
complexes.  
The introduction of a phenyl substituent into the Cp* ring switches on cancer cell 
cytotoxicity. For example, complex [(η5-C5Me4C6H5)Ir(phen)Cl]
+
 (5) is more than 
one order of magnitude more potent than the Cp* complex [(η5-C5Me5)Ir(phen)Cl]
+
 
(4), and the biphenyl complex [(η5-C5Me4C6H4C6H5)Ir(phen)Cl]
+ 
(6) is more than 2 
orders of magnitude more potent than complex 4, and twice as potent as cisplatin in 
the same cell line. This increase in activity parallels the increase in hydrophobicity, 
increase in cell accumulation and DNA binding. Complexes 5 and 6 can exhibit 
dual mode binding to DNA: iridium binding to G N7 accompanied by intercalation 
of the phenyl substituents on the Cp* ring. On the other hand, the chelating ligand 
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can also play an important role in the anticancer activity. For example, the pico 
complex [(η5-C5Me4C6H5)Ir(pico)Cl] (13) shows no activity toward the A2780 cell 
line while the bpy analogue complex 8 [(η5-C5Me4C6H5)Ir(bpy)Cl]
+
, shows good 
activity, and the bpy complex [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]
+ 
(9) is more than one 
order of magnitude more potent than the pico analogue, complex 14 [(η5-
C5Me4C6H4C6H5)Ir(pico)Cl]. 
Figure 3.22A provides an overview of the relationships between cancer cell 
cytotoxicity, intercalative ability, cellular accumulation, hydrophobicity, and rates 
and extents of hydrolysis for the phen complexes 4–6. Figure 3.22B shows how the 
chelating and Cp
x
 ligands affect the anticancer activity, nucleobase binding, and 
aqueous chemistry of the bpy complexes 7–9 and pico complexes 12–14. These 
[(η5-Cpx)Ir(XY)Cl]0/+ complexes hydrolyse rapidly (the slowest half-life < 4 min at 
310 K), and the nature of the cyclopentadienyl and chelating ligands significantly 
influence their aqueous chemistry. In general, the introduction of phenyl and 
biphenyl Cp* ring substituents slows down the hydrolysis rate, increases the extent 
of hydrolysis, and increases the acidity of the respective aqua species. The chelating 
ligand appears to determine the selectivity of nucleobase binding. The complexes 
containing N,N-chelating ligands discriminate strongly between the purine 
nucleobases guanine and adenine, showing little binding to the latter for either for 
Cp*, Cp
xph
 or
 
Cp
xbiph
 complexes. In contrast, complexes 12−14 containing the N,O- 
chelating ligand picolinate bind both to 9-EtG and 9-EtA. 
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Figure 3.22. (A) Bar charts illustrating the relationship between cytotoxicity toward 
human cancer cells, intercalative ability, cellular accumulation, hydrophobicity, and 
rates (288 K) and equilibrium constants (278 K) of hydrolysis for iridium 
complexes [(η5-Cpx)Ir(phen)Cl]+ containing Cpx = Cp* (4), Cpxph (5), and Cpxbiph 
(6). (B) Bar charts illustrating the influence of N,N-, N,O-chelating ligands and Cp
x
 
ligands on the cytotoxicity, nucleobase binding, hydrolysis and pKa of the aqua 
adducts of the bpy complexes 7–9, and pico complexes 12–14. 
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The work in this Chapter demonstrates that rational chemical design can be 
applied to Ir
III
 complexes to achieve potent cancer cell cytotoxicity. It is notable that 
Cp ring substituents can also play a major role in controlling the chemical and 
biological properties of ferrocenyl and titanocenyl anticancer complexes.
97,98
 In 
general, organometallic complexes offer much promise for the design of novel 
therapeutic agents.
3-8,94,95
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4.1  Introduction 
Organometallic complexes offer enormous scope for the design of anticancer 
candidates due to their versatile structures, potential redox features and wide range 
of ligand substitution rates.
1-6
 Iridium complexes are best known for their 
inertness,
7,8
 and indeed inert organometallic Ir
III
 scaffolds are finding use as potent 
enzyme inhibitors.
9
 The half-sandwich fragment {Cp*Ir
III
} (Cp* = 
pentamethylcyclopentadienyl) has been used as a stabilising entity in many 
organometallic iridium complexes.
10,11
 However, in Chapter 3 it was shown that 
Cp* Ir
III
 complexes with N,N-bound ethylenediamine (en), 2,2′-bipyridine (bpy), 
1,10-phenanthroline (phen), and N,O-bound picolinate (pico), are all inactive 
towards A2780 human ovarian cancer cells with IC50 values > 100 μM. Also Cp* 
Ir
III
 PTA complexes (PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane),
12
 and 
Cp* Ir
III
 pyTz complexes (pyTz = 2-(pyridine-2-yl)thiazole),
13
 are reported to be 
noncytotoxic against A2780 cells (IC50 values > 300 μM). It has been demonstrated 
in Chapter 3 that introduction of phenyl or biphenyl substituents on Cp* can switch 
on cancer cell cytotoxicity of N,N- or N,O-chelated Cp* Ir
III
 complexes. Chelating 
ligands are already known to have a major influence on the DNA base specificity 
and cytotoxicity of organometallic half-sandwich complexes of the type 
[(η6-arene)Ru/Os(XY)Z].14-16 In this Chapter, a different switch involving a single 
atom change (C
−
 for N) in chelating ligand to afford a neutral complex is introduced. 
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The Cyclometallated organometallic complexes incorporating C^N-chelating 
ligands have attracted much attention because of their wide applications in both 
catalysis and luminescence.
17,18
 However, few such previous studies have involved 
their anticancer activity.
19-21
  
In this Chapter, the aqueous chemistry (hydrolysis, acidity of the resultant aqua 
adducts), nucleobase binding and cancer cell toxicity of Ir
III
 complexes containing 
C^N-chelating ligands based on 2-phenylpyridine (phpy) with electron-donating or 
electron-withdrawing substituents, and with Cp* and substituted Cp* ligands, 
Figure 4.1, is studied. The differences between C^N-bound complex 
[(η5-C5Me5)Ir(phpy)Cl] (32) and N,N-bound complex [(η
5
-C5Me5)Ir(bpy)Cl]
+
 (7) in 
the structure, reactivity and cancer cell cytotoxicity are also compared. The results 
suggest that this new class of organometalic Ir(III) complexes is well suited for 
development as anticancer agents. 
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Figure 4.1 C^N-chelated iridium cyclopentadienyl complexes studied in this 
Chapter. 
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Figure 4.1 C^N-chelated iridium cyclopentadienyl complexes studied in this 
Chapter. 
 
4.2  Experimental Section 
4.2.1  Materials 
2-Phenylpyridine (phpy), 2-(2,4-difluorophenyl)pyridine (dfphpy), 2-(p-tolyl)- 
pyridine (tpy), 2-phenylquinoline (phq), benzo[h]quinoline (bq), 9-ethylguanine 
(9-EtG), 9-methyladenine (9-MeA), octan-1-ol (≥ 99%), and NaCl (> 99.999%) 
were purchased from Sigma-Aldrich. Nitric acid (72%) from Sigma Aldrich was 
double distilled and diluted using double de-ionized water. Methanol was distilled 
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over magnesium/iodine prior to use. The syntheses of the dimer 
[(η5-C5Me4C6H5)IrCl2]2 (2) and [(η
5
-C5Me4C6H4C6H5)IrCl2]2 (3) is described in 
Chapter 2. Dimer [(η5-C5Me5)IrCl2]2 (1),
22
 complexes [(η5-C5Me5)Ir(phpy)Cl] 
(32)
23
 and [(η5-C5Me5)Ir(bq)Cl] (35)
23
 were prepared according to reported 
methods. 
 
4.2.2  Syntheses 
[(η5-C5Me5)Ir(tpy)Cl] (29). A solution of [(η
5
-C5Me5)IrCl2]2 (48 mg, 0.06 
mmol), 2-(p-tolyl)pyridine (20 mg, 0.12 mmol) and sodium acetate (20 mg, 0.24 
mmol) in CH2Cl2 (15 mL) was stirred for 2 h at ambient temperature. The solution 
was filtered through celite. The filtrate was evaporated to dryness on a rotary 
evaporator, and washed with diethyl ether. The product was recrystallised from 
CHCl3/hexane. Yield: 45 mg (70%). 
1
H NMR (CDCl3): δ = 8.65 (d, 1H, J = 5.7 Hz), 
7.75 (d, 1H, J = 8.3 Hz), 7.62 (m, 2H), 7.57 (d, 1H, J = 8.0 Hz), 7.03 (t, 1H, J = 6.3 
Hz), 6.86 (d, 1H, J = 7.8 Hz), 1.68 (s, 15H). Anal. Calcd. for C22H25ClNIr (531.14): 
C, 49.75; H, 4.74; N, 2.64. Found: C, 49.66; H, 4.65; N, 2.68. 
 
[(η5-C5Me5)Ir(phq)Cl] (30). The synthesis was performed as for 29 using 
[(η5-C5Me5)IrCl2]2 (48 mg, 0.06 mmol), 2-phenylquinoline (25 mg, 0.12 mmol), and 
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sodium acetate (20 mg, 0.24 mmol). Yield: 43 mg (75%). 
1
H NMR (CDCl3): δ = 
8.71 (d, 1H, J = 8.8 Hz), 8.02 (d, 1H, J = 8.7 Hz), 7.93 (d, 2H, J = 8.8 Hz), 7.77 (m, 
2H), 7.69 (t, 1H, J = 8.1 Hz), 7.53 (t, 1H, J = 6.7 Hz), 7.24 (t, 1H, J = 7.8 Hz), 7.07 
(t, 1H, J = 7.7 Hz), 1.57 (s, 15H). Anal. Calcd. for C25H25ClNIr (567.13): C, 52.94; 
H, 4.44; N, 2.47. Found: C, 53.06; H, 4.41; N, 2.42. Crystals suitable for X-ray 
diffraction were obtained by slow evaporation of a methanol/diethyl ether solution 
at ambient temperature. 
 
[(η5-C5Me5)Ir(dfphpy)Cl] (31). The synthesis was performed as for 29 using 
[(η5-C5Me5)IrCl2]2 (48 mg, 0.06 mmol), 2-(2,4-difluorophenyl)pyridine (23 mg, 
0.12 mmol), and sodium acetate (20 mg, 0.24 mmol). Yield: 46 mg (70%). 
1
H NMR 
(CDCl3): δ = 8.71 (d, 1H, J = 6.0 Hz), 8.19 (d, 1H, J = 8.8 Hz), 7.69 (t, 1H, J = 8.0 
Hz), 7.31 (d, 1H, J = 8.8 Hz), 7.10 (t, 1H, J = 6.3 Hz), 6.49 (t, 1H, J = 9.5 Hz), 1.67 
(s, 15H). Anal. Calcd. for C21H21ClF2NIr (553.10): C, 45.60; H, 3.83; N, 2.53. 
Found: C, 45.76; H, 3.71; N, 2.46. 
 
[(η5-C5Me5)Ir(phpy)(9-EtG-N7)]NO3 (32G·NO3). A solution of 
[(η5-C5Me5)Ir(phpy)Cl] (32) (52 mg, 0.1 mmol) and AgNO3 (17 mg, 0.1 mmol) in 
MeOH (10 mL) and water (20 mL) was stirred at ambient temperature for 24 h. The 
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precipitate (AgCl) was removed by filtration through a glass wool plug, and 
9-ethylguanine (19 mg, 1.1 mol equiv) was added to the filtrate. The solution was 
stirred at ambient temperature for 12 h, and evaporated to dryness on a rotary 
evaporator. The residue was extracted with CH2Cl2 (10 mL), and the volume 
reduced to ca. 2 mL on a rotary evaporator. A yellow precipitate formed at 253 K 
on addition of hexane and was collected by filtration, washed with diethyl ether and 
dried in air. Yield: 23 mg (32%). 
1
H NMR (MeOD-d4): δ = 9.35 (d, 1H, J = 5.8 Hz), 
8.10 (d, 1H, J = 7.5 Hz), 7.84 (d, 1H, J = 8.0 Hz), 7.79 (t, 1H, J = 7.0 Hz), δ = 7.72 
(d, 1H, J = 7.5 Hz), 7.44 (t, 1H, J = 7.8 Hz), 7.42 (s, 1H), 7.26 (t, 1H, J = 6.3 Hz), 
7.21 (t, 1H, J = 8.0 Hz), 3.82 (q, 2H, J = 7.3 Hz), 1.62 (s, 15H), 1.12 (t, 3H, J = 7.3 
Hz). Anal. Calcd for C28H32IrN7O4 (722.82): C, 46.53; H, 4.46; N, 13.56. Found: C, 
46.74; H, 4.21; N, 13.23%. Crystals suitable for X-ray diffraction were obtained as 
32G·NO3·1.5CH2Cl2 by slow evaporation of a CH2Cl2/hexane solution at ambient 
temperature. 
 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (33). A solution of [(η
5
-C5Me4C6H5)IrCl2]2 (46 mg, 
0.05 mmol), 2-phenylpyridine (15 mg, 0.10 mmol) and sodium acetate (16 mg, 0.20 
mmol) in CH2Cl2 (15 mL) was heated under reflux in an N2 atmosphere for 24 h. 
The solution was filtered through celite. The filtrate was evaporated to dryness on a 
rotary evaporator and washed with diethyl ether. The product was recrystallised 
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from CHCl3/hexane. Yield: 37 mg (57%). 
1
H NMR (MeOD-d4): δ = 8.60 (d, 1H, J 
= 5.3 Hz), 8.04 (d, 1H, J = 8.3 Hz), 7.84 (m, 2H), 7.65 (d, 1H, J = 7.8 Hz), 7.38 (m, 
3H), 7.33 (m, 2H), 7.16 (t, 1H, J = 6.1 Hz), 7.13 (t, 1H, J = 7.2 Hz), 7.09 (t, 1H, J = 
7.3 Hz), 1.85 (s, 3H), 1.74 (s, 3H),1.72 (s, 3H), 1.56 (s, 3H). Anal. Calcd. for 
C26H25ClNIr (579.16): C, 53.92; H, 4.35; N, 2.42. Found: C, 53.77; H, 4.31; N, 
2.41. 
 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34). The synthesis was performed as for 33 
using [(η5-C5Me4C6H4C6H5)IrCl2]2 (53 mg, 0.05 mmol), 2-phenylpyridine (15 mg, 
0.10 mmol) and sodium acetate (16 mg, 0.20 mmol). Yield: 37 mg (57%). 
1
H NMR 
(CDCl3): δ = 8.51 (d, 1H, J = 5.3 Hz), 7.81 (d, 1H, J = 7.3 Hz), 7.72 (m, 2H), 7.64 
(m, 5H), 7.51 (m, 4H), 7.37 (d, 1H, J = 7.6 Hz), 7.16 (t, 1H, J = 7.3 Hz), 7.05 (t, 1H, 
J = 6.0 Hz), 6.94 (t, 1H, J = 7.3 Hz), 1.92 (s, 3H), 1.82 (s, 3H),1.79 (s, 3H), 1.67 (s, 
3H). Anal. Calcd. for C32H29ClNIr (655.25): C, 58.66; H, 4.46; N, 2.14. Found: C, 
58.46; H, 4.35; N, 2.18. Crystals suitable for X-ray diffraction were obtained by 
slow evaporation of a methanol/diethyl ether solution at ambient temperature. 
 
[(η5-C5Me4C6H5)Ir(bq)Cl] (36). The synthesis was performed as for 33 using 
[(η5-C5Me4C6H5)IrCl2]2 (46 mg, 0.05 mmol), benzo[h]quinoline (18 mg, 0.10 mmol) 
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and sodium acetate (16 mg, 0.20 mmol). Yield: 28 mg (46%). 
1
H NMR (CDCl3): δ 
= 8.68 (d, 1H, J = 5.5 Hz), 8.09 (d, 1H, J = 7.5 Hz), 7.93 (dd, 1H, J = 5.3 Hz), 7.81 
(d, 1H, J = 9.0 Hz), 7.56 (m, 5H), 7.39 (m, 3H), 7.31 (dd, 1H, J = 7.5 Hz), 1.83 (s, 
3H), 1.81 (s, 3H),1.55 (s, 3H), 1.53 (s, 3H). Anal. Calcd for C28H25ClNIr (603.13): 
C, 55.75; H, 4.18; N, 2.32. Found: C, 55.05; H, 3.16; N, 2.27. Crystals suitable for 
X-ray diffraction were obtained by slow evaporation of a methanol/diethyl ether 
solution at ambient temperature. 
 
[(η5-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37). The synthesis was performed as for 
33 using [(η5-C5Me4C6H4C6H5)IrCl2]2 (53 mg, 0.05 mmol), 
2-(2,4-difluorophenyl)pyridine (19 mg, 0.10 mmol), and sodium acetate (16 mg, 
0.20 mmol). Yield: 25 mg (37%). 
1
H NMR (CDCl3): δ = 8.53 (d, 1H, J = 5.5 Hz), 
8.19 (d, 1H, J = 8.5 Hz), 7.64 (m, 5H), 7.50 (m, 4H), 7.38 (t, 1H, J = 7.3 Hz), 7.22 
(d, 1H, J = 8.3 Hz), 6.96 (t, 1H, J = 6.5 Hz), 6.51 (t, 1H, J = 10.3 Hz), 1.81 (s, 3H), 
1.77 (s, 3H), 1.75 (s, 3H), 1.59 (s, 3H). Anal. Calcd for C32H27ClF2NIr (691.23): C, 
55.60; H, 3.94; N, 2.03. Found: C, 55.96; H, 3.95; N, 2.08. Crystals suitable for 
X-ray diffraction were obtained by slow evaporation of a methanol/diethyl ether 
solution at ambient temperature. 
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4.2.3  Methods 
4.2.3.1  X-ray Crystallography 
The details of the diffraction instrumentation are described in Chapter 2. The 
structures of complexes 30, 32G·NO3·1.5CH2Cl2, 34, 36 and 37 were solved by Dr. 
Guy Clarkson (Department of Chemistry, University of Warwick) using SHELXS 
(TREF)
24
 with additional light atoms found by Fourier methods. Complexes were 
refined against F
2
 using SHELXL,
25
 and hydrogen atoms were added at calculated 
positions and refined riding on their parent atoms. There is one CH2Cl2 molecule in 
a general position in the cell and one CH2Cl2 molecule that straddles a cell face in 
32G·NO3·1.5CH2Cl2. X-ray crystallographic data for complexes 30, 
32G·NO3·1.5CH2Cl2 and 34 have been deposited in the Cambridge 
Crystallographic Data Centre under the accession numbers CCDC 829525, 816981, 
and 829524, respectively. 
 
4.2.3.2  Determination of pKa Values 
The pKa* and pKa values of complexes 29A–34A were determined as described 
in Chapter 2. 
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4.2.3.3  Computation  
Details of computational methods are described in Chapter 2. Geometry 
optimization calculations for complexes [(η5-C5Me5)Ir(phpy)Cl] (32), 
[(η5-C5Me5)Ir(bpy)Cl]
+
 (7), and their aqua derivatives were performed in the gas 
phase with the gradient-corrected correlation functional PBE0.
26
 9-EtA was chosen 
instead of 9-MeA (used in experimental work) for the sake of comparison in the 
DFT work. Electrostatic potential surfaces (EPSs) for complexes 32, 7, and their 
aqua derivatives were calculated and mapped on electron density (isovalue 0.04) of 
the molecules. The electrostatic potential is represented with a colour scale ranging 
from red (–0.500 au) to blue (0.500 au). This work was carried out by Dr. Luca 
Salassa (Department of Chemistry, University of Warwick). 
 
4.2.3.4  Interactions with Nucleobases 
The reaction of complexes 29–34 (ca. 1 mM) with nucleobases typically involved 
addition of a solution containing 1 mol equiv of nucleobase in D2O to an 
equilibrium solution of complexes 29–34 in 20% MeOD-d4/80% D2O (v/v). 
1
H 
NMR spectra of these solutions were recorded at 310 K after various time intervals. 
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4.2.3.5  log P Determination  
The partition coefficients (log P) were determined for complexes 32 and 7 as 
described in Chapter 2. 
 
4.2.3.6  Cytotoxicity 
Cytotoxicity assays on A2780 human ovarian cancer cell line was performed by 
Dr. Ana M. Pizarro (Department of Chemistry, University of Warwick) as described 
in Chapter 2 for complexes 29–34 and 37. Complexes 32 and 34 were further 
evaluated by the NCI/DTP as described in Chapter 2 for in vitro cytotoxic test 
against ca. 60 human cancer cell lines. 
 
4.2.3.7  ICP-MS Analysis 
ICP analysis for the determination of the partition coefficients (log P) was 
performed as described in Chapter 2. 
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4.3  Results 
4.3.1  Synthesis and Characterisation 
Nine Ir
III
 half-sandwich complexes of the type [(η5-Cpx)Ir(C^N)Cl], where Cpx is 
pentamethylcyclopentadienyl Cp*, or its phenyl (Cp
xph
) or biphenyl (Cp
xbiph
)
 
derivatives, and the C^N-chelating ligands are 2-(p-tolyl)pyridine (tpy, 29), 
2-phenylquinoline (phq, 30), 2-(2,4-difluorophenyl)pyridine (dfphpy, 31 and 37), 
2-phenylpyridine (phpy, 32–34), or benzo[h]quinoline (bq, 35 and 36) were 
synthesised in moderate yields by reaction of the chelating ligand with the 
appropriate dimer [(η5-Cpx)IrCl2]2 in CH2Cl2. All the synthesised complexes were 
fully characterised by 
1
H NMR and CHN elemental analysis. All the complexes in 
this study are chiral, but no attempt was made to resolve them and racemates are 
used in the following studies. Complexes 29–34 as typical complexes containing 
C^N-chelating ligands are studied in more detail. 
The X-ray crystal structures of [(η5-C5Me5)Ir(phq)Cl] (30), 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), [(η
5
-C5Me4C6H5)Ir(bq)Cl] (36) and 
[(η5-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37) were determined. The structures and atom 
numbering schemes are shown in Figure 4.2. Crystallographic data are shown in 
Table 4.1, and selected bond lengths and angles are listed in Table 4.2. All 
complexes adopt the expected half-sandwich pseudo-octahedral “three-legged 
piano-stool” geometry with the iridium bound to a η5-cyclopentadienyl ligand (Ir to 
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ring centroid 1.817−1.829 Å). The Ir−Cl bond distances range from 2.3886(8) to 
2.4013(8) Å. In general, the Ir−C(chelating ligand) bond lengths are significantly 
shorter than the Ir−N bond lengths, except in 36. For complex 34, the twist angle 
between the bound cyclopentadienyl ring and the central phenyl ring is 48.93°, 
while that between the bound ring and the terminal phenyl ring is 28.50°. The 
phenyl rings are twisted by 21.55°. No intermolecular π-ring stacking in the unit 
cell is observed in the two crystal structures. 
 
 
Figure 4.2. X-ray crystal structures and atom numbering schemes for complexes 
[(η5-C5Me5)Ir(phq)Cl] (30), [(η
5
-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), [(η
5
-C5Me4- 
C6H5)Ir(bq)Cl] (36) and [(η
5
-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37). 
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Table 4.1. Crystallographic Data for Complexes [(η5-C5Me5)Ir(phq)Cl] (30), 
[(η5-C5Me5)Ir(phpy)(9-EtG-N7)]NO3·1.5CH2Cl2 (32G·NO3·1.5CH2Cl2), [(η
5
- 
C5Me4C6H4C6H5)Ir(phpy)Cl] (34), [(η
5
-C5Me4C6H5)Ir(bq)Cl] (36) and [(η
5
- 
C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37) 
 30 34 36 37 32G·NO3·1.5CH2Cl2 
formula C25H25ClIrN C32H29ClIrN C28H25ClIrN C32H27ClF2IrN C29.50H35Cl3IrN7O4 
MW 567.11 655.21 603.14 691.20 850.20 
cryst colour orange block orange block orange block yellow block yellow block 
cryst size  
(mm) 
0.40 × 0.40  
× 0.10 
0.22 × 0.18  
× 0.12 
0.28 × 0.20  
× 0.06 
0.16 × 0.14  
× 0.12 
0.40× 0.40  
× 0.10 
λ (Å) 0.71073 0.71073 0.71073 0.71073 0.71073 
temp (K) 100 100 100 100 100 
cryst syst orthorhombic monoclinic triclinic monoclinic triclinic 
space group P2(1)2(1)2(1) P2(1)/n P1 P2(1)/c P-1 
a (Å) 8.05090(13) 10.0094(4) 8.4631(3) 14.8865(3) 11.00314(16) 
b (Å) 15.9169(3) 22.9497(6) 16.1135(4) 9.09997(18) 12.2976(2) 
c (Å) 16.0586(3) 11.2128(4) 8.4706(3) 19.9316(5) 13.3976(2) 
α (°) 90 90 90 90 76.7310(14) 
β (°) 90 103.473(3) 107.513(3) 103.267(2) 67.6432(14) 
γ (°) 90 90 90 90 88.3673(13) 
vol(Å3) 2057.84(6) 2504.84(14) 1101.61(6) 2628.00(10) 1628.35(5) 
Z 4 4 2 4 2 
R(Fo2) 0.0370 0.0293 0.0321 0.0314 0.0218 
Rw(Fo2) 0.0890 0.0699 0.0774 0.0559 0.0555 
GOF 1.053 0.999 1.069 1.019 1.070 
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Table 4.2. Selected Bond Lengths (Å) and Angles (deg) for [(η5-C5Me5)Ir(phq)Cl] 
(30), [(η5-C5Me5)Ir(phpy)(9-EtG-N7)]NO3·1.5CH2Cl2 (32G·NO3·1.5CH2Cl2), 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), [(η
5
-C5Me4C6H5)Ir(bq)Cl] (36) and 
[(η5-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37)  
Bond(s) 30 34 36 37 Bond(s) 32G·NO3·1.5CH2Cl2 
Ir−C  2.139(6) 2.151(3) 2.134(7) 2.150(3) Ir(1)−C(Cp*) 2.156(2) 
(Cpx) 2.157(6) 2.163(3) 2.160(5) 2.156(4)  2.166(2) 
 2.167(5) 2.183(3) 2.203(7) 2.185(3)  2.166(2) 
 2.243(6) 2.240(3) 2.216(7) 2.235(3)  2.233(2) 
 2.304(6) 2.243(3) 2.235(8) 2.236(3)  2.277(3) 
Ir−C 
 
1.829 1.825 1.817 1.819 Ir−C 1.827 
(centroid)     (centroid)  
Ir−C 2.045(6) 2.057(3) 2.073(7) 2.035(3) Ir(1)−C(12) 2.048(2) 
Ir−N 2.128(5) 2.080(3) 2.051(7) 2.078(3) Ir(1)−N(1) 2.097(2) 
Ir−Cl 
Ir−Ir 
 
2.3989(16) 2.3886(8) 2.3952(16) 2.4013(8) Ir(1)−N(23)  2.114(2) 
 
       
C−Ir−N 77.4(2) 78.27(13) 78.9(3) 78.40(12) C(12)−Ir(1)−N(1) 77.92(9) 
C−Ir−Cl 89.66(17) 88.20(9) 86.12(18) 89.64(10) C(12)−Ir(1)−N(23) 86.32(8) 
N−Ir−Cl 87.23(13) 86.34(8) 86.47(19) 84.85(8) N(1)−Ir(1)−N(23) 91.56(8) 
 
 
4.3.2  Structural and Electronic Differences between Complexes 32 and 7 
There is a change in the overall charge on the complex from positive for complex 
7, where the chelating ligand is N,N-bound 2,2′-bipyridine, to neutral for complex 
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32 which contains C^N-bound 2-phenylpyridine. Geometry optimization 
calculations for complexes 7 and 32 were performed using the PBE0 functional. 
Selected bond distances for [(η5-C5Me5)Ir(bpy)Cl]
+
 (7) and [(η5-C5Me5)Ir(phpy)Cl] 
(32) are listed in Table 4.3. In complex 32, the chelating ligand is closer to the Ir
III
 
centre than in complex 7; a short Ir–C(phenyl) distance causes elongation of the 
Ir–Cl bond as well as the Ir–Cp*(centroid) distance (Table 4.3). 
 
Table 4.3. Selected Bond Distances for [(η5-C5Me5)Ir(bpy)Cl]
+
 (7) and 
[(η5-C5Me5)Ir(phpy)Cl] (32) Calculated at the PBE1PBE/LANLD2Z/6-31G** 
Level 
 Complex Ir–Cl Ir–N1/C1 Ir–N2 Ir–Centroid 
7 2.398 2.083 2.083 1.816 
32 2.411 2.009 2.077 1.863 
 
Electrostatic potential surfaces (EPS) for complexes 7, 32, and their aqua 
adducts were calculated. The N,N-chelating bpy complex 7 shows more positive 
electrostatic potentials than the C^N-chelating phpy complex 32 (Table 4.4). The 
same trend is observed in the electrostatic potential surfaces of the aqua derivatives 
[(η5-C5Me5)Ir(bpy)(H2O)]
2+
 (7A) and [(η5-C5Me5)Ir(phpy)(H2O)]
+
 (32A), which as 
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expected show more positive surfaces compared to their chlorido analogues, 7 and 
32. 
 
Table 4.4. Electrostatic Potential Surfaces (EPSs) for Chlorido Complexes 7, 32, 
and Their Aqua Adducts 7A and 32A. 
Complex Structure 
EPS (isovalue = 0.04) 
 
7 
  
32 
 
 
7A 
  
32A 
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4.3.3  Hydrolysis Studies 
The hydrolysis of complexes 29–34 in 20% MeOD-d4/80% D2O (v/v) was 
monitored by 
1
H NMR spectroscopy at different temperatures. The presence of 
methanol ensured the solubility of the complexes. All these Ir
III
 complexes undergo 
rapid hydrolysis. Equilibrium was reached by the time the first 
1
H NMR spectrum 
was acquired (~5 min) even at 278 K. At equilibrium 20%–50% of complex 29–34 
was in the hydrolysed form, based on 
1
H NMR peak integrals. 
 
 
Figure 4.3. Confirmation of hydrolysis of Ir
III
 complex [(η5-C5Me5)Ir(tpy)Cl] (29). 
(A) 
1
H NMR spectrum of an equilibrium solution of 29 (1 mM) in 20% 
MeOD-d4/80% D2O (v/v) at 298 K. (B) 
1
H NMR spectrum recorded 10 min after 
addition of NaCl (final concentration, 4 mM) to the equilibrium solution of 29. 
Complex 29A corresponds to the aqua complex [(η5-C5Me5)Ir(tpy)(D2O)]
+
.  
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To confirm the hydrolysis of the complexes, 4 mol equiv of NaCl was added to 
equilibrium solutions containing the chlorido complexes and their aqua adducts. 
1
H 
NMR spectra were then recorded within 10 min of the Cl
−
 additions at 298 K. Upon 
addition of NaCl, the 
1
H NMR peaks corresponding to the chlorido complexes 
increased in intensity whilst peaks for the aqua adducts decreased, Figure 4.3. These 
data confirm the formation of the aqua adducts and the reversibility of the process. 
 
4.3.4  pKa Determination 
Changes in the 
1
H NMR chemical shifts of the methyl protons of Cp* or protons 
of the coordinated chelating ligands in aqua complexes 29A−34A, were followed 
with change in pH* over a range of 2−10 (Figure 4.4). 1H NMR peaks assigned to 
aqua complexes gradually shifted to high field with increase in pH*. The resulting 
pH titration curves were fitted to the Henderson-Hasselbalch equation, from which 
the pKa* values of the coordinated water were determined. This gave pKa values 
between 8.31 and 8.87 (Table 4.5), with the Cp
xbiph
 aqua complex 34A and 
fluoro-substituted phenylpyridine Cp* complex 31A having the lowest pKa values 
(8.31 and 8.32, respectively) and the methyl-substituted phenylpyridine complex 
29A having the highest (8.87).  
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Figure 4.4. Dependence of the 
1
H NMR chemical shifts for Cp* methyl groups in 
aqua complexes 29A and 30A, and for coordinated chelating ligands in aqua 
complexes 31A−34A on pH* for complexes (A) [(η5-C5Me5)Ir(tpy)(D2O)]
+
 (29A), 
(B) [(η5-C5Me5)Ir(phq)(D2O)]
+
 (30A), (C) [(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (31A), (D) 
[(η5-C5Me5)Ir(phpy)(D2O)]
+
 (32A), (E) [(η5-C5Me4C6H5)Ir(phpy)(D2O)]
+
 (33A), 
and (F) [(η5-C5Me4C6H4C6H5)Ir(phpy)(D2O)]
+
 (34A). The curves are computer fits 
giving the pKa* values shown in Table 4.5. 
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Table 4.5. pKa* and pKa Values
a
 for the Deprotonation of the Coordinated D2O in 
Complexes 29A−34A 
Aqua Complex pKa* pKa 
[(η5-C5Me5)Ir(tpy)(D2O)]
+
 (29A) 9.10 8.87 
[(η5-C5Me5)Ir(phq)(D2O)]
+
 (30A) 8.86 8.65 
[(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (31A) 8.51 8.32 
[(η5-C5Me5)Ir(phpy)(D2O)]
+
 (32A) 8.97 8.75 
[(η5-C5Me4C6H5)Ir(phpy)(D2O)]
+
 (33A) 8.64 8.45 
[(η5-C5Me4C6H4C6H5)Ir(phpy)(D2O)]
+
 (34A) 8.50 8.31 
a
 pKa values calculated from pKa* according to Krezel and Bal.
27
 
 
During the pH titrations for aqua complexes 29A−34A, the appearance of a new 
set of peaks was detected with increasing pH* (>8.7). The new peaks are 
attributable to the free C^N-chelating ligands and to the hydroxo-bridged dimers 
{[(η5-Cpx)Ir]2(μ-OD)3}
+
 (Cp
x
 = Cp*, 38; Cp
xph
, 39; Cp
xbiph
, 40, see Figure 4.1). The 
1
H NMR peaks for hydroxo-bridged dimers 38−40 increased in intensity with 
increase in pH*. For complex [(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (31A), the amount of 
dimer 38 increased from 23% at pH* 9.0 to 50% at pH* 9.6, Figure 4.5. ESI-MS 
studies on the diluted sample (0.2 mM) gave a major peak at m/z 709.2, consistent 
with the presence of {[(η5-C5Me5)Ir]2(μ-OD)3}
+
 (calcd m/z 710.2). 
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Figure 4.5. Methyl region of 
1
H NMR spectra from the pH titration of the aqua 
complex [(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (31A), showing an increase in intensity of 
the peak for the hydroxo-bridged dimer {[(η5-C5Me5)Ir]2(μ-OD)3}
+
 (38) with 
increase in pH*. 
 
4.3.5  Interactions with Nucleobases 
  Since DNA is a potential target for transition metal anticancer drugs,
28,29
 
nucleobase binding reactions of complexes [(η5-C5Me5)Ir(tpy)Cl] (29), 
[(η5-C5Me5)Ir(phq)Cl] (30), [(η
5
-C5Me5)Ir(dfphpy)Cl] (31), [(η
5
-C5Me5)Ir(phpy)Cl] 
(32), [(η5-C5Me4C6H5)Ir(phpy)Cl] (33) and [(η
5
-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), 
with 9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA) were investigated. 
Solutions of 29−34 (ca. 1 mM, containing an equilibrium mixture of 29−34 and 
their respective aqua adducts 29A−34A) and 1 mol equivalent of 9-EtG or 9-MeA 
in 20% MeOD-d4/80% D2O (v/v) were prepared, and 
1
H NMR spectra were 
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recorded at different time intervals at 310 K. The percentages of nucleobase adducts 
formed by the complexes after 24 h reaction, based on 
1
H NMR peak integrals, are 
shown in Table 4.6 and Figure 4.6.  
 
 
Figure 4.6. Bar chart showing the extent of binding of complexes 29−34 (ca. 1 mM 
in 20% MeOD-d4/80% D2O) to the nucleobases 9-EtG and 9-MeA at equilibrium 
(24 h), based on 
1
H NMR peak integrals. 
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Table 4.6. Extent of 9-EtG and 9-MeA Adduct Formation for Complexes 29−34 (ca. 
1 mM) at 310 K after 24 h. 
Complex 
9-EtG adduct 
(%) 
9-MeA adduct 
(%) 
9-EtG/9-MeA competition 
G adduct (%)    A adduct (%) 
29 100 90 80 20 
30 45 <5 -
a
 -
a
 
31 100 35 100 0 
32 96 86 85 15 
33 100 46 100 0 
34 100 63 100 0 
a
 Not determined. 
 
 
Figure 4.7. Low field region of 
1
H NMR spectra showing reaction of 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (33) with 9-ethylguanine.
 
(A) Equilibrium solution of 
33 (0.8 mM) in 20% MeOD-d4/80% D2O (v/v, pH* 7.4) at 310 K, containing an 
equilibrium mixture of 33 and its aqua adduct 33A. (B) 10 min after addition of 1 
mol equiv 9-ethylguanine, showing the complete formation of the 9-EtG adduct 
33G.  
Chapter 4: Cyclopentadienyl Iridium Complexes Containing C^N-Chelating Ligands 
168 
 
In the 
1
H NMR spectrum of a solution containing [(η5-C5Me4C6H5)Ir(phpy)Cl] 
(33) (0.8 mM) and 1 mol equiv 9-ethylguanine (20% MeOD-d4/80% D2O, pH* 7.4, 
310 K), one set of new peaks assignable to the 9-EtG adduct 33G appeared, 
showing that 100% of 33 had reacted after 10 min (Figure 4.7). A significant 
change in chemical shift from 8.62 ppm for the chlorido complex 33 to 9.28 ppm 
for 9-EtG adduct 33G for the CH=N (phpy ligand) proton was observed. A new 
9-EtG H8 peak appeared at 7.44 ppm (singlet), shifted by 0.34 ppm to high field 
relative to that of free 9-EtG. After 24 h, no further change was observed. The 
ESI-MS of an equilibrium solution contained a major peak at m/z 723.2, confirming 
the formation of the 9-EtG adduct 33G, [(η5-C5Me4C6H5)Ir(phpy)(9-EtG)]
+
 (calcd 
m/z 722.9). Similarly, complexes 29, 31, 32 and 34 also formed 9-EtG adducts to 
the extent of 96%−100% after 24 h. Only complex 30 containing 2-phenylquinoline 
showed less strong binding to 9-EtG (45%, Table 4.6 and Figure 4.6). 
The 9-EtG adduct of complex 32, [(η5-C5Me5)Ir(phpy)(9-EtG)]NO3 (32G·NO3) 
was isolated and the X-ray crystal structure confirmed that 9-EtG is bound through 
N7 (Figure 4.8A). Crystallographic data are shown in Table 4.1, and selected bond 
lengths and angles are listed in Table 4.2. The nitrate counter ion shows H-bonding 
to a 9-EtG ligand, with distances of 1.987(19) Å (O12∙∙∙H26) and 1.975(19) Å 
(O10∙∙∙H27A), Figure 4.8B and Table 4.7. The H-bonded chains are linked by two 
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hydrogen bonds N27−H27B∙∙∙N28 (2.105(19) Å) between two symmetrical 
guanines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. X-ray crystal structure of [(η5-C5Me5)Ir(phpy)(9-EtG-N7)] 
NO3·1.5CH2Cl2 (32G·NO3·1.5CH2Cl2). (A) Atom numbering scheme. Only the 
cation is shown for clarity. (B) Formation of dimers linked by N27−H27B∙∙∙N28 
hydrogen bonds of 9-EtG (2.105(19) Å). The NO3
−
 counter anions form H-bonds 
with N26H and N27H (O12∙∙∙H26 1.987(19) Å and O10∙∙∙H27A 1.975(19) Å). 
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Table 4.7. H-bond Interactions between Nitrate Counter Ion and Guanine in the 
X-ray Crystal Structure of [(η5-C5Me5)Ir(phpy)(9-EtG-N7)]NO3·1.5CH2Cl2 
(32G·NO3·1.5 CH2Cl2) 
D–H∙∙∙A D–H (Å) H∙∙∙A (Å) D∙∙∙A (Å) ∠D–H∙∙∙A(°) 
N27–H27A∙∙∙O10 0.888(18) 1.987(19) 2.871(3) 174(3) 
N26–H26∙∙∙O12 0.877(18) 1.975(19) 2.850(3) 175(3) 
N27–H27B∙∙∙N28 0.910(18) 2.105(19) 3.004(3) 169(3) 
 
Complexes [(η5-C5Me5)Ir(dfphpy)Cl] (31), [(η
5
-C5Me4C6H5)Ir(phpy)Cl] (33) and 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), formed moderately strong 9-MeA adducts 
(35−63% at equilibrium after 24 h, Table 4.6 and Figure 4.6). Only complex 29 
[(η5-C5Me5)Ir(tpy)Cl] and 32 [(η
5
-C5Me5)Ir(phpy)Cl] showed an exceptionally high 
affinity for 9-MeA, with 90% and 86% adduct formation after 24 h, respectively. 
Complex [(η5-C5Me5)Ir(phq)Cl] (30) containing 2-phenylquinoline formed almost 
no 9-MeA adduct (<5%). Except for 30, two adenine nucleobase adducts were 
formed in the reactions between complexes 29, 31−34 with 9-MeA, most likely 
through iridium binding to N1 or N7 of adenine in a ratio typically of 1:5. 
To understand the mode of binding to adenine, 1:1 mol equiv of 9-MeA and 
complex 32 were dissolved in MeOD-d4 (7 mM), and 2D 
1
H–1H TOCSY (Figure 
4.9) and NOESY spectra were recorded (Figure 4.10). Only 40% of complex 32 
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reacted with 9-MeA in MeOD-d4 at 310 K after 24 h. Complex 32 also formed two 
9-MeA adducts in a 6.6:1 ratio in MeOD-d4 based on the integration of the Cp* 
1
H 
NMR peaks. The 
1
H NMR peaks of the minor adduct in the low field region are 
weak and overlapped by the peaks of the major adduct, Figure 4.9.  
   
 
Figure 4.9. 
1
H–1H TOCSY 2D NMR spectrum of an equimolar equilibrium 
solution of 9-MeA and complex 32 [(η5-C5Me5)Ir(phpy)Cl] (7 mM) in MeOD-d4. 
Peak assignments are indicated on the structures. 
 
An NOE cross-peak between H2 of 9-MeA and the HC=N proton of phpy was 
observed (Figure 4.10), suggesting that coordination of 9-MeA through N1 is the 
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major binding mode. This result is consistent with the DFT calculations which show 
that [(η5-C5Me5)Ir(phpy)(9-EtA-N1)]
+
 is more stable than [(η5-C5Me5)Ir(phpy)- 
(9-EtA-N7)]
+
 by 18.36 kJ/mol. 
 
 
Figure 4.10. (A) Optimized geometry of [(η5-C5Me5)Ir(phpy)(9-EtA-N1)]
+
 showing 
a short distance of 2.275 Å between the HC=N proton of phpy ( ) and H2 of bound 
9-EtA ( ); (B) 
1
H–1H NOESY 2D NMR spectrum of adduct in the reaction mixture 
of complex 32 [(η5-C5Me5)Ir(phpy)Cl] with 1 mol equiv of 9-MeA (7 mM, 
MeOD-d4), which confirms coordination of 9-MeA through N1 as the major 
binding mode. 
 
Chapter 4: Cyclopentadienyl Iridium Complexes Containing C^N-Chelating Ligands 
173 
 
The calculations suggest that there is a π orbital interaction between N(NH2 of 
adenine) and C1 and C2(phpy) for the DFT-optimized complex 
[(η5-C5Me5)Ir(phpy)(9-EtA-N1)]
+
, Figure 4.11. This may explain the formation of 
adenine adducts [(η5-C5Me5)Ir(phpy)(9-MeA)]
+
 by complex 32. These 
negatively-charged carbons on the phenyl ring appear to be favoured for such 
interactions compared with the analogous atoms in the pyridine ring where C1 is 
positively charged and C2 is slightly negative. 
 
 
 
 
 
 
 
 
Figure 4.11. (A) DFT optimized structure of complex 
[(η5-C5Me5)Ir(phpy)(9-EtA-N1)]
+
. (B) HOMO–2 orbital for the DFT-optimized 
complex [(η5-C5Me5)Ir(phpy)(9-EtA-N1)]
+
 showing the N(NH2 of 9-EtA)∙∙∙C1/C2 
(phpy) interactions. 
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Competition reactions between equi-molar amounts of 9-EtG and 9-MeA and 
complexes 29, and 31−34 (ca. 1 mM) in 20% MeOD-d4/80% D2O (v/v, pH* ca. 7.4) 
at 310 K were investigated. In the competitive experiment, 9-EtG adducts 31G, 
33G or 34G were observed as the only product for complexes 31, 33 or 34, and as 
ca. 80% 9-EtG adduct for complex 29 and 32 (20% 9-MeA adduct), Table 4.6. The 
1
H NMR spectra for the competition reaction for 31 are shown in Figure 4.12. 
 
 
Figure 4.12. Low field region of the 
1
H NMR spectra for the competitive reaction 
between 9-EtG and 9-MeA and complex 31 [(η5-C5Me5)Ir(dfphpy)Cl].
 
(A) 
Equilibrium solution of 31 (1.0 mM) in 20% MeOD-d4/80% D2O (v/v, pH* 7.4) at 
310 K, containing both the chlorido complex 31 and its aqua adduct 31A. (B) 10 
min after addition of equimolar amounts of 9-EtG and 9-MeA, showing the 
complete formation of 9-EtG adduct 31G. 
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4.3.6  Cytotoxicity 
The cytotoxicity of complexes 29−34, and 37 towards A2780 human ovarian 
cancer cells was investigated, Table 4.8. The IC50 value (concentration at which 
50% of the cell growth is inhibited) for Cp* Ir
III
 complexes 29−32 is comparable 
with that of cisplatin. Complexes 33, 34 and 37 containing Cp
xph 
or Cp
xbiph
 were 
even more potent, especially complexes 34 and 37 with an IC50 value of 0.7 μM (ca. 
twice as active as cisplatin). Overall, the cytotoxic potency increases with phenyl 
substitution on Cp*: Cp
xbiph
 > Cp
xph
 > Cp*, Table 4.8. 
 
Table 4.8. Inhibition of Growth of A2780 Human Ovarian Cancer Cells by 
Complexes 29−34, 37 and Comparison with Cisplatin 
Complex IC50
 a
 (μM) 
[(η5-C5Me5)Ir(tpy)Cl] (29) 3.28±0.14 
[(η5-C5Me5)Ir(phq)Cl] (30) 2.55±0.03  
[(η5-C5Me5)Ir(dfphpy)Cl] (31) 6.53±0.50 
 
[(η5-C5Me5)Ir(phpy)Cl] (32) 10.78±1.72 
 
 
 
 
 
 
 
 
 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (33) 2.14±0.50 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34) 0.70±0.04  
[(η5-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37) 0.67±0.11 
±0.04 cisplatin 1.19±0.12 
a
 Drug-treatment period was 24 h. 
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Complexes [(η5-C5Me5)Ir(phpy)Cl] (32) and [(η
5
-C5Me4C6H4C6H5)Ir(phpy)Cl] 
(34) were further evaluated by the National Cancer Institute Developmental 
Therapeutics Program (NCI/DTP, U.S.A.) for in vitro cytotoxic test against ca. 60 
human cancer cell lines within nine tumour type subpanels.
30
 The cells were treated 
by iridium complexes for 48 h at five concentrations ranging from 0.01 to 100 μM. 
Three endpoints are calculated: GI50 (the concentration that causes 50% cell growth 
inhibition), TGI (the concentration where causes 100% cell growth inhibition), and 
LC50 (the concentration that the drug decreases the original cell number by 50%).  
The mean graphs for complexes 32 and 34 are listed in Figure 4.13. Complex 32 
containing Cp* shows high potency in wide range of cancer cell lines, selectively 
for leukemia, non-small cell lung cancer and CNS cancer (highlighted by red 
squares in Figure 4.13A). Complex 34 containing Cp
xbiph
 ligand is selective for 
leukemia, colon cancer, and melanoma (Figure 4.13B), particularly active towards 
colon COLO 205, melanoma SK-MEL-5, and breast MDA-MB-468, with GI50 
values less than 0.2 μM. The mean GI50, TGI and LC50 of complexes 32, 34 and 
cisplatin against ca. 60 cell lines are shown in Figure 4.14. Complex 32 is ca. 2.5× 
as potent as cisplatin toward NCI cancer cell lines, whilst complex 34 is ca. 15× as 
potent as cisplatin.  
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Figure 4.13. (A) Mean graph for complex [(η5-C5Me5)Ir(phpy)Cl] (32) from the 
National Cancer Institute Developmental Therapeutic Program. The complex is 
particularly active towards cell lines highlighted by red squares. 
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Figure 4.13. (B) Mean graph for complex [(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34) 
from the National Cancer Institute Developmental Therapeutic Program. The 
complex is particularly active towards cell lines highlighted by red squares. 
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Figure 4.14. Mean graph midpoint (MG-MID) GI50, TGI and LC50 values of 
complexes
 
[(η5-C5Me5)Ir(phpy)Cl] (32), [(η
5
-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), and 
comparison with cisplatin. Data for cisplatin are from NCI/DTP screening: October 
2009, after 48 h treatment of the cells.
31
 
 
4.3.7  Hydrophobicity (log P) 
Lipophilicity often correlates with cytotoxic potency and has therefore been used 
extensively in structure-activity correlations.
32-38
 The octanol-water partition 
coefficients (log P) for complex [(η5-C5Me5)Ir(bpy)Cl]Cl (7·Cl) containing 
N,N-chelating 2'2-bipyridine and 
 
[(η5-C5Me5)Ir(phpy)Cl] (32) containing 
C^N-chelating 2-phenylpyridine were determined. Instead of water alone, 0.2 M 
NaCl was used to suppress hydrolysis of the complexes. Complex 7 is 
positively-charged and shows a negative log P value of –0.95 (partitions 
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preferentially into water ca. 10-fold), whilst the neutral complex 32 is much more 
hydrophobic with log P value of 1.57 (partitions preferentially into octanol ca. 
30-fold). The difference in partition coefficients between complexes 7 and 32 is 
thus directly related to the difference in their charges. 
 
4.4  Discussion 
4.4.1  X-ray Crystal Structures 
A search of the Cambridge Crystallographic Database showed that the crystal 
structure of complexes [(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34) and 
[(η5-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37) in this Chapter, with complexes 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) and [(η
5
-C5Me4C6H4C6H5)Ir- 
(bpy(OH)O)Cl] (21) in Chapter 3 are the only examples containing the Cp
xbiph
 
ligand. Complexes 9·PF6 containing N,N-bound 2,2'-bipyridine and 34 containing 
C^N-bound 2-phenylpyridine are structurally very similar. In complex 34, the 
chelating ligand is closer to the Ir
III
 centre than in 9·PF6 since the Ir−C bond length 
[2.057(3) Å] in complex 34 is significantly shorter than the Ir−N bond length 
[2.091(5) Å] in the latter complex. The short Ir–C(phenylpyridine) distance causes a 
slight elongation of the Ir–cyclopentadienyl (centroid) bond with distance of 1.825 
Å in complex 34 (Table 4.2), compared to 1.787 Å in complex 9·PF6. The Ir–Cl 
Chapter 4: Cyclopentadienyl Iridium Complexes Containing C^N-Chelating Ligands 
181 
 
bond lengths are similar in the two complexes, with distances of 2.3886(8) Å (Table 
4.2) and 2.3840(14) Å, respectively. This behavior is similar to that observed for the 
C^N-chelated complex [(η5-C5Me5)Ir(phpy)Cl]
23
 (32) when compared to the 
N,N-chelated complex [(η5-C5Me5)Ir(bpy)Cl]Cl (7·Cl), and [(η
5
-C5Me4C6H5)Ir- 
(bq)Cl] (36) compared to [(η5-C5Me4C6H5)Ir(phen)Cl]PF6
 
(5·PF6), Tables 4.2 and 
3.1. 
The bond lengths and bond angles in complexes [(η5-C5Me5)Ir(phq)Cl] (30) and 
[(η5-C5Me5)Ir(phpy)Cl] (32)
23
 are similar, except that the Ir−N bond for 30 [2.128(5) 
Å] is longer than that of [(η5-C5Me5)Ir(phpy)Cl] [2.080(2) Å], implying weaker σ 
donation from N to the iridium centre due to the electron-withdrawing phenyl ring 
in the quinoline moiety. 
From a search of the Cambridge Database, [(η5-C5Me5)Ir(phpy)(9-EtG)]NO3 
(32G·NO3) appears to be the first example of an X-ray structure of a guanine adduct 
containing a chiral iridium centre. 
 
4.4.2  Hydrolysis and pKa of Aqua Adducts 
Since M–OH2 (M = metal) aqua complexes are often more reactive than the 
equivalent chlorido complexes,
39,40
 hydrolysis of the M–Cl bonds can represent an 
activation step for transition metal anticancer complexes.
41
 There are only a few 
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previous studies of the aquation (substitution of Cl by H2O) of organometallic Ir
III
 
complexes.
42,43
 In this Chapter, all the [(η5-Cpx)Ir(C^N)Cl] complexes 29–34 
hydrolysed too rapidly for determination of their hydrolysis rates by NMR, even for 
the biphenyl substituted Cp
xbiph
 complex 34 [(η5-C5Me4C6H4C6H5)Ir(phpy)Cl]. In 
Chapter 3, half-lives for the hydrolysis of some Cp
xph
 or Cp
xbiph
 Ir
III
 complexes 
containing N,N-bound 2,2′-bipyridine (bpy) or 1,10-phenanthroline (phen) chelating 
ligands of ca. 4 min at 310 K were determined. The electron-donor methyl groups 
on the Cp ring and the negatively-charged C^N-chelating ligands may together 
contribute to the fast hydrolysis observed for the complexes studied here since the 
increased effective charge on the Ir centre may facilitate chloride loss. Fast 
hydrolysis rates have been reported for some hexamethylbenzene Ru
II
 complexes,
44
 
acetylacetonate Ru
II
 and Os
II
 complexes,
16,45
 and picolinate Ir
III
 complexes 12–14. 
These results illustrate that Ir
III
 complexes are not always inert and that Ir−Cl bonds 
can be labile. 
The aqua complexes [(η5-C5Me5)Ir(tpy)(D2O)]
+
 (29A), [(η5-C5Me5)Ir(phq)- 
(D2O)]
+
 (30A), [(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (31A), [(η5-C5Me5)Ir(phpy)(D2O)]
+
 
(32A), [(η5-C5Me4C6H5)Ir(phpy)(D2O)]
+
 (33A), and [(η5-C5Me4C6H4C6H5)Ir- 
(phpy)(D2O)]
+
 (34A), have similar pKa values, ranging from 8.31 to 8.87 (Table 
4.5). Although the substituents on the Cp* ring and the 2-phenylpyridine chelating 
ligand do not significantly affect the acidity of the bound water, the observed trend 
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caused by these substituents is clear, following the order 29A > 32A > 30A > 33A > 
34A ≈ 31A. The presence of phenyl and biphenyl substituents on the Cp* ring 
lower the pKa value by ca. 0.3 to 0.4 units, consistent with the electron-withdrawing 
properties of these groups. Substitution of cyclometalated 2-phenylpyridine by the 
fluorinated chelating ligand 2-(2,4-difluorophenyl)pyridine leads to a decrease in 
pKa by 0.4 units. However, replacing cyclometalated 2-phenylpyridine by 
2-(p-tolyl)pyridine or by the more π-delocalized 2-phenylquinoline, has little effect 
on the pKa value (ca. 0.1 unit).  
However, the aqua complexes [(η5-C5Me5)Ir(phpy)(D2O)]
+
 (32A), 
[(η5-C5Me4C6H5)Ir(phpy)(D2O)]
+ 
(33A) and [(η5-C5Me4C6H4C6H5)Ir(phpy)(D2O)]
+
 
(34A) containing the C^N-chelated 2-phenylpyridine ligand, have significantly 
higher pKa values (average 1.9 units higher) than those for the structurally similar 
Ir
III
 Cp
x
 analogues 7−9 bearing the N,N-bound 2,2'-bipyridine (bpy) ligand. 
Therefore, the replacement of the neutral bpy ligand by the anionic phpy ligand 
plays a significant role in decreasing the acidity of the aqua complexes, consistent 
with previous reports.
16
 The high pKa values of 29A−34A thus ensure that most of 
the hydrolysed complexes would be present in the active aqua form at physiological 
pH. 
The pH titration also showed that additional species were formed for all 
complexes studied here above pH 8.7 (Figure 4.5), indicating the formation of the 
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hydroxo-bridged dimers {[(η5-Cpx)Ir]2(μ-OD)3}
+
 (38−40, Figure 4.1). However, this 
does not occur when the chelating ligand is N,N-chelated bipyridine ligand. Clearly 
the Ir−C bond shows less stability with respect to the formation of dimers 38−40 
than the Ir−N bond. It seems likely that the mechanism of formation of 38−40 
involves initial cleavage of the Ir−C bond, followed by Ir−N bond breakage. Some 
Os
II
 and Ru
II
 complexes containing N,O-bound or O,O-bound ligands have been 
reported to form hydroxo-bridged dimers readily during their hydrolysis, resulting 
in their inactivity toward cancer cell lines.
46-48
 In this Chapter, no hydroxo-bridged 
dimers of 38−40 were observed during hydrolysis, and all the complexes are active 
toward A2780 human ovarian cancer cells. This indicates that the C^N-chelated Ir
III
 
complexes are stable in aqueous solution and the dimers 38−40 formed only appear 
at high pH and have no negative effect on their cytotoxicity at physiological pH. 
 
4.4.3  Interaction with Nucleobases 
Interaction with DNA is often associated with the cytotoxicity of metal 
anticancer drugs.
28,29
 In this study, the interactions of model nucloebases, 9-EtG and 
9-MeA, with complexes [(η5-C5Me5)Ir(tpy)Cl] (29), [(η
5
-C5Me5)Ir(phq)Cl] (30), 
[(η5-C5Me5)Ir(dfphpy)Cl] (31), [(η
5
-C5Me5)Ir(phpy)Cl] (32), [(η
5
-C5Me4C6H5)Ir- 
(phpy)Cl] (33) and [(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), were investigated 
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(Figure 4.6 and Table 4.6). All C^N-chelated Ir
III
 complexes, except 30, showed an 
exceptionally high nucleobase affinity with ca. 100% guanine adduct formation for 
9-EtG, which may contribute to their high cytotoxicity. Compared with 
N,N-chelated Ir
III
 complexes in Chapter 3, complexes containing a C^N-bound 
chelating ligand bind more significantly to 9-EtG, which may be due to their 
inherent advantage of having higher pKa values. Under similar pH conditions, 
hydrolysed C^N- complexes are more likely to be present as the reactive aqua form 
compared to the N,N-chelated complexes. 
Complexes 29−34 bind more weakly to adenine compared to guanine. The 
competition between 9-EtG and 9-MeA for the C^N-bound Ir
III
 complexes give rise 
to 9-EtG adducts as the only product for complexes [(η5-C5Me5)Ir(dfphpy)Cl] (31), 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (33) and [(η
5
-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), and 
as major product for [(η5-C5Me5)Ir(tpy)Cl] (29) and [(η
5
-C5Me5)Ir(phpy)Cl] (32), 
Table 4.6, confirming that binding to guanine is stronger than to adenine. This may 
be due to the steric hindrance caused by the NH2 group at the 6-position of the 
adenine ring. In addition, guanine is usually considered to be a stronger electron 
donor than adenine.
49
 The widely used anticancer drug in clinical, cisplatin, also 
prefers guanine over adenine.
50
 Organometallic Ru
II
, Os
II
 and Ir
III
 complexes 
containing N,O-chelating ligands or O,O-chelating ligands such as picolinate and 
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acetylacetonate, which possess oxygen as an H-bond acceptor for adenine C6NH2, 
also bind to both guanine and adenine residues.
16,47,51
 
Ir
III
 cyclopentadienyl complexes in Chapter 3 containing a neutral N,N-chelating 
ligand (phen, bpy, or ethylenediamine) bind selectively to 9-EtG, but not to adenine. 
The formation of adenine adducts in this Chapter may be due to the interaction 
between NH2 of 9-MeA and negatively-charged carbons on the C^N-chelating 
ligand, Figure 4.11. Thus complexes 29−31 containing different substituents on the 
phenylpyridine bind to 9-MeA differently. The electron donating methyl group on 
the phenyl ring in complex [(η5-C5Me5)Ir(tpy)Cl] (29) increases electron density 
and may facilitate the interaction with 9-MeA (>90%). In contrast, only 35% of 
complex [(η5-C5Me5)Ir(dfphpy)Cl] (31) formed 9-MeA adducts which may be due 
to the presence of the electron-withdrawing fluoro group. Complex 30 
[(η5-C5Me5)Ir(phq)Cl] has the lowest affinity for both model nucleobases among the 
five complexes, with 45% and <5% binding to 9-EtG and 9-MeA, respectively. The 
weaker binding is most likely due to the steric hindrance caused by the quinoline 
ligand.  
2D NMR spectra (Figures 4.9 and 4.10) show that complex 32 binds to adenine 
mainly through N1, which is consistent with DFT calculations. The N7 atoms of 
guanine and adenine are accessible to metal ions, such as Pt in cisplatin,
52
 for 
coordination in the major groove of DNA, whereas N1 of A is involved in 
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Watson-Crick base-pairing. Complex 32 reacted with guanine via N7 (as confirmed 
by X-ray crystal structure of 32G·NO3), and formed adenine adducts mainly via N1. 
In addition, complex 32 has a higher affinity for guanine compared to adenine. 
Binding to guanine may therefore play a more significant role in its cytotoxicity. 
 
4.4.4  Hydrophobicity (log P) 
The log P value as a measure for hydrophobicity, has been investigated as a 
factor relevant to anticancer activity of metal-based drugs for many years. Neutral 
complex [(η5-C5Me5)Ir(phpy)Cl] (32) is more hydrophobic than negatively charged 
complex [(η5-C5Me5)Ir(bpy)Cl]
+
 (7), with log P values of 1.57 and –0.95, 
respectively. The difference in partition coefficients between complexes 32 and 7 is 
thus related to the difference in their charges. 
The hydrophobicity and cancer cell activity correlate significantly in this study. 
Complex 7 is less hydrophobic and inactive. Complex 32 displays much higher 
hydrophobicity, and is cytotoxic. This hydrophobicity difference is likely to result 
in higher cancer cell uptake and contribute to the higher cytotoxicity of complex 32. 
For compounds in the Comprehensive Medicinal Chemistry (CMC) database, which 
is often used to validate new pharmacophores, log P values range between –0.4 and 
5.6, with an average value of 2.52.
53
 The log P value of 1.57 for complex 32 is 
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within this range, whilst the log P of –0.95 for complex 7 is more negative, i.e. the 
complex 7 may be too hydrophilic for optimum drug-like properties.  
 
4.4.5  Cytotoxicity 
Some Cp* Ir
III
 complexes studied in Chapter 3 containing N,N-, or N,O-chelating 
ligands are inactive toward A2780 human ovarian cancer cells. However, all Cp* 
complexes [(η5-C5Me5)Ir(tpy)Cl] (29), [(η
5
-C5Me5)Ir(phq)Cl] (30), 
[(η5-C5Me5)Ir(dfphpy)Cl] (31), and [(η
5
-C5Me5)Ir(phpy)Cl] (32) studied here 
showed promising activity toward the human ovarian A2780 cancer cell line with 
IC50 values ranging from 2.5−10.8 μM (Table 4.8). Thus the introduction of 
C^N-chelating ligands is an effective method for switching on the cancer cell 
cytotoxicity of Cp* Ir
III
 complexes. The Cp* complex [(η5-C5Me5)Ir(phpy)Cl] (32) 
containing C^N-chelating ligand is even as potent as the Cp
xbiph
 complex 
[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6
 
(9·PF6) against NCI 60 cancer cell lines, 
Figures 3.16 and 4.14. The strong binding of Ir to nucleobases, especially to 
guanine bases, may provide an important contribution towards the cytotoxicity. 
Also the neutral C^N- complexes display more hydrophobic character than the 
positively-charged N,N- complexes and therefore possess enhanced cellular uptake 
which may also contribute to the cytotoxicity. The introduction of substituents on 
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the phenylpyridine ring enhanced the cytotoxicity of 32 [(η5-C5Me5)Ir(phpy)Cl], 
Table 4.8. Particularly active is the complex [(η5-C5Me5)Ir(phq)Cl] (30), which is 4 
times more potent than 32. The ability of the phq ligand to intercalate into DNA 
may contribute to this enhanced potency.
54,55
  
Compared to the parent Cp* complex [(η5-C5Me5)Ir(phpy)Cl] (32), the 
introduction of phenyl or biphenyl substituents onto the tetramethylcyclopenta- 
dienyl ring to give complexes [(η5-C5Me4C6H5)Ir(phpy)Cl] (33) and 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34), results in a dramatic increase in cytotoxicity, 
Table 4.8. Complex 34 is more than 5 times more potent than complex 32 against 
NCI 60 cancer cell lines, Figure 4.14. The Cp
xbiph
 complex 
[(η5-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37) is one order of magnitude more potent 
than Cp* complex [(η5-C5Me5)Ir(dfphpy)Cl] (31). The activity of Ru
II
 arene 
complexes also increases with the size of the coordinated arene.
56,57
 This suggests 
that phenyl groups may play a crucial role in the mechanism of action of these 
phenylpyridine complexes. First, the phenyl or biphenyl ring increases the 
hydrophobicity of the molecule, which may assist with passage across cell 
membranes. In addition, the extended phenyl rings can intercalate into DNA, thus 
causing distortion of DNA structure. It was shown in Chapter 3 that the intercalative 
ability of 1,10-phenanthroline Ir
III
 chlorido complexes increases in the order of 
Cp
xbiph
 > Cp
xph
 > Cp*. Complexes [(η5-C5Me4C6H5)Ir(phpy)Cl] (33), 
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[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34) and [(η
5
-C5Me4C6H4C6H5)Ir(dfphpy)Cl] (37) 
containing phenyl or biphenyl substitutions may interact with DNA by a dual mode: 
nucleobase binding to iridium accompanied by intercalation of the phenyl groups, 
which is a different mechanism of action from that of cisplatin. 
 
4.5  Conclusions 
Iridium-based anticancer agents, including organometallic iridium complexes, are 
currently attracting attention as potential anticancer agents with novel mechanisms 
of action. The effects of changing the Cp
x
 ligand and negatively-charged 
C^N-chelating ligand of Ir
III
 cyclopentadienyl complexes of the type 
[(η5-Cpx)Ir(C^N)Cl] on the hydrolysis of the chlorido complexes, acidity of the 
aqua adducts, nucleobase binding, and cancer cell cytotoxicity have been studied in 
this Chapter. 
All the studied complexes undergo rapid hydrolysis (<5 min at 278 K) due to the 
strongly electron-donating methyl groups on Cp ring and negatively-charged 
C^N-chelating ligand. Generally, the aqua adducts of the C^N- complexes studied 
here possess low acidity, with pKa values 1.9 units higher than N,N- analogues, 
which ensures that the active aqua adduct is the major form after hydrolysis at 
physiological pH, and may contribute to the strong binding to guanine. The 
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substituents on both the Cp* ring and on 2-phenylpyridine can fine-tune the acidity 
of aqua adduts according to their electronic effects. Hydroxo-bridged dimers 
{[(η5-Cpx)Ir]2(μ-OD)3}
+
 (38–40) are observed at high pH (>8.7), indicating the 
stability of C^N- complexes is not as high as N,N- analogues under strongly basic 
conditions.  
Complexes 29 and 31–34 show strong binding to the nucleobase guanine. Unlike 
the Ir
III
 complexes containing N,N-chelating ligands, the C^N- complexes can also 
bind to adenine. However, they show a strong preference for binding to guanine 
over adenine. Complex 30 displayed the lowest extent of nucleobase binding among 
the complexes studied due to steric hindrance from the chelating ligand 
2-phenylquinoline.  
The C^N- complexes showed very promising anticancer activity toward A2780 
human ovarian cancer cells and NCI 60 cancer cell lines. The Cp* complexes 
possess more potent activity than cisplatin. The introduction of phenyl or biphenyl 
substituent significantly improved their cytotoxicity, especially for the Cp
xbiph
 
complexes 34 and 37 which have submicromolar activity against 60 cancer cells. 
The strong binding to guanine bases and hydrophobicity may contribute to their 
high activity. This study shows that desirable features can be introduced into this 
class of complexes to optimize their design as anticancer agents. 
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5.1 Introduction 
Coenzymes are small organic molecules that link to enzymes and whose 
presence is essential to the activity of those enzymes. NAD
+
 (β-nicotinamide 
adenine dinucleotide) is an important coenzyme found in all living cells. In 
metabolism, NAD
+
 and its reduced form 1,4-NADH (Figure 5.1) are involved in 
redox reactions, carrying electrons from one reaction to another. Both NAD
+
 and 
1,4-NADH play important roles as cofactors in numerous biocatalysed processes, 
including energy metabolism, antioxidation and oxidative stress, immunological 
functions and cell death.
1
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Figure 5.1. Structures and numbering schemes for NAD
+
 and 1,4-NADH. 
 
There is an increasing demand for regeneration of the coenzyme 1,4-NADH in 
biocatalysis.
2,3
 Conversion of NAD
+
 to 1,4-NADH by enzymatic, chemical, 
photochemical or electrochemical methods has been extensively studied.
4-7
 For 
example, Ir
III
 and Rh
III
 pentamethylcyclopentadienyl complexes have been shown to 
catalyse the regioselective reduction of NAD
+
 to 1,4-NADH with formate as the 
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hydride source.
8,9
 However, the reverse reaction, i.e. conversion from 1,4-NADH to 
NAD
+
, has little been reported.
10
 
In our group, it was shown that [(η6-arene)Ru(en)Cl)]+ complexes (where arene = 
hexamethylbenzene (hmb), p-cymene (p-cym), indane (ind), and en = 
ethylenediamine) can convert NAD
+
 to 1,4-NADH using formate as hydride 
source.
11
 Such reactions might be feasible in cells which can tolerate millimolar 
levels of formate, a potential basis for the design of catalytic drugs. In an attempt to 
improve the efficiency of the Ru
II
 arene catalyst, the effect of replacing en by π-
acceptor ligands has been investigated.
12
 It has been discovered that not only can 
these complexes convert NAD
+
 to 1,4-NADH using formate as the hydride source, 
but also that the reverse reaction, hydride donation from 1,4-NADH to a metal 
centre, is facile, the first observation of such a transfer.  
In this Chapter, hydride-transfer reactions of cyclopentadienyl Ir
III
 aqua complex 
to regioselectively reduce NAD
+
 in the presence of formate under biologically 
relevant conditions are described. The reverse reaction, i.e. hydride-transfer reaction 
from 1,4-NADH to the iridium complexes and formation of NAD
+
, was also 
investigated. Moreover it is shown that these organometallic Ir
III
 complexes can act 
as robust hydrogenation catalysts using 1,4-NADH as a source of hydride, including 
the production of H2. A preliminary elucidation of the mechanisms involved is 
proposed.  
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5.2 Experimental Section 
5.2.1 Materials  
β-Nicotinamide adenine dinucleotide hydrate (NAD+), β-nicotinamide adenine 
dinucleotide reduced dipotassium salt (1,4-NADH), alcohol dehydrogenase from 
saccharomyces cerevisiae (ADH), sodium formate (NaHCO2), silver nitrate 
(AgNO3), and sodium pyruvate  were obtained from Sigma-Aldrich.  
The Ir
III
 precursor [(η5-C5Me5)Ir(phen)Cl]Cl (4) was synthesised according to 
literature methods.
13
 The synthesis of the Ir
III
 precursor [(η5-
C5Me4C6H5)Ir(phen)Cl]PF6 (5) was described in Chapter 3. To generate the aqua 
complexes [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) and [(η5-C5Me4C6H5)Ir(phen)- 
(H2O)]
2+
 (5A), their respective chlorido complexes 4 and 5 were dissolved in 10% 
MeOD-d4/90% H2O (v/v), then 1.96 and 0.98 mol equiv of AgNO3 were added. The 
solution was stirred for 24 h at 298 K, and AgCl was removed by filtration.  
The solvent used for UV-Vis absorption spectroscopy was deionised water. The 
solvents used for 
1
H NMR spectroscopy were methanol-d4 from Aldrich, and 
deionised water. 
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5.2.2 Methods 
5.2.2.1   NMR Spectroscopy  
1
H and 
1
H–1H TOCSY 2D NMR spectra were acquired in 5 mm NMR tubes at 
298 K (unless otherwise stated) on either Bruker DRX 500, Bruker AV III 600 or 
Bruker AV II 700 NMR spectrometers. For NMR experiments using 90% H2O/10% 
MeOD-d4, the water peak was suppressed as described in Chapter 2. 
 
5.2.2.2   UV-Vis Absorption Spectroscopy 
Reactions of Ir
III
 complex 5A with 1,4-NADH produced from reaction of the 
enzyme alcohol dehydrogenase (ADH) and NAD
+
, and catalytic conversion of 1,4-
NADH to NAD
+
 by Ir
III
 complex 5A were studied by UV-Vis spectroscopy. UV-
Vis absorption spectra were recorded at different temperatures ranging from 298 K 
to 315 K, from 220 to 500 nm as described in Chapter 2. The concentrations of 1,4-
NADH, NAD
+
, enzyme ADH and complex [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) 
in UV-Vis spectroscopy studies were obtained using the Beer–Lambert law and 
extinction coefficients: 259 nm ε(NAD
+
) = 16900 M
–1
cm
–1
;
14
 339 nm ε(1,4-NADH) = 
6220 M
–1
cm
–1
;
15
 280 nm ε 1%(ADH) = 14.6;
16
 274 nm ε (5A) = 8900 M
–1
cm
–1
. 
 
5.2.2.3   pH Measurements 
pH values were measured at ambient temperature using a Corning 240 pH meter 
as described in Chapter 2.  
Chapter 5: Hydride-Transfer Reactions of Cyclopentadienyl Iridium Aqua Complexes 
 
 
203 
 
5.2.2.4   Reduction of NAD
+
 by 4A Using Formate as a Hydride Source 
NAD
+
 (1.5 mol equiv) was added to an NMR tube containing a 1 mM solution of 
the [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) and an excess of NaHCO2 (25 mol equiv) in 
10% MeOD-d4/90% H2O at ambient temperature. The 
1
H NMR spectra of the 
resulting solutions were recorded at 298 K at various time intervals for 3 h.  
 
5.2.2.5   NMR Spectroscopy Studied Reactions with 1,4-NADH  
Two or 3 mol equiv of 1,4-NADH were added to an NMR tube containing a 1 
mM solution of [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) or [(η5-C5Me4C6H5)Ir- 
(phen)(H2O)]
2+
 (5A) in 10% MeOD-d4/90% H2O at ambient temperature. The 
1
H 
NMR spectra of the resulting solutions were recorded at 298 K at various time 
intervals for 33 h. A
 1
H–1H TOCSY 2D NMR spectrum was recorded for the 
reaction of 5A with 1,4-NADH after 22 h. 
 
5.2.2.6   Detection of H2 by Gas Chromatography 
A solution containing complex [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A, 0.9 mM) 
and 1,4-NADH (1.3 mM), was prepared in 5 mM phosphate buffer, pH 7.2 in a 5 
mm NMR tube equipped with a suba seal from stock solutions of the reactants 
which had been thoroughly purged with N2 before mixing. Aliquots of the head 
space (100 uL) were sampled by using a gas-tight syringe immediately, after 40 min, 
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80 min, 130 min, 160 min, 5 h, and 23 h of incubation at 298 K, and analysed on an 
Agilent GC 7890A instrument equipped with a thermal conductivity detector, a 5-Å 
molecular sieve column, using N2 as the carrier gas. Under these conditions 
different amounts of H2 were detected with a retention time of 0.39 min.  
 
5.2.2.7   Hydrogenation of Pyruvate 
Three mol equiv of 1,4-NADH were added to an NMR tube containing a 1 mM 
solution of 5A in 10% MeOD-d4/90% H2O (v/v) at ambient temperature, followed 
by the addition of 3 mol equiv of sodium pyruvate. The 
1
H NMR spectra of the 
resulting solutions were recorded at 298 K at various time intervals for 24 h. 
 
5.2.2.8   Catalytic Conversion of 1,4-NADH to NAD
+
 by 5A 
Kinetic experiments were performed with changes in concentration of 1,4-NADH 
at 70, 110, 156 and 173 µM, while keeping concentration of the catalyst [(η5-
C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) constant at 1.5 µM (ca. pH 7.4), or with changes 
in concentration of 5A at 1.0, 1.5 and 3.0 µM in water (pH 7.5) at different 
temperatures, while keeping concentration of 1,4-NADH at 160 µM. UV-Vis 
spectra were recorded after different time intervals to monitor the course of reaction 
at 310 K from 220 nm to 500 nm. The absorbance at 339 nm, assignable to 1,4-
NADH, was used to analyse data. 
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5.3 Results 
Two cyclopentadienyl Ir
III
 aqua complexes [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) 
and [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) (where phen = 1,10-phenanthroline, 
Figure 5.2), generated from their respective chlorido complexes using Ag
+
 to 
remove Cl
–
, were exploited in this Chapter. 
 
N
N
Ir
OH2
2+
N
N
Ir
OH2
2+
4A 5A  
Figure 5.2. Iridium cyclopentadienyl complexes studied in this Chapter. 
 
5.3.1 Reduction of NAD
+
 Using Formate as a Hydride Source 
The possibility that Ir
III
 aqua complex [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) could 
react directly with sodium formate to generate hydride species (Ir–H) was 
investigated. Addition of 25 mol equiv of NaHCO2 to 1 mM solution of 4A in 10% 
MeOD-d4/90% H2O at 298 K formed a set of new peaks immediately, which was 
attributed to the formation of a formato adduct (Ir–O2CH), Figure 5.3B. Peak 
assigned to the bound formate are high-field shifted ca. 0.9 ppm in comparison to 
those of free formate (8.43 ppm). The 
1
H NMR peaks of the formato adduct 
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decreased in intensity rapidly and a second set of new peaks was observed over time 
and was assigned to formation of hydride adduct [(η5-C5Me5)Ir(phen)(H)]
+
 (Ir–H, –
11.1 ppm), Figures 5.3C and 5.3D.  
 
 
Figure 5.3. 
1
H NMR spectra of a 1 mM solution of [(η5-C5Me5)Ir(phen)(H2O)]
2+
 
(4A, spectrum A) with sodium formate (molar ratio 1:25) in 10% MeOD-d4/90% 
H2O at 298 K at various time intervals. Peak assignments are indicated on the 
structures. The 3 sections from left to right show the low-field region, methyl 
groups on Cp* ring (×0.25), and Ir-H hydride peak (×4), respectively.  
 
Next the hydride-transfer reaction from Ir
III
 aqua complex [(η5-
C5Me5)Ir(phen)(H2O)]
2+
 (4A) to NAD
+ 
using sodium formate as a source of hydride 
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was studied. The 
1
H NMR spectra of [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) (1 mM) 
with NAD
+
 and sodium formate (molar ratios 1:1.5:25) in 10% MeOD-d4/90% H2O 
at 298 K at various time intervals shown the fast reduction of NAD
+
 to 1,4-NADH 
as indicated by a decrease on the intensity of the signals of free NAD
+
 (H2 at 9.45 
ppm) and the new peaks assignable to 1,4-NADH (H2 at 7.05 ppm and H4a/H4b at 
2.80 ppm), Figure 5.4. The results show that complex 4A can convert NAD
+
 to 1,4-
NADH through hydride-transfer using formate as a hydride source. 
 
 
Figure 5.4. 
1
H NMR spectra of a 1 mM [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) with 
NAD
+
 and sodium formate (molar ratios 1:1.5:25) in 10% MeOD-d4/90% H2O at 
298 K at various time intervals. Peak assignments are indicated on the structures. 
The 3 sections show the low-field region, H4a & H4b peaks (×2) of 1,4-NADH, and 
Ir-H hydride region (×8), respectively.  
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5.3.2 NMR Spectroscopy of Reactions with 1,4-NADH 
When two mol equiv of 1,4-NADH were added to a 1 mM solution of [(η5-
C5Me5)Ir(phen)(H2O)]
2+
 (4A), the colour of solution changed from light to dark 
yellow immediately. 
1
H NMR spectra of the resulting solution recorded at 298 K 
after various time intervals (Figure 5.5) contained a sharp singlet at –11.3 ppm 
within the first 10 min of the reaction corresponding to an iridium(III) hydride 
adduct together with a new set of signals attributable to NAD
+
. Over the next 33 h, 
the signal for the hydride adduct decreased in intensity and the major signals 
present were those for NAD
+
 and aqua complex 4A. During that time the pH of the 
solution increased significantly from 6.8 to 8.9. Addition of 2 further mol equiv of 
1,4-NADH again rapidly gave rise to an Ir–H peak (top spectrum in Figure 5.5). 
Similar results were obtained for reactions of [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) 
(Figure 5.6). 
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Figure 5.5. Conversion of 1,4-NADH to NAD
+
 in the presence of complex [(η5-
C5Me5)Ir(phen)(H2O)]
2+
 (4A). 
1
H NMR spectra of a 1 mM 4A with 1,4-NADH 
(molar ratio 1:2) in 10% MeOD-d4/90% H2O at 298 K at various time intervals 
during 33 h. After 33 h, a further 2 mol equiv of 1,4-NADH were added to the 
solution and the resulting 
1
H NMR spectrum was recorded after 10 min (top 
spectrum). Peak assignments are indicated on the structures. Left: low-field region; 
right: Ir-H hydride region (×2). 
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Figure 5.6. Reactions of [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) and 1,4-NADH. 
(A) 
1
H NMR spectra of 1 mM of 5A with 3 mol equiv of 1,4-NADH in 10% 
MeOD-d4/90% H2O at 298 K at various time intervals during 33 h. Left: low-field 
region; right: region of Ir-H hydride peak (×2). (B) 1H–1H TOCSY 2D NMR 
spectrum recorded after 22 h. Peak assignments are indicated on the structures.  
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5.3.3 Hydrogenation of Pyruvate 
Next it was shown that hydride-transfer from 1,4-NADH to Ir
III
 complexes can be 
coupled to the reduction of biologically relevant substrates. The conversion of 
pyruvate to lactate was studied, a reduction carried out in vivo by 1,4-NADH as 
cofactor for the enzyme lactate dehydrogenase (LDH), Eq. 5.1.
17
  
 
Eq. 5.1
 
 
 
Figure 5.7. 
1
H NMR spectra showing conversion of pyruvate to lactate in the 
presence of [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A). (A) 
1
H NMR spectrum 
recorded 10 min after addition of 3 mol equiv of 1,4-NADH to a 1 mM solution of 
5A in 10% MeOD-d4/90% H2O (v/v) at 298 K. (B) 
1
H NMR spectrum recorded 10 
min after addition of 3 mol equiv of sodium pyruvate to the solution in (A). Peak 
assignments are indicated on the structures. 
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Addition of 3 mol equiv of sodium pyruvate to a solution containing 3 mol equiv 
of 1,4-NADH and 1 mM [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) in 10% MeOD-
d4/90% H2O (v/v), resulted in a doublet at ca 1.45 ppm corresponding to protons of 
methyl group of lactate, suggested conversion of ca. 30% of the pyruvate to lactate 
after 10 min at 298 K (Figure 5.7). However, no further pyruvate was converted 
after 24 h.  
 
5.3.4 Reaction with Enzymatically Produced 1,4-NADH 
Then it was shown that Ir–H generation can be coupled to the enzymatic 
production of 1,4-NADH, Eq. 5.2. Complex 5A (final concentration 72 µM) was 
added to a solution containing 1,4-NADH (final concentration 33 µM) generated 
from NAD
+
 by enzymatic oxidation of ethanol by alcohol dehydrogenase (ADH, in 
6 mM Na2HPO4/NaH2PO4 buffer, 3.4 M ethanol, pH 7.2). UV-Vis spectroscopy 
indicated that all the 1,4-NADH produced was immediately consumed after 
addition of complex 5A, as judged by the decrease in absorption at 339 nm (Figure 
5.8). This reaction was also studied by 
1
H NMR spectroscopy, with similar results 
(Figure 5.9).  
 
CH3CH2OH + NAD
+ ADH CH3CHO + 1,4-NADH
Ir-OH2 Ir-H Eq.5.2+ NAD+  
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Figure 5.8. UV-Vis spectra showing reaction of 1,4-NADH (produced as a result of 
an enzymatic reaction) with [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) in 6 mM 
Na2HPO4/NaH2PO4 buffer, 3.4 M ethanol, pH 7.2, at 298 K. Spectra of NAD
+
 (blue 
line), complex 5A (green line), and ADH (pink line) were recorded separately as 
controls before mixing, with final concentrations of 34 μM, 72 μM and 3.8×10–3 
mg/ml, respectively. After mixing NAD
+
 and ADH, the UV-Vis spectrum was 
recorded after 10 min (dark red line). No change was observed after 30 min. An 
absorption band at 339 nm was observed, suggesting the generation of 1,4-NADH 
(33 μM). Then to this solution, complex 5A (final concentration 72 μM) was added 
and the resulting UV-Vis spectrum (black line) was recorded immediately. The 
decrease of absorption at 339 nm suggested that 1,4-NADH was oxidised (to NAD
+
) 
in the presence of aqua complex 5A. 
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Figure 5.9. 
1
H NMR spectra showing the rapid reaction of 1,4-NADH (produced as 
a result of the enzymatic reaction) with [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A). (A) 
NAD
+
 (3 mM, ) in 6 mM Na2HPO4/NaH2PO4 buffer, 3.4 M ethanol, and 4% (v/v) 
of MeOD-d4 (as NMR lock signal), pH = 7.2, 298 K. (B) Addition of enzyme ADH 
(ca. 0.03 mM) resulted the formation of 1,4-NADH ( ) after 10 min. (C) Formation 
of more 1,4-NADH and addition of 0.3 mol equiv of complex 5A. (D) Addition of a 
further 0.3 mol equiv of 5A decreased the intensity of 1,4-NADH. Left: low-field 
region; right: Ir-H hydride peak region (×4).  
 
5.3.5 Detection of H2 
Strikingly, these initial data showing the turnover of more than one mol equiv of 
NAD
+
 per Ir
III
 suggested that the Ir complex might act as a catalyst and be recycled 
via Ir–H protonation and formation of H2, Eq. 5.3. The possible production of H2 
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was investigated by gas chromatography for solutions containing [(η5-
C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A, 0.9 mM) and 1,4-NADH (1.3 mM in 5 mM 
phosphate buffer pH 7.2). The time dependence of H2 evolution was monitored 
from the peak with retention time of ca. 0.39 min (Figure 5.10). The sum of H2 
detected in the headspace and H2 dissolved in solution (1.6×10
‒2
 mL), was in good 
agreement with the amount of H2 which would be produced if all the available 
hydride from 1,4-NADH is converted to H2 (1.8×10
–2
 mL).  
 
Ir-OH2
1,4-NADH
Ir-H Eq.5.3Ir-OH2
H+, H2O
+  H2  
 
 
Figure 5.10. H2 formation with time during reaction of [(η
5
-C5Me4C6H5)Ir- 
(phen)(H2O)]
2+
 (5A, 0.9 mM) with 1,4-NADH (1.3 mM) in phosphate buffer (5 mM, 
pH 7.2) at 298 K as detected by gas chromatography. 
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5.3.6 Catalytic Studies on Reactions with 1,4-NADH 
The turnover of 1,4-NADH using [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) as 
catalyst was investigated in more detail. 
 
5.3.6.1   Effect of 1,4-NADH on the Catalytic Reaction 
Kinetic experiments on aqueous solutions (ca. pH 7.4) with 1,4-NADH 
concentrations of 70, 110, 156 and 173 µM, and a constant catalyst 5A 
concentration of 1.5 µM were monitored by UV-Vis absorption spectroscopy at 310 
K. Typical UV-Vis spectra recorded are shown in Figure 5.11, in which the 
absorption band at 339 nm decreased with time while the band at ca. 259 nm 
increased,
14,15
 suggested the conversion of 1,4-NADH to NAD
+
 in the presence of 
5A as catalyst. Figure 5.12 shows the time dependence of 1,4-NADH absorption at 
339 nm, and plots of lnA (A = absorbance of 1,4-NADH at 339 nm) against time, 
indicating reactions are first-order with respect to 1,4-NADH. From the slop of 
these lines an average rate constant k of 6.14 × 10
–4
 min
–1
 and half life 403 min 
were determined. 
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Figure 5.11. Typical UV-Vis spectra in kinetic experiments, showing degeneration 
of 1,4-NADH (initial concentration 110 µM) catalysed by [(η5-C5Me4C6H5)Ir- 
(phen)(H2O)]
2+
 (5A, 1.5 µM) in water (pH = 7.4) at 310 K. 
 
 
Figure 5.12. [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) catalysed decomposition of 
1,4-NADH studied detected by UV-Vis spectroscopy. (A) Time dependence of 1,4-
NADH absorption at 339 nm, showing degeneration of 1,4-NADH catalysed by 5A 
(1.5 µM) in water (ca. pH 7.4) at 310 K. (B) Plots of lnA (A = absorbance of 1,4-
NADH at 339 nm) against time, suggest that conversion of 1,4-NADH is first-order 
reaction with respect to 1,4-NADH. 
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The turnover numbers (TON) of these reactions increased with time and 1,4-
NADH concentration (Figure 5.13A). The maximum TON reached 75 after 24 h for 
173 µM 1,4-NADH. Initial turnover frequencies (TOF) expressed as the number of 
moles of consumed 1,4-NADH per mole of catalyst after an initial 1 h of the 
reaction, increased with [1,4-NADH] (Figure 5.13B), 4.3 h
–1
 for 173 µM 1,4-
NADH and double that for 70 µM 1,4-NADH. 
 
 
Figure 5.13. Turnover number (TON) and initial turnover frequencies (TOF) for 
the oxidation of 1,4-NADH catalysed by [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) at 
310 K in aqueous solution (ca. pH 7.4). (A) Plots of TON against time. (B) 1,4-
NADH concentration dependence of TOF. The concentration of 5A in each case 
was 1.5 µM. 
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5.3.6.2   Effect of 5A and Temperature on the Catalytic Reaction 
Kinetic experiments on aqueous solutions (pH 7.5) with [(η5-
C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) concentrations of 1.0, 1.5 and 3.0 µM, and a 
constant 1,4-NADH concentration of 160 µM were monitored by UV-Vis 
absorption spectroscopy at different temperatures ranging from 300 K to 315 K. 
Rate constant k of these reactions increased with 5A concentration and temperature, 
Table 5.1. An Arrhenius plot (lnk vs. 1/T) of these reactions yielded straight lines 
between 300 K and 315K, Figure 5.14, with activation energies Ea listed in Table 
5.1. The increase of concentration of 5A from 1.0 µM to 3.0 µM resulted in the 
decrease of Ea of ca. 9.1 kJ·mol
–1
, and then increased the rate of reaction. 
 
Table 5.1. Rate Constant k and Activation Energy Data for 5A Catalysed 
Conversion of 1,4-NADH 
[5A] k × 10
–4
 (min
–1
) Ea 
(µM) 300 K 305 K 310 K 315 K   (kJ·mol–1) 
1.0 2.3 3.4 5.2 8.2 66.4 
1.5 2.9 4.1 6.1 9.6 62.6 
3.0 4.0 5.6 8.0 12.0 57.3 
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Figure 5.14. Arrhenius plots of lnk against 1/T for the oxidation of 1,4-NADH (160 
µM) catalysed by [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A, 1.0, 1.5 and 3.0 µM, 
respectively) in water (pH 7.5) at various temperatures from 300 K to 315 K. 
 
5.4 Discussion 
5.4.1 Reduction of NAD
+
 Using Formate as a Hydride Source 
Most studies of Ru
II
, Rh
III
 or Ir
III 
complexes as transfer hydrogenation catalysts 
for the reduction of ketones and aldehydes have been carried out in non-aqueous 
solvents such as glycerol, 2-propanol or formic acid/triethylamine,
18-20
 although 
recently it has been discovered that some hydrogenations can also be carried out 
efficiently in water.
21
 Applications of these organometallic complexes to 
biocatalysis have so far mainly been concerned with the conversion of the 
coenzyme NAD
+
 to its reduced form 1,4-NADH using formate as the hydride 
source.
8,11,22
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In this study, the interaction of cyclopentadienyl Ir
III
 aqua
 
complex 4A [(η5-
C5Me5)Ir(phen)(H2O)]
2+
 with an excess of sodium formate in aqueous solution 
resulted in the formation of formato adduct (Ir–O2CH), Figure 5.3B. A significant 
high-field chemical shift (0.9 ppm) was observed between free and bound formate, 
consistent with previous report for Ru
II
 arene formato complex.
23
 The formato 
adduct (Ir–O2CH)
 
degenerated rapidly, and was followed by the formation of 
hydride adduct [(η5-C5Me5)Ir(phen)(H)]
+
 (Ir–H, –11.1 ppm). A signal at –11.8 ppm 
corresponding to hydrido ligand of [(η5-C5Me5)Ir(bpy)(H)]
+
 (bpy = 2'2-bipyridine) 
has been reported.
24
 The observation of stable hydride complex in aqueous solution 
using formate as the hydride donor provides a basis for following hydride-transfer 
from [(η5-C5Me5)Ir(phen)(H)]
+
 to NAD
+
, confirmed by the reduction of 
1
H NMR 
signal of NAD
+ 
and the observation of 1,4-NADH peaks (H2 at 7.05 ppm and 
H4a/H4b at 2.80 ppm, Figure 5.4). 
The mechanism in Figure 5.15 can be proposed for hydride-transfer from the 
formato adduct of the cyclopentadienyl Ir
III
 aqua
 
complex 4A to NAD
+
, based on 
the data obtained here and reported studies of hydride-transfer from formate.
8,22
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Figure 5.15. Proposed mechanism for the regioselective reduction of NAD
+
 to 1,4-
NADH by the Ir
III
 complex [(η5-C5Me5)Ir(phen)(H2O)]
2+
 (4A) using formate as a 
hydride source. 
 
The first step of the reaction shown in Figure 5.15(A) proceeds via a rapid 
binding of formate to the Ir
III
 centre in the Ir–OH2 complex. In the followed step (B), 
hydride adduct [(η5-C5Me5)Ir(phen)(H)]
+
 formed after a β-hydrogen elimination 
reaction to produce CO2. In Figure 5.15(C), an open coordination site made 
available by the well documented ring-slippage mechanism
25,26
 of the Cp* ring by a 
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change from 5 to 3 coordination. It is believed that NAD+ can coordinate to IrIII 
via its amide oxygen, and ring-slippage then allows formation of a kinetically-
favoured six-membered-ring transition state. This intermediate further provides the 
driving force for regioselective hydride-transfer to C4 of NAD
+
,
 
Figure 5.15(D); by 
an induced electronic effect of the bound carbonyl group, the C4 position might 
become a more electrophilic site towards hydride-transfer. This step also includes 
the reversion of the 3 to 5 coordination of the Cp* ring, along with binding and 
hydride-transfer. Finally, displacement of the 1,4-NADH by H2O recycles the Ir
III
 
aqua complex, completing the catalytic cycle, Figure 5.15(E). 
 
5.4.2 Hydride-Transfer from 1,4-NADH 
The interactions of the cyclopentadienyl Ir
III
 aqua complexes [(η5-
C5Me5)Ir(phen)(H2O)]
2+
 (4A) and [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) with 1,4-
NADH were followed by 
1
H NMR spectroscopy and UV-Vis spectroscopy. The 
1
H 
NMR spectra of the reaction suggest that 1,4-NADH could be transferring a hydride 
anion to the corresponding Ir–OH2 adducts to generate a detectable Ir–H species 
(sharp singlet ca. –11.1 ppm) and the observed accumulation of NAD+. In addition, 
complex 5A can convert 1,4-NADH produced from enzymatic reaction between 
ADH and ethanol, Figures 5.8 and 5.9. Hence 1,4-NADH produced by various 
biochemical pathways might readily react with iridium complexes such as this in 
cells. This study appears to be the first report of the catalytic transfer of hydride 
from 1,4-NADH to organometallic iridium complexes, although the conversion of 
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1,4-NADH to NAD
+
 catalysed by Ru
II
 arene complexes
12
 and Pd-Au 
nanoparticles
10
 has recently been achieved.  
Interestingly, the reduction of pyruvate to lactate, a reaction catalysed by the 
enzyme lactate dehydrogenase, can be achieved by Ir
III
 complexes via hydride-
transfer from 1,4-NADH, Figure 5.7. Organometallic Ir
III
 complexes offer the 
prospect of carrying out such reactions without the presence of an enzyme. 
The transient appearance of 
1
H NMR signals for Ir–H species at high field 
together with rises in pH during the course of the reactions with 1,4-NADH, 
suggested that the protonation of the Ir–H adducts might be facile with the 
generation of H2. Gas chromatography experiments for the Ir complex 5A showed 
that this was indeed the case, Figure 5.10. This may provide a new route to produce 
H2. A total H2 yield of 1.33 mol per mol glucose has been reported by using an 
NAD
+
-dependent formate dehydrogenase in enterobacter aerogenes.
29
 Molecular 
hydrogen has recently reported to be an efficient antioxidant, such as quenching 
injurious reactive oxygen species (ROS) and suppressing oxidative stress-induced 
injury.
30,31
  
A possible mechanism for the oxidative conversion of 1,4-NADH to NAD
+
 by 
Ir
III
 aqua complexes [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) is shown in Figure 5.16. 
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Figure 5.16. Proposed mechanism for hydride-transfer from 1,4-NADH to complex 
[(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A), followed by protonation to give H2 and 
regenerate the reactive aqua adduct. 
 
The first step, Figure 5.16(A), proceeds via plausible coordination of the amide 
functionality in 1,4-NADH to iridium centre, most probably through direct 
displacement of the bound water. Figure 5.16(B) involves direct hydride-transfer 
from 1,4-NADH to 5A via the formation of a kinetically-favoured six-membered-
ring transition state, through a coordination site which becomes available by a ring-
slippage mechanism (suggested previously for other hydride-transfer reactions). 
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Figure 5.16(C) includes the reversal of the 3 to 5 coordination of the Cp ring, and 
finally the release of the NAD
+
 product and generation of the Ir–H complex. 
Protonation of bound hydride can then give rise to H2 release which is detectable by 
gas chromatography. Coordination of water then completes the cycle, Figure 
5.16(D). 
It is shown here for the first time that the Ir
III
 catalyst 5A is efficient in the course 
of conversion 1,4-NADH to NAD
+
, with turnover number (TON) of 75 in a 173 µM 
solution of 1,4-NADH within 24 h when present at 0.9 mol %. TOF values up to 4.3 
h
–1
 have been obtained at 310 K and pH 7.4. In addition, 5A catalysed conversion of 
1,4-NADH showed first-order behaviour with respect to 1,4-NADH, which is 
consistent with study using Pd-Au nanoparticles.
10
 Both temperature and the 
concentration of 1,4-NADH and 5A have significant influences on the oxidation of 
1,4-NADH. Increasing the concentration of 5A can significantly decrease the 
activation energy of the reactions and increase the rate of reaction. 
 
5.5 Conclusions 
In summary, cyclopentadienyl Ir
III
 aqua complexes [(η5-C5Me5)Ir(phen)(H2O)]
2+
 
(4A) and [(η5-C5Me4C6H5)Ir(phen)(H2O)]
2+
 (5A) mediate the interconversion of 
1,4-NADH and NAD
+
 through hydride-transfer reactions. It is shown that the Ir
III
 
aqua complexes can not only convert NAD
+
 to 1,4-NADH using formate as the 
hydride source, but also catalyse the reverse reaction with hydride donation from 
1,4-NADH to a iridium centre, recovered by protonation of bound hydride with 
Chapter 5: Hydride-Transfer Reactions of Cyclopentadienyl Iridium Aqua Complexes 
 
 
227 
generation of H2. Possible mechanisms for the two types of hydride-transfer 
reactions are also proposed. This appears to be the first report that organometallic 
Ir
III
 complexes can use 1,4-NADH as a hydride source for hydrogenation reactions, 
converting pyruvate to lactate in the absence of an enzyme. The iridium complex 
5A appears to be a robust catalyst for the oxidation of 1,4-NADH with high TON of 
75 after 24 h and TOF values up to 4.3 h
–1
 under physiologically relevant conditions 
(pH 7.4, 310 K, in water). These new findings open up wide possibilities for the 
coupling of hydrogenations to biological processes, including control of the redox 
status of cells.  
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This Chapter explores possible areas of future work for this project. In some 
cases this is based on preliminary results obtained in this thesis. 
 
6.1 Cyclopentadienyl Ligand, Chelating Ligand and Leaving 
Group 
It was shown that the iridium complexes of the type [(η5-Cpx)Ir(XY)Cl]0/+, where 
Cp
x
 is pentamethylcyclopentadienyl, Cp*, or its phenyl Cp
xph
 or biphenyl Cp
xbiph 
derivatives, and XY is the N,N-, NO-, or C^N-chelating ligand discussed in this 
thesis can lead not only to significant changes in the chemical reactivity in relation 
to hydrolysis and acidity of aqua adducts but also in the interaction with 
biologically relevant molecules such as nucleobases and DNA. Furthermore, some 
of the complexes show potent cytotoxicity against the A2780 human ovarian cancer 
cell line and against the NCI panel of ca. 60 human cancer cell lines that is 
comparable to clinically used chemotherapeutics, cisplatin and carboplatin.  
However, the complexes studied in this thesis make up only a small section of 
half-sandwich cyclopentadienyl Ir
III
 complexes that can be envisaged. There are still 
large numbers of active cyclopentadienyl Ir
III
 complexes that can be designed and 
synthesised by changing the cyclopentadienyl ligand, chelating ligand or leaving 
group. The use of functionalised cyclopentadienyl ligands and other kinds of 
chelating ligands with hetero atoms such as sulphur, selenium or phosphorus may 
result in more potent iridium complexes which would be interesting to investigate 
for future work.
1-7
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In addition, the effect of the leaving group (chloride was used in this thesis) has 
also been largely unexplored for these organometallic iridium complexes. For Ru
II
 
and Os
II
 arene complexes, it was reported that substituting the chloride by iodide 
can increase the potency for some classes of these complexes.
8,9
 Also the complex 
[(η5-C5Me4C6H4C6H5)Ir(phpy)(py)]PF6 (ZL105, where py = pyridine) showed more 
potent activity than complex [(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (34) toward A2780 
human ovarian cancer cells, with IC50 values of 0.12 μM and 0.70 μM, respectively. 
For future work it would be interesting to investigate the influence of leaving 
groups (idodide, bromide, pyridine, thiophenolate) on the cytotoxicity of the several 
classes of iridium cyclopentadienyl compounds. 
There is no report yet for an organometallic half-sandwich iridium complex 
which shows activity in vivo. Improving the potency of the iridium complexes even 
more (nanomolar) and investigating the anticancer efficacy in vivo are also included 
in the future. 
 
6.2 Intercalation into DNA 
It was shown in Chapter 3 that addition of phenyl substituents to the Cp* ring in 
organometallic iridium complexes enhances the intercalative ability into DNA by 
EtBr displacement and viscometry experiments. For future work, it would be useful 
to study further the intercalation of the extended phenyl rings into DNA with more 
experimental methods and instrumentation, such as UV-Vis spectroscopy, circular 
dichroism (CD), linear dichroism (LD), DNA melting.
10,11
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Interaction with small oligonucleotides is also a useful method to study the 
intercalation of iridium complexes with DNA, defining more fully the structural 
changes induced by intercalating ligands. Interactions of Ru
II
 complex [(η6-
biphenyl)Ru(en)Cl][PF6] (en = ethylenediamine) with the single-stranded (ss) DNA 
hexamer d(CGGCCG) and the duplex d(CGGCCG)2 have been reported, Figure 
6.1.
12,13
 
 
 
Figure 6.1. Model showing intercalation of a Ru
II
 arene complex into DNA.
12
 
 
6.3 Enantiomer Separation 
In Chapter 4, Ir
III
 cyclopentadienyl complexes of the type [(η5-Cpx)Ir(C^N)Cl] 
show strong binding to the nucleobases and low IC50 values towards cancer cells. 
This new class of organometalic Ir(III) complexes has potential for development as 
potent anticancer agents. However, the C^N-bound complexes are chiral, and no 
attempt was made to resolve them here.  
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Normally, the enantiomers of a molecule behave identically to each other. For 
example, they will migrate with identical Rf in thin layer chromatography. Their 
NMR and IR spectra are identical. However, enantiomers behave differently in the 
presence of other chiral molecules or objects. For example, enantiomers do not 
migrate identically on chiral HPLC column.
14
 Chiral counterions, such as trisphat 
(Figure 6.2), are also used to separate enantiomers by addition of other chiral centre 
in the molecules.
15
 Sometimes crystallisation is also effective in separation of 
enantiomers.
16
 
 
 
Figure 6.2. The chemical structure of trisphat.  
 
Can the chiral anticancer iridium enantiomers be separated? Are the separated 
enantiomers stable? Do the enantiomers exhibit different cytotoxicity toward the 
same cancer cells? All the questions need to be answered in the future.  
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6.4 Other Biological Targets 
Organometallic Ir
III
 complexes containing N,N-, N,O-, or C^N-chelating ligands 
studied in Chapters 3 and 4 can bind moderately or strongly with nucleobases 
guanine and adenine, suggesting DNA may be a target for these complexes. 
However, DNA may not be the only biological target. In other word, the iridium 
complexes may also react with other biological targets. In addition, a drawback of 
traditional anticancer drugs which target DNA is the fact that healthy cells are 
affected as well when malignant cells are inhibited or killed, causing severe toxic 
side-effects. Previous studies have shown that other biological targets, such as 
proteins,
17
 enzymes,
18
 mitochondria,
19
 and peptides
20
 can be a relevant target for 
organometallic transition metal complexes. For future work it would be interesting 
to explore more potential targets for the organometallic iridium complexes. 
 
6.5 Bio-inspired Hydride-Transfer Reactions 
In Chapter 5, it was shown that 1,4-NADH can readily donate hydride to iridium 
in organometallic complexes, forming Ir−H species and NAD+. This reaction is of 
importance since it mimics the function of NADH in cells. The bio-inspired 
hydride-transfer is currently being explored in our laboratory towards the reduction 
of biologically relevant substrates. It was shown that it is possible to mimic enzyme 
reactions by coupling hydride donation from an iridium half-sandwich centre to 
substrates such as pyruvate. In addition, iridium complexes at micromolar 
concentrations can also catalyse the generation of hydrogen. The results imply that 
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these organometallic iridium complexes should be able to mediate the redox states 
of cells, since the NAD
+
/NADH couple plays a central role in controlling cellular 
redox potentials. It would be interesting in the future to evaluate the effect of 
iridium complexes on the cellular redox state. Future work can also involve the use 
of other important biologically substrates and improvements in the design of the 
catalytic iridium complexes. 
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Chemical Structures of Iridium Complexes Studied in This Thesis 
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